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IX 
Abstract 
Cardiac fibroblasts make up a considerable fraction of the total heart cell content. How 
cardiac fibroblasts signaling affects heart muscle function in normal heart development 
and disease remains, however, largely unresolved. Engineered heart muscle (EHM) 
developed from human pluripotent stem cell-derived cardiomyocytes (CMs) and fibroblasts 
in a collagen I hydrogel can be considered a human heart surrogate, allowing for precise 
assessments of fibroblast-CM crosstalk under defined in vitro conditions. We hypothesized 
that EHM development and function are controlled by fibroblast-mediated cardio-
instructive cues. In line with this hypothesis, we found that macroscopically contracting 
EHM fail to form in the absence of fibroblasts. Biophysical analyses confirmed that 
fibroblasts control early collagen gel compaction and stiffening, suggesting a fine-tuning 
function as to the biomechanical properties of the extracellular matrix (ECM) 
environment. Transcriptome data suggested that EHM formation in the presence of 
fibroblasts recapitulates important aspects of early cardiac morphogenesis, including 
cardiac cushion formation. In line with these findings, we identified hyaluronan (HA) as a 
crucial component of EHM development and function. However, excessive HA deposition 
resulted in functional deterioration of EHM, pointing to the need for a fine-tuning of 
fibroblast-mediated processes during cardiomyogenesis. By systematically comparing 
primary fibroblasts of different origin (skin, gingiva, cardiac) to their cardiomyogenesis-
supporting activity, we found that the developmental cues needed for EHM formation were 
to a certain extent universally present in all tested fibroblast species. We further observed 
that fibroblasts from patients with dilated cardiomyopathy (DCM) elicited a pathological 
contractile phenotype, underscoring the relevance of fibroblast-CM crosstalk in health and 
disease. Collectively these findings provide strong evidence for the active role of fibroblasts 
in determining development, function, and disease states of the human heart. 
To further improve our in vitro model and allow for the future use of EHM in vivo, we 
developed EHM under chemically defined conditions. We furthermore identified 
pluripotent stem cell (PSC)-derived cardiac fibroblast-like cells as a potential source of 
fibroblasts for EHM application. 
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Introduction 
1 
1 Introduction 
1.1 Cardiovascular diseases 
Cardiovascular diseases (CVDs) remain the leading cause of death worldwide, both in 
industrial, as well as developing nations (Mendis et al., 2011). CVDs include coronary 
/ischemic heart disease, which is most prevalent, followed by congenital and 
cerebrovascular disease (stroke), as well as pathologies that underlie arrhythmias and 
other disorders of the myocardium (cardiomyopathies; WHO global atlas 2011 (Mendis et 
al., 2011), Figure 1-1). 
 
Figure 1-1 Cardiovascular disease worldwide 
A Global distribution of CVD mortality rates (age standardized, per 100 000) B Distribution of global CVD 
burden (NCD - non-communicable disease). Approximately a third of NCDs are also CVDs. Taken from WHO 
global atlas 2011 Figures 6,7,10 (Mendis et al., 2011). 
Deaths due to coronary heart disease have risen sharply since the beginning of the 20th 
century and peaked in the 1960s (Dalen et al., 2014) as a result of multiple risk factors 
(lifestyle, smoking, diabetes, hypertension) (Bentzon et al., 2014; Yusuf et al., 2004). In 
coronary heart disease, a buildup of plaques in the coronary arteries leads to impaired 
blood flow causing myocardial infarction (MI). As a consequence, areas of the myocardium 
undergo cellular death by apoptosis, necrosis and autophagic mechanisms (Whelan et al., 
2010). 
In contrast, non-ischemic cardiomyopathies are a large and diverse group of disorders that 
are the result of genetic predispositions, a consequence of (auto)immune reactions, or the 
cardiotoxicity of certain drugs. Among these are hypertrophic cardiomyopathies (HCMs) 
and dilated cardiomyopathies (DCMs). In HCMs, the left ventricle is found enlarged, while 
the latter are characterized by a dilatation of the left (or both ventricles) and myocardial 
fibrosis. Genetic aberrations identified in HCM and DCM typically affect the 
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cardiomyocyte (CM) contractile apparatus (sarcomere and cytoskeleton), ion channels, or 
mitochondrial proteins. Indeed, about 20% of the DCM cases can be attributed to 
mutations in titin (Braunwald, 2017). 
1.1.1 The failing heart 
The final consequence of an injured or otherwise impaired myocardium is progressive 
heart failure (HF), the state at which the heart has sustained excessive injury or is 
pathologically so impaired that it is unable to sustain the blood flow and pressure needed 
to supply the body with the required amount of oxygen and nutrients. HF is graded by the 
severity and symptoms patients present with and clinically stratified according to left 
ventricular ejection fraction, which is either preserved or reduced (Berliner and 
Bauersachs, 2017; Mosterd and Hoes, 2007; Ponikowski et al., 2016). Despite considerable 
efforts and advances in the pharmacological field, none of the current treatments targeting 
HF are curative. Thus, current therapeutics can only slow HF progression and aim to 
improve quality of life, while preventing hospital admission and reducing mortality 
(Berliner and Bauersachs, 2017; Ponikowski et al., 2016). At a terminal state, only a 
replacement of the diseased heart remains as therapeutic option. For transplant patients, 
the 1-year and 5-year survival are high with 84% and 76%, respectively, and a fifth of 
patients are alive 20 years after successful transplantation (Lund et al., 2014). 
Unfortunately, suitable donor hearts are highly limited (Johnson et al., 2014; Kittleson, 
2016) and given the further increase in HF prevalence, it is clear that new therapies have 
to be introduced to target this challenge. This requires both novel in vitro systems to aid 
drug development (see 1.5 and 1.6) and new regenerative strategies to support or repair 
the diseased myocardium (1.1.2 and Figure 1-2). 
1.1.2 Regenerative approaches in cardiovascular medicine 
1.1.2.1 Direct reprogramming approaches 
One approach in cardiovascular regenerative medicine is to target resident cells in the 
affected myocardium and stimulate their survival and/or proliferation (Doppler et al., 
2013; Ishikawa et al., 2015) or to directly reprogram one resident cell-type into another 
(Figure 1-2) (Doppler et al., 2013; Luigi, Anastasia et al., 2006). This approach has been 
predominantly aimed at the conversion of myofibroblasts into functional CMs (Miyamoto 
et al., 2018; Nam et al., 2013; Song et al., 2012). First encouraging reports from in-vivo 
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models of mice reported preserved cardiac function and a reduction of adverse remodeling 
and fibrosis after MI (Miyamoto et al., 2018; Song et al., 2012). 
1.1.2.2 Transplantation of stem cells and derivatives 
Stem-cells provide an infinite source for the repair of any cell type and tissue of the body. 
It has thus been a primary strategy to directly deliver stem cells to the failing heart 
(Figure 1-2) (Doppler et al., 2013). The benefit of embryonic stem (ES) cells and induced 
pluripotent stem (IPS) cells have been studied extensively in animal transplantation 
models but there remains concern about the risk of teratoma formation when 
transplanting PSCs (Nelson et al., 2009; Nussbaum et al., 2007). In contrast, the use of a 
variety of different adult, bone marrow-derived stem cell populations and stem cells from 
adipose tissue have been categorized as safe, but with limited clinical improvements 
(Doppler et al., 2013). 
Hence, a strategy has been to support the heart with in vitro PSC-derived CMs. This 
provides the myocardium with bona fide CMs and could circumvent the teratoma risk of 
näive PSC cells. Chong and colleagues demonstrated the potential use of human ES cell-
derived CMs in a clinically relevant macaque model. Here, large numbers of CMs were 
delivered via epicardial injection. Retained cells coupled to the host myocardium and 
supported neovascularization of the infarct area (Chong et al., 2014). Of note, a great 
limitation when transplanting cells in suspension has been their effective and long-lasting 
engraftment onto host myocardium. Several groups have attempted to resolve this by 
transplanting cells together with suitable matrices (Blondiaux et al., 2017; Tang et al., 
2017; Wang et al., 2017, 2018) (see also next section) an approach termed “tissue-
engineering”. 
1.1.2.3 Tissue engineering 
In tissue engineering, one or more cell types are embedded into matrices to provide a more 
natural environment (Figure 1-2) and enhance cell retention after implantation (Doppler 
et al., 2013; Karikkineth and Zimmermann, 2013; Ogle et al., 2016) (Figure 1-2 and Figure 
1-8). Tissue engineering can additionally be utilized for in vitro research and using PSCs, 
as an infinite cell source, allow for large and highly standardized screening applications 
(see also 1.5 and Figure 1-10). 
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Figure 1-2 Different regenerative approaches targeting cardiac disease 
The approaches in regenerative medicine to target the many types of cardiac disease are highly versatile and 
may ultimately be applied best in a disease specific or individualized approach. In direct cell transplantation 
both pluripotent/multipotent stem and progenitor cells may be used, but also cells derived from them (as in 
the case of EHM for instance). Cells can either be delivered via direct injection as a cell suspension or in a 
tissue engineering approach. Alternatively, resident cells may be stimulated to proliferate (CMs) or be 
reprogrammed (myofibroblasts) to differentiate into the required cell types (image taken from (Doppler et al., 
2013). 
In order to understand the perquisites for successful tissue engineering, an in-depth 
knowledge of the myocardial cell types and their interactions is required. Reciprocally, 
findings from engineered tissues that display organotypic functionality can be applied to 
decipher cell-cell and cell-matrix interactions that underlie developmental and 
pathological processes within the endogenous myocardium (see focus of this work 1.6). 
1.2 The cellular components of the myocardium 
1.2.1 Cardiomyocytes 
The heart is a large muscular pump with four chambers that maintains pulmonary and 
systemic blood flow to support all tissues and organs with sufficient oxygen and nutrients. 
The CMs whose elaborate cytoskeleton with myofibrils drives contractile motion can be 
found in the muscular walls of the atria and ventricle in the heart. Another type of CMs, 
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the cardiac pacemaker cells, are an integral part of the heart’s conduction system that 
controls the heart rate. 
During embryonic development, CMs first proliferate (hyperplastic growth) and then 
enlarge (hypertrophic growth), resulting in an increased heart mass and size. During this 
development, their shape changes from a polygonal morphology to a more elongated one, 
as myofibrils develop and elongate parallel to the axis of the growing cell. Concurrently, 
the mechanical adherens junctions and desmosomes (containing cadherins and 
desmoplakin) assume a bipolar distribution connecting both ends of the elongated cell to 
adjacent cells and the ECM, together with gap junctions, in large intracellular complexes 
termed intercalated discs (Hirschy et al., 2006). Eventually, elongated and tightly 
connected CMs, form a functional syncytium (Gregorio and Antin, 2000; Severs, N., 2000). 
In the fully developed myocardium, the connection of the cytoskeleton to ECM and cell-
cell contacts via gap junctions allows for the synchronized transmission of biomechanical 
and electric signals which results in the generation of directional forces across the 
ventricle. 
1.2.2 Non-myocytes 
There has been a long debate about the non-myocyte composition of the heart. Due to a 
lack of proper cell type specific markers, the identification of individual non-myocyte 
populations and their characterization has been intrinsically difficult with standard 
histological and fluorescence activated cell sorting (FACS) techniques. As the growth of 
the postnatal myocardium is mediated by hypertrophic expansion of CMs, the vast volume 
in the heart is occupied by CMs. However in numbers, only around 20-30% of cells in the 
postnatal heart are CMs (Bergmann et al., 2015; Nag, 1980; Pinto et al., 2015), the 
remaining cell fraction consists of endothelial cells, smooth muscle cells, cardiac 
fibroblasts and resident and transient immune cell populations. Recently, Pinto and 
colleagues used an elaborate bioinformatics algorithm, Spanning-tree Progression 
Analysis of Density-normalized Events (SPADE), to further stratify individual non-
myocyte populations of the murine heart. They identified the predominant cell type of the 
heart were endothelial cells (40%) that constituted even more than 60% of non-myocytes 
in the heart. Of the non-myocyte population, (using platelet-derived growth factor α 
receptor (PDGFRα)-GFP, collagen type 1 α-chain 1 (Col1α1)-GFP, MEF-SK4 and TCF21 
lineage tracing) cardiac fibroblasts only contributed 15% and cells of hematopoietic origin 
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between 5-10%. In the human heart they could recapitulate their findings and identified 
20-30% CMs and 50% endothelial cells (Pinto et al., 2015) (Figure 1-3). 
 
Figure 1-3 Cellular components of the myocardium 
The cellular composition of the heart has been of long debate as it is intrinsically difficult to stratify the many 
different cell populations with appropriate markers. This figure summarizes the findings that were generated 
with SPADE analysis using FACS according to (Pinto et al., 2015). (Heart graphic by 
www.wikispaces.com/open access graphics). 
1.2.3 Cardiac fibroblasts 
Cardiac fibroblasts are elongated, spindle shaped cells with an elaborate endoplasmic 
reticulum and Golgi apparatus, reflecting their high secretory activity. They are 
furthermore characterized by the lack of a basement membrane (Camelliti et al., 2005; 
Fan et al., 2012; Souders et al., 2009). To date, cardiac fibroblasts remain poorly defined 
(Ivey and Tallquist, 2016): The individual use of commonly recognized markers vimentin, 
Discoidin domain-containing receptor 2 (DDR2), and fibroblast-specific protein 1 (FSP1) 
have not been sufficiently specific to faithfully characterize these cells. Recently, cardiac 
fibroblast populations could be better stratified from other mesenchymal cell populations 
by using a combination of the markers PDGFRα, collagen type I and TCF21 (Ivey and 
Tallquist, 2016; Ivey et al., 2018; Pinto et al., 2015; Snider et al., 2009). Myofibroblasts 
could furthermore be distinguished from resident fibroblast populations by using TCF21 
and periostin combined in lineage tracing experiments (Kanisicak et al., 2016) 
1.2.3.1 Origin and role of cardiac fibroblasts in myocardial development 
Cardiac fibroblasts are predominantly derived from epicardial cells at E12.5 (embryonic 
day) of mouse heart development (Sullivan and Black, 2013). These cells undergo 
periostin- and TGFβ-dependent epithelial-to-mesenchymal transition (EMT) (Olivey et al., 
2006) and subsequently differentiate into cardiac fibroblasts (Fan et al., 2012) (Figure 1-4). 
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Moreover, some fibroblasts arise from the endocardium through endothelial- to 
mesenchymal transition (endMT) (Brutsaert, 2003; Fan et al., 2012). 
As the embryonic heart develops, epicardial-derived signals guide CMs into the formation 
of a higher order multicellular syncytium, necessary for the development of contractile 
forces (Takahashi et al., 2014). Ablation of signals from the epicardium such as (fibroblast-
specific) PDGFα (Bax et al., 2010) and insulin-like growth factor (IGF) 2 (Li et al., 2011) 
lead to failure of hyperplasia and cardiac compaction (Gittenberger-de Groot et al., 2012). 
Interestingely, the first time cardiac fibroblasts emerge is contemporaneous with 
compacted myocardium and Ieda and colleagues could establish a direct connection 
between epicardial fibroblast-derived signals and CM development. They demonstrated 
that collagen I and fibronectin secreted by cardiac fibroblasts mediate the proliferation of 
CMs during the hyperplastic growth phase via binding to integrin β1 receptor (Ieda et al., 
2009). These findings emphasize the crucial role of fibroblast-CM crosstalk in the proper 
spatiotemporal development of the compacting myocardium and how fibroblast-derived 
ECM components directly influence CM mitotic behavior. 
Eventually, following a short peak in CM and fibroblast proliferation during large 
structural changes of the postnatal heart (Ivey et al., 2018), the cardiac fibroblast 
populations ceases proliferation and remains stable. In the adult heart, the predominant 
function of resident cardiac fibroblasts is the maintenance and homeostasis of the ECM 
(see 1.3.3). Upon pathological stimuli and insults, resident cardiac fibroblasts can be 
reactivated and transition into myofibroblasts (Camelliti et al., 2005; Fan et al., 2012) (see 
section 1.3 and 1.4.2). In addition, (myo)fibroblasts can be recruited from various origins, 
including the bone marrow (CD45+ myofibroblasts) (Ivey et al., 2018) or originate from 
resident fibroblasts precursors (Moore-Morris et al., 2014) and fibrocytes (Fan et al., 2012) 
(Figure 1-4). 
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Figure 1-4 Origin of cardiac fibroblasts 
In the development of the endogenous myocardium, the majority of cardiac fibroblasts arise from the cells of 
the pro-epicardium by epithelial-to-mesenchymal transition (EMT). Endothelial cells undergoing EMT are a 
second source of cardiac fibroblasts. During pathological processes other cell types such as hematopoietic 
progenitor cells can contribute to cardiac (myo)fibroblasts. Figure from (Fan et al., 2012). 
1.3 Crosstalk between cardiac fibroblasts and cardiomyocytes 
In the heart, cardiac fibroblasts can be found interspersed between CMs (Camelliti et al., 
2005) allowing for the exchange of information by means of 1) direct cell-to cell contacts 2) 
paracrine signals (cytokines/chemokines) 3) indirect ECM-mediated signal transduction, 
both via biochemical (cell-ECM contacts) and biomechanical signal transmission (for an 
overview on the following chapter see Figure 1-5). 
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Figure 1-5 Fibroblast-cardiomyocyte communication in the myocardium 
Overview on the mechanisms via which fibroblasts and CMs can communicate during physiological and 
pathological processes (upper/lower panel, respectively). Cardiac fibroblasts may connect to CMs via direct 
cell-cell contacts (both mechanically via adherens junctions and electrically via gap junctions), as depicted on 
the left side of the illustration (red boxes). They can furthermore influence CM behavior via paracrine signal 
mediators. Concurrently, cardiac fibroblasts control the integrity and viscoelasticity of the ECM (right side, 
grey boxes), which indirectly affects CMs. Adapted from (Sullivan and Black, 2013). 
1.3.1 Direct cell-cell contacts 
Although still a matter of intensive debate, there is some evidence of direct fibroblast-CM 
contacts in the myocardium. Fibroblasts were long thought to be electrically inert but may 
be crucial for the transmission of signals (for instance in the sinoatrial node (Camelliti, 
2004; Gaudesius, 2003) in the myocardium. The presence of fibroblast-CM and fibroblast-
fibroblast gap junctions has been suggested that would allow direct transmission of 
electrical signals (containing connexins 40,43 and 45) (Camelliti, 2004; Chilton et al., 2007; 
Gaudesius, 2003; Kohl, 2003; Kohl and Gourdie, 2014; Mahoney et al., 2016; Ongstad and 
Kohl, 2016). Although cardiac conduction is generally impaired in areas of firosis (Spach 
and Boineau, 1997), functional fibroblast-fibroblast gap junctions in the MI scar were 
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hypothesized to electrically connect two healthy areas of myocardium that are separated 
by the scar (Camelliti, 2004; Mahoney et al., 2016). 
Recently, an in vitro study indicated that mechanical fibroblast-CM connections could 
potentially be established via adherens junctions (Pedrotty et al., 2008) that would allow 
for the direct transmission of mechanical signals between the cells in addition to the 
connection between cells and ECM (see 1.3.3). Further work is needed to evaluate the 
physiological relevance of these findings. 
1.3.2 Paracrine mediators 
Most is known about paracrine signaling circuits in the diseased heart involving cardiac 
(myo)fibroblasts and CMs. Signaling of factors such as Angiotensin II (AngII), TGFβ, 
IGF1, different fibroblast growth factors (FGFs) and interleukin 6 (IL-6) has been 
extensively studied (Kakkar and Lee, 2010). Recently it has become clear, that secreted 
metabolites and micro RNAs (miRs) also play a crucial role in intramyocardial signaling 
(Bang et al., 2014, 2015; Sassi et al., 2014, 2017). 
TGFβ, secreted by both CM and fibroblasts is an important paracrine mediator of cellular 
communication (Kakkar and Lee, 2010). TGFβ signaling in cardiac fibroblasts leads to 
myofibroblast transition followed by secretion of excessive ECM (Petrov et al., 2002) and 
thus fibrosis (Baum and Duffy, 2011; Weber et al., 2013). Concurrently, TGFβ induces 
hypertrophy in CMs (Gray et al., 1998; Schultz et al., 2002). For instance, in 
cardiomyopathies, such as HCM, it could be demonstrated that BRAF mutations caused 
aberrant RAF/MAPK signaling specifically in cardiac fibroblasts. This subsequently led to 
enhanced secretion of TGFβ, effectively stimulating hypertrophy in target CMs (Josowitz 
et al., 2016). 
AngII acts closely together with TGFβ and targets both CMs and cardiac fibroblasts. 
AngII-treated CMs induce TGFβ signaling which stimulates fibroblasts to synthesize 
collagen and secrete cytokines such as IL-6 and tumor necrosis factor α (TNFα) (Sarkar et 
al., 2004). Autocrine signaling of IL-6 in cardiac fibroblasts causes the restructuring of the 
ECM via hyaluronan synthases (HASs) and the abundance of excessive hyaluronan (HA) 
can subsequently result in myofibroblast transformation of resident fibroblasts (Müller et 
al., 2014). IL-6 upregulation in turn, together with leukemia induced factor (LIF) and 
cardiotrophin-1 result in CM hypertrophy (Sano et al., 2000). AngII also induces FGF-2 
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signaling in cardiac fibroblasts which drives CM hypertrophy (Jiang et al., 2007; Pellieux 
et al., 2001). 
Intriguingly, as a response to AngII stimulation, cardiac fibroblasts can also enhance CM 
hypertrophy via exosomes containing the microRNA passenger strand miR21*(Bang et al., 
2014). Other micro RNAs such as miR29 also stimulate CM hypertrophy and myocardial 
fibrosis (Sassi et al., 2017). 
1.3.3 Communication via the extracellular matrix 
In the myocardium, resident cardiac fibroblasts secrete collagen types I and III followed 
by less abundant, collagens and proteins such as fibronectin, laminin and elastin (Fan et 
al., 2012). While collagens and elastins provide structural support, the ECM contains 
many non-structural components such as glycoproteins, (for instance fibronectin, 
laminins, thrombospondins and periostin), proteoglycans (such as versican and aggrecan), 
and glycosaminoglycans (the most common one, HA) (Rienks et al., 2014). 
The ECM provides an indispensable structural scaffold for the myocardium during 
development. By controlling its integrity, in particular the subtypes of deposited collagen, 
cardiac fibroblasts can indirectly modulate CM-ECM receptor interactions and subsequent 
signaling. Indeed, inhibition of collagen synthesis abrogates embryonic CM 
myofibrillogenesis, demonstrating that these structural cues are crucial for CM sarcomere 
assembly and elongation (Fisher and Periasamy, 1994). The importance of structural 
information for CMs has also been demonstrated in experiments with decellularized 
cardiac ECM: The presence of structural information enhanced the upregulation of mature 
CM genes in fetal-like CM populations that resided on the matrix (Fong et al., 2016). 
Furthermore, when IPS cell-derived CMs were seeded onto decellularized human 
myocardial ECM they could form fully functional syncytia (Guyette et al., 2016). 
In order to maintain homeostasis and allow for changes in the ECM composition, cardiac 
fibroblasts also produce matrix metalloproteinases (MMPs), whose temporal expression 
and activities are highly controlled by the secretion of tissue inhibitors of matrix 
metalloproteinases (TIMPs) (Fan et al., 2012), receptor-ECM binding (Olaso et al., 2002) 
and mechanical stimuli (Xie et al., 2014). Reciprocally, the activity of MMPs can affect 
cardiac fibroblasts, causing release of ECM components such as fibronectin, laminin, 
collagen I and also TGFβ that then further stimulate collagen secretion in a positive 
feedback loop (Fan et al., 2012). Fibroblast-specific MMP expression, was shown to be 
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crucial for CMs to assume higher order structures and elongate properly in 3D coculture 
systems (Nichol et al., 2008), clearly emphasizing the importance of matrix remodeling for 
CMs development and functionality. 
Cells integrate mechanical information from the surrounding ECM through integrins that 
bind ECM components (often within specialized signaling clusters, the focal adhesion 
complexes). Integrin-mediated binding of cardiac cells is important for CM proliferation 
and hypertrophy, but also EMT, angiogenesis and the control of cardiac fibroblast 
activation (Civitarese et al., 2017). There is a variety of different integrin subunits whose 
expression depends on the spatiotemporal development of the myocardium or its 
pathological state (Civitarese et al., 2017). In vitro, it could be demonstrated that integrins 
are crucial for fibroblast-mediated compaction of the ECM (Carver et al., 1995; Jokinen et 
al., 2004; Klein et al., 1991; Kondo et al., 2004; Schiro et al., 1991; Sur, 2016) and paracrine 
signals such as AngII can enhance gel contraction by cardiac fibroblasts, which can be 
abrogated by blockage of β1 integrin. AngII furthermore stimulates the upregulation of β1 
subunit in treated cells (Burgess et al., 1994). In CMs, signaling through integrin β1-
binding of collagen I and fibronectin mediates hyperplastic growth (Ieda et al., 2009) and 
CM- specific deletion of the β1 subunit leads to DCM and fibrosis (Shai et al., 2002). 
1.4 Viscoelasticity in cardiomyocyte development and function 
The ECM is strain and stretch sensitive and CMs interspersed with fibroblasts are highly 
responsive to changes in their viscoelastic surroundings (see also direct cell-cell contacts 
and how myofibroblast change viscoelasticity). Thus, by changing the properties of the 
ECM, fibroblasts can indirectly affect CMs behavior and function. 
1.4.1 Viscoelasticity during physiological development of cardiomyocytes 
During embryonic to postnatal cardiac development the stiffness of mouse ventricle 
increases from an elastic modulus of 12±4 up to 39±7 kPa (Jacot et al., 2010). The ideal 
substrate viscoelasticity is crucial for CM myofibril development and alignment, which is 
best at physiological values of 10 kPa substrate stiffness in 2D (Ribeiro et al., 2015). 
Indeed, embryonic CMs beat best when faced with an environment comparable to that of 
endogenous embryonic stiffness (Engler et al., 2008) and CM action potentials were found 
to be longest in cultures on physiological substrate stiffness of 10 kPa, which indicates a 
rather mature phenotype (Boothe et al., 2016). Also, in 3D gelatin matrices, CMs clearly 
prefer a physiological stiffness over softer and harder environments, as evidenced by 
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increased α-actinin and Cx43 expression, improved sarcomeric alignment and enhanced 
contraction force (Lee et al., 2017). 
1.4.2 (Myo)fibroblasts affect myocardial viscoelasticity 
Most studies so far have focused on the viscoelastic changes the heart undergoes upon 
pathological stimuli, but the myocardium also stiffens as a result of normal aging (Marín-
García, 2007). The ECM viscoelasticity is determined by its composition which is in turn 
controlled by cardiac fibroblasts (an overview, see Figure 1-5 and for myofibroblasts Figure 
1-6). In the healthy myocardium, the cardiac fibroblasts maintain homeostasis by carefully 
controlling the synthesis and deposition as well as the degradation of ECM components. 
Upon pathological stimuli, resident cardiac fibroblasts transition into myofibroblasts. 
These are characterized by high secretory activity, in particular of collagen (Baum and 
Duffy, 2011; Petrov et al., 2002) and the enhanced expression of adhesion genes such as 
paxillin, vinculin and tensin (Baum and Duffy, 2011), as well as periostin (Kanisicak et 
al., 2016; Kaur et al., 2016; Snider et al., 2009). As a crucial mediator of inflammatory 
signaling in the heart, myofibroblasts are also highly responsive to cytokines and secrete 
both chemokines (IL1 α and β, IL-6, TNF-α) and cytokines, as well as various growth 
factors (FGF-1 and FGF-2, TGFβ, IGF-1) and other inflammatory mediators (metabolites 
and nitrous oxide) (Baum and Duffy, 2011. Hence, myofibroblast transition is mediated 
both by mechanical stimuli as well as inflammatory signaling (Baum and Duffy, 2011; 
Kawaguchi et al., 2011; Schroer and Merryman, 2015; Tomasek et al., 2002; Travers et al., 
2016) (Figure 1-6). 
The role of TGFβ in this process is best understood (Baum and Duffy, 2011; Tomasek et 
al., 2002) (see also 1.3). Other important mediators include connective tissue growth factor 
(CTGF) and growth factors of the PDGF family (Travers et al., 2016). Integrins are 
furthermore involved in the regulation of TGFβ signaling (Thannickal et al., 2003), thus 
connecting mechanical and paracrine signaling in the myofibroblast response (Travers et 
al., 2016). TGFβ was shown to drive myofibroblast transition followed by enhanced 
collagen production and secretion (Petrov et al., 2002). TGFβ also boosts α-SMA expression 
and thereby contractility in fibroblasts (Hinz et al., 2001). It has furthermore been shown 
that myofibroblast specific expression of periostin is a consequence of TGFβ signaling and 
mechanical stretch (Kanisicak et al., 2016; Kaur et al., 2016; Snider et al., 2009), and 
periostin itself also regulates fibroblast to myofibroblasts conversion and boosts 
contractility (Elliott et al., 2012; Norris et al., 2007). 
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Myofibroblasts upregulate α-SMA (Baum and Duffy, 2011; Hinz et al., 2001; Tomasek et 
al., 2002) and embryonic smooth muscle myosin heavy chain (Frangogiannis et al., 2000; 
Shiojima et al., 1999) during the transition process. This allows for the development of an 
elaborate cytoskeleton which is connected via the fibronexus adhesion complex to 
fibronectin in the ECM (Baum and Duffy, 2011; Tomasek et al., 2002). Through these, 
contractile forces can be transmitted from myofibroblasts to the surrounding ECM. This 
contractile system also integrates ECM stretch and compression into intracellular signals, 
allowing the integration of mechanical signaling (Tomasek et al., 2002) (see also Figure 
1-6). 
As a consequence of myofibroblast transition, detrimental changes in ECM integrity, 
turnover and thus viscoelasticity result (Tomasek et al., 2002) (Figure 1-6). It could for 
instance be demonstrated, that expression of collagen III is upregulated upon both static 
and cyclic mechanical stretch (Carver et al., 1991). It has been hypothesized that under 
such conditions collagen III deposition would provide more elasticity while collagen I 
provides rigidity (Sullivan and Black, 2013). It has also been shown that increased matrix 
stiffness leads to enhanced gel contraction by myofibroblasts (Galie et al., 2011). To 
transmit mechanical stress, myofibroblasts preferentially express OB-cadherins in 
adherens junctions which can transmit stronger forces than N-cadherin found in CMs and 
resident cardiac fibroblasts and acts itself as a fibrotic stimulus enhancing transitions 
(Schroer and Merryman, 2015). Myofibroblasts furthermore respond to high strain as a 
result of ECM breakdown (Figure 1-6) (Schroer and Merryman, 2015; Travers et al., 2016). 
Concurrent with higher secretion of ECM components, cardiac myofibroblasts secrete 
more MMPs, which further degrade ECM, (left side, Figure 1-6) (Schroer and Merryman, 
2015; Travers et al., 2016). 
Collectively, prolonged activation of cardiac fibroblasts and transition to myofibroblasts 
thus lead to progressive stiffening and local changes in ECM strain that further enhance 
the myofibroblast response in a positive feedback loop (see in summary Figure 1-6). 
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Figure 1-6 Myofibroblasts modulate and respond to viscoelastic stimuli 
Fibroblast-to-myofibroblasts conversion is a highly regulated and complex process that depends on the 
integration of many environmental stimuli. Once activated, myofibroblasts secrete proinflammatory and 
profibrotic factors. These will recruit inflammatory cells and stimulate some hematopoietic progenitors to 
undergo fibrocyte differentiation. Myofibroblasts degrade ECM with the aid of MMPs to allow for cell 
migration and simultaneously also deposit new ECM with specific characteristics to replace the injured tissue. 
The myofibroblasts conversion process and myofibroblasts activity are highly mechanosensitive. An increase 
in myofibroblasts abundance typically leads to progressive stiffening of the ECM and matrix remodeling by 
MMPs leads to localized increase of strain. These changes in ECM viscoelastic further activate fibroblasts to 
undergo transition into myofibroblasts. Adapted from the reviews of (Schroer and Merryman, 2015; Travers 
et al., 2016). 
1.5 Towards better in vitro models of the myocardium  
The study of cellular crosstalk in the endogenous myocardium is intrinsically difficult 
through the complex interplay of various cell types, direct cell-cell contacts, the presence 
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of countless soluble mediators and the indirect control of cellular behavior by the ECM. 
Thus defined, yet physiological, fibroblast-CM coculture systems are necessary to simplify 
the study of the endogenous myocardium. 
1.5.1 Limitations of 2D in vitro models for the study of fibroblasts 
While the healthy human myocardium is estimated to be of 10 kPa, the stiffness of fibrotic 
heart undergoing failure is of 40-100 kPa. However, in standard 2D culture system 
substrate stiffness range in the GPa magnitude (Herum et al., 2017). Thus, it remains 
difficult to study fibroblasts in vitro, as 2D cell cultures on stiff non-physiological surfaces 
do not recapitulate the 3D environment of these cells in vivo. Artifical 2D culture systems 
thus effectively simulate a pathological environment not comparable to that of resident 
cardiac fibroblasts found in the healthy heart. These prerequisites have to be taken into 
account when interpreting findings from such studies, as the culture of cardiac fibroblasts 
in 2D quickly results in fibroblast-to-myofibroblast conversion (Petrov et al., 2002; Rhee, 
2009; Soares et al., 2012). This limitation can be overcome by culturing fibroblasts in 3D 
hydrogels, for example as Engineered Connective Tissue (ECT) (Figure 1-7 A; C). Here, 
low α-SMA expression is indicative for a stable fibroblast phenotype (Figure 1-7 D). While 
fibroblasts in 2D require serum supplementation to survive, 3D ECT cultures can be 
maintained long-term serum-free (Figure 1-7 B), allowing in vitro testing under highly 
standardized conditions. 
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Figure 1-7 Conservation of fibroblast state in engineered connective tissue 
Fibroblasts survive long-term in 3D tissue cultures under serum-free conditions: A Schematic of fibroblast 
standard 2D cultures vs fibroblasts 3D cultures within collagen I hydrogels under serum-free conditions (ECT) 
B Viability of cells after enzymatic digestion of 4-week-old tissues maintained under serum-free conditions, 
containing both CMs and HFFs (EHM), CMs or only HFFs (ECT). n=3/3/3. C ECT morphology and detailed 
histological analysis (Procollagen, red, F-actin in green and nuclei in blue). Scale bar 100 µm. D SMA+ median 
fluorescence per cell (AU: arbitrary units) in fibroblasts isolated for flow cytometry from 2D and 3D culture 
(ECT); n≥3/group. *p<0.05 by unpaired, two-sided Student t-test). C and D: data from (Grishina, Elina, 2017). 
1.5.2 Engineered Heart Muscle (EHM) 
It has now become clear, that mutations in genes of the CM contractile apparatus and 
calcium handling machinery that underlie cardiomyopathies (Herman et al. 2012, 
Streckfuss-Bömeke et al. 2017) also affect cellular crosstalk of CMs with cardiac 
fibroblasts resulting in their proliferation and the excessive secretion of ECM 
(Teekakirikul et al., 2012). During neonatal to adult development, both CMs and non-
myocytes in the myocardium undergo vast transcriptional changes. This is contrasted 
after MI; while CM transcription remains fairly quiescent, the fibroblast population gets 
transcriptionally reactivated into a neonatal and proliferative state (Quaife-Ryan et al., 
2017). A better understanding of cardiac fibroblasts as to their pathophysiological role, 
may help to define novel therapeutic targets for HF treatment. Studying this in a human 
heart muscle model composed of defined CM and fibroblast populations in a “physiological” 
collagen environment, such as provided by EHM (Tiburcy et al. 2011, Tiburcy et al. 2017) 
may be instrumental. 
1.5.2.1 EHM recapitulates bona fide heart development and allows the in-depth 
analysis of fibroblast-cardiomyocyte crosstalk 
The introduction of human PSCs (Takahashi et al., 2007; Thomson et al., 1998) has 
enabled the translation of rodent models of heart muscle engineering (Tiburcy et al., 2017; 
Zimmermann et al., 2002) to the human. The required minimum cellular components for 
the generation of functional human EHM are PSC-derived CMs with either endogenous 
mesenchymal stroma cell “contaminants” or the supplementation with defined fibroblast 
populations (Soong et al., 2012; Streckfuss-Bomeke et al., 2013; Tiburcy and 
Zimmermann, 2014; Tiburcy et al., 2014, 2017) (Figure 1-8). 
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Figure 1-8 Engineered Heart Muscle 
The minimal requirements for functional EHM generation are a mixture of PSC-derived cardiomyocytes and 
fibroblasts in a collagen hydrogel. The cell matrix mixtures are cast into molds to establish the desired 
geometries. Other cell types, matrix components, and culture medium supplements may be added. 
CMs and fibroblasts suspended in collagen type I hydrogel co-consolidate in casting molds 
with the desired geometry. We prefer circular EHM geometries to allow for robust dynamic 
loading on central silicone poles (Figure 1-9). 
 
Figure 1-9 EHM generation and temporal development 
EHM hydrogels undergoes rapid consolidation within hours after casting. After 72 h maximally, 
condensed EHM are transferred onto dynamic stretchers to facilitate auxotonic contractions and 
support organotypic maturation. (Images from (Tiburcy et al., 2014, 2017). 
EHM recapitulates the development of bona fide human myocardium (Soong et al., 2012; 
Tiburcy et al., 2014, 2017) and can be used to study cardiac disease phenotypes (Borchert 
et al., 2017; Long et al., 2018; Streckfuss-Bömeke et al., 2017, 2017; Tiburcy et al., 2017). 
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EHM exhibit organotypic properties of postnatal human myocardium such as registered 
sarcomeres with M-bands, physiological responses to load (Frank-Starling mechanism) 
and pacing (Bowditch phenomenon) as well as a transcriptome profile indicating advanced 
maturation. By precise supplementation with fibroblasts, EHM can be used to define the 
role of these cells for heart muscle assembly and function (Tiburcy et al., 2017). This 
includes the investigation of distinct CM and fibroblasts pathologies and their impact on 
integrated heart muscle function (Figure 1-10), effectively closing the bridge between 
complex, yet difficult to transfer, in vivo animal models and highly artificial 2D human 
cell culture systems. 
 
Figure 1-10 Possible in vitro application of EHM 
A EHM recapitulate native myocardial development and can be subjected to a number of standard and 
advanced assays for deep phenotyping. B Disease modeling: EHM can be generated from IPS-derived 
cardiomyocytes and fibroblasts as well as from primary fibroblasts to assess cell specific phenotypes, which 
may ultimately allow for cell-type specific targeting of innovative therapeutics. 
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1.5.2.2 EHM can be used in vivo to replace damaged myocardium 
EHM can be used as a regenerative source of myocardium for clinical application (Figure 
1-11). Its beneficial effect has been demonstrated in a MI model of rats (Zimmermann et 
al., 2006) and is currently being investigated in larger animal models. For that, suitable 
fibroblast sources must be identified. 
 
Figure 1-11 EHM as a regenerative therapeutic for cardiovascular disease 
A Schematic geometry of an EHM tissue patch for implantation. B Patch can be implanted onto the injured 
myocardium. C Comparison of different EHM types and sizes (from left to right: small human EHM for 
pharmacological screening/ multi-loop fusions and patches for heart repair applications (taken from (Tiburcy 
et al., 2017)). 
1.6 Hypotheses to be tested 
The following overarching hypothesis was investigated: 
Fibroblasts, by controlling the extracellular environment, are key for heart 
muscle assembly and homeostasis. 
Specific aims of the thesis are summarized below: 
1) Define the impact of fibroblasts on ECM/EHM compaction. 
2) Define the viscoelastic properties of EHM. 
3) Comparative analysis of different fibroblast species as to their cardio-instructive 
properties. 
4) Modeling of fibroblast-CM specific interactions in physiological and disease models. 
5) Defining suitable fibroblast sources for in vitro modeling and clinical application. 
6) Development of chemically defined culture conditions for EHM. 
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2 Materials and methods 
2.1 Cells 
Table 2-1 List of cells 
2.1.1 Ventricular cardiac fibroblasts from Lonza 
Cardiac fibroblasts from ventricular myocardium were obtained from Lonza (CFB). All 
were from non-failing hearts: CFB1: 50-year-old male, CFB2: 45-year-old male, CFB3: 52-
year-old-male. CFB3 was used as a healthy control in DCM disease modeling study. 
Cell type Abbreviation 
in protocols 
Source Used for 
HES2 RFP RFP+ Kindly provided by Gordon Keller 
(Irion et al., 2007) 
CM 
production 
hES2 HES2 (Reubinoff et al., 2000) CM 
production 
Human neonatal foreskin 
fibroblast 
HFF  
 
ATCC SCRC-1041 Feeders, 
EHM 
Ventricular CFB 
vCFBv26025  
CFB1 Lonza, NHCF-V Human Cardiac 
Fibroblast- Ventricular CC2904 
EHM 
Ventricular CFB 
vCFBv25981  
CFB2 Lonza, NHCF-V Human Cardiac 
Fibroblast- Ventricular CC2904 
EHM 
Ventricular CFB 
vCFBv27741  
CFB3 Lonza, NHCF-V Human Cardiac 
Fibroblast- Ventricular CC2904 
EHM 
Gingiva fibroblast  Patient  
B3 (GFB1),  
6A (GFB2),  
10A (GFB3),  
11A (GFB4) 
Kindly provided by Dirk Ziebolz Clinic 
for Cariology, University Medical 
Center (Präventive Zahnmedizin, 
Parodontologie und Kariologie) 
(Ethics votum: 16/6/09)  
EHM 
DCM CMs from patient DCM CMs Kindly provided by Katrin Streckfuß-
Bömeke (Ethics votum: Az 21/1/11) 
EHM 
DCM control CMs CTR CMs Kindly provided by Katrin Streckfuß-
Bömeke (Ethics votum: Az 21/1/11) 
EHM 
DCM CFBs from patient DCM CFB Kindly provided by Katrin Streckfuß-
Bömeke (Ethics votum: Az 21/1/11) 
EHM 
Human embryonic kidney 
SV40 transformed cells 
TSA Sigma 96121229 Plasmid 
validation 
and virus 
production 
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2.1.2 Dilated cardiomyopathy modeling study 
Cells from a DCM patient (45-year-old male) and a healthy control donor (39-year-old 
female) were provided by Dr. Katrin Streckfuß-Bömeke. The patient underwent heart 
transplantation with an ejection fraction of ~20%. Cardiac fibroblasts (DCM CFBs) were 
prepared by Steffen Köhne from the ventricle of the DCM patient’s heart. 
Skin fibroblasts from the DCM patient were derived from punch biopsies. For 
reprogramming according to the Yamanaka protocol (Takahashi et al., 2007) using non-
integrative Sendai virus, skin fibroblasts of DCM patient and blood of the healthy control 
were used, respectively. Biopsy cultures, reprogramming, IPS cell culture and CM 
derivation were carried out as described previously (Borchert et al., 2017). DCM CFBs 
were maintained in FGM3 medium (Lonza). 
2.1.3 Standard cell culture conditions 
All mammalian cells were grown at +37°C, 5% CO2 and 21% O2. 
2.1.4 Human embryonic kidney SV40 transformed cells  
Human embryonic kidney SV40 transformed cells (TSA) were maintained in Dulbecco’s 
Modified Eagle Medium (DMEM) containing 10% fetal calf serum (FBS), 100 U/ml 
penicillin, 100 µg/ml streptomycin (P/S) and 2 mmol/L L-Glutamine (Gibco). TSA cells 
were used for the validation of plasmids via transfection (Turbofect) and the production of 
lentivirus containing target plasmids (2.3). 
2.1.5 Ethics statement 
The import and use of human embryonic stem (hES) cells was approved by the Robert-
Koch-Institute (www.rki.de; approval #12 from 13.09.2005) to W.H. Zimmermann 
according to §11 Embryonic Stem Cell Act. The use of human cell material was approved 
by the responsible ethics committee (refer to Table 2-1). 
2.1.6 Cell culture, maintenance and stock preparation 
All cells were cultured as in Table 2-2. For detailed culture media and ingredients see 
A2.6. 
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Table 2-2 Overview of standard culture media for cells and tissues 
For a detailed description of all used ingredients, buffers and media preparations, see 
A2.6. 
2.1.7 Derivation of human gingiva fibroblasts from biopsies 
Gingiva surgical leftovers were collected by Dr. Dirk Ziebolz (Clinic for Cariology, 
University Medical Center, Göttingen). Samples were provided at 4 °C within 24 h of 
harvest to the Institute of Pharmacology and Toxicology after pseudonymization. All 
samples were derived from healthy donors between 16 to 30 years of age. GFB 1,2,3 were 
derived from females, GFB4 from a male subject. 
Tissue was washed in PBS containing P/S and 1% Fungizone (2.5 µg Amphotericin B and 
2.05 µg sodium desoxycholat per ml; all Gibco). Tissue was cut into small pieces and placed 
on a 10 cm cell culture dishes coated with 25 µg/ml Synthemax II (Corning; see also A2.6). 
Per tissue piece, 5-10 µl of FBS were dropped onto the dish and tissue pieces were 
incubated in the drops to facilitate adhesion to the culture dish for 30 min at 37 °C and 
5% CO2. Then, HFF medium (A2.6) containing fungizone was added carefully and tissues 
left to adhere for 48 h. After 48 h, medium was changed. Generally, within 2 d, first 
epithelioid cell outgrowth could be observed, followed by fibroblasts on the edge of colonies. 
Epithelioid cells would die off within a week and fibroblast cells could then be subcultured 
Cell type Medium Culture conditions 
Primary fibroblast cardiac FGM3 medium (Lonza), 
supplemented with FGM3 bullet 
kit 
Uncoated 
Primary fibroblast skin HFF Medium Uncoated 
Primary biopsy HFF Medium Synthemax coated dishes 
HES2 cell HES2 Medium HFF feeders 
PSC derived CM CM Basal medium Coated, Matrigel or Synthemax 
CMs during selection Selection Medium Coated, Matrigel or Synthemax 
TSA cells TSA Medium Uncoated 
EHM- coculture of CMs and 
fibroblasts (2:1) in collagen 
EHM Medium: Serum-free 
maturation medium (SFMM) 
+TGFβ1 culture days 1- 3  
-TGFβ1 culture days 4- 28 
ECT- fibroblasts in collagen  EHM Medium: Serum-free 
maturation medium (SFMM) 
+TGFβ1 culture days 1- 3  
-TGFβ1 culture days 4- 28 
CMs in collagen  EHM Medium: Serum-free 
maturation medium (SFMM) 
+TGFβ1 culture days 1- 3  
-TGFβ1 culture days 4- 28 
Materials and methods 
24 
onto standard cell culture dishes without special coating. For further culture, see next 
section. 
2.1.8 Standard cell culture techniques 
2.1.8.1 Cell dissociation 
Cells (fibroblasts and TSA cells) were washed one time with PBS and then incubated with 
TrypLE (Table 2-3) for 3-7 min, depending on cell type and confluence at 37°C and 5% 
CO2. Cells were then gently dissociated from plates with standard growth medium and 
collected into a 50 ml tube for counting and seeding. For standard subculture, cells were 
also transferred directly to new culture flasks. 
Table 2-3 Volumes for cell dissociation 
2.1.8.2 Passaging 
Cells were passaged according to confluence and experimental needs in ratios of 1:4 to 1:6. 
2.1.8.3 Freezing 
If not indicated otherwise, cells were dissociated by enzymatic digestion (TrypLE), 
resuspended in standard growth medium and counted. Cells were pelleted by 
centrifugation at 300 g (Heraeus Cell Culture Centrifuge; Thermo Scientific) for 5 min at 
room temperature and resuspended in FBS containing 10% DMSO (Sigma). Cells were 
transferred into cryovials (Invitrogen) and frozen at -80°C utilizing a freezing aid (Mr. 
Frosty, Nalgene). Subsequently, cells were transferred into a -152 °C deep freezer 
(Herafreeze) or the vapor phase of a nitrogen long-term storage device (Askion). Cryo-
culture vials were labeled as indicated in Table 2-4. 
 
Culture plate size Volume (V) of TrplE used for dissociation 
6- well 750 µl 
T25 1 ml 
T75 2.5 ml 
T175 6 ml 
Materials and methods 
25 
Table 2-4 Labeling of cryovials 
2.1.9 Standard culture and passaging of TSA 
TSA cells were maintained in DMEM with 10% FBS and P/S. Cells were subcultured at 
ratios of 1:4 (for transfection) to 1:20 for standard maintenance, according to cell 
dissociation protocol (see previous section 2.1.8). 
2.1.10 Human feeder cells 
HFF were maintained in DMEM with 10% FBS and P/S. HFF were irradiated with 30 
Gray (Gy) γ-irradiation (STS Biobeam 8000, Germany) and plated at 2.500 cells/cm2 to 
serve as feeder layer for HES2 cultures. 
2.1.11 Culture of human embryonic stem cells 
HES2 cells were kept on feeder layers of irradiated HFF cells in HES medium (Table 2-2, 
A2.6) and grown to 80-90% confluency. For passaging, HES2 were washed once with PBS 
and then incubated with TrypLE at 37 °C for 3 min. Cells were resuspended in HES 
medium, centrifuged at 200 g for 4 mins and finally replated in HES medium. 
2.1.11.1 Derivation and culture of CMs from HES2 cells 
CM differentiations were routinely performed by the technical staff of the Institute of 
Pharmacology and Toxicology according to a standard operating procedure (Tiburcy et al., 
2017). In short, pluripotent stem cells were transferred from irradiated HFF feeder 
cultures onto Matrigel (1:120) for 96 h at 4.000-25.000/cm2 in TESR-E8 medium (Stemcell 
Technologies) with 5 µmol/L ROCK-inhibitor (ROCKi, Y27632 Stemolecule). Mesodermal 
differentiation was induced by a combination of CHIR (CHIR99021, Stemgent), BMP4 
(R&D systems), FGF-2 (Stemgent) and Activin A (R&D systems) (Table 2-5). After 72 h, 
the Wnt antagonist IWP4 (Stemgent) was used to induce cardiac specification (Table 2-5), 
followed by cardiac maturation in CM basal medium. CMs were then metabolically 
selected by the use of lactate in the absence of glucose (Table 2-2, A2.6) to obtain high 
purity CM cultures (flow cytometry for α-actinin: 95±2% n=3) for EHM generation. Cells 
 Cell 
type 
P number Frozen by Date Vial 
content 
Number/Amount of 
vial frozen 
Example HFF  19 SS 19.10.2017 3 X 106 2/5 
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during differentiation and the resulting CMs were maintained in CM basal medium (Table 
2-2, A2.6) until use. 
Table 2-5 Small molecules for cardiac differentiation 
2.1.11.2 CM dissociation 
CMs were washed twice with PBS and then incubated with Accutase dissociation solution 
(A2.6) for 10 min at room temperature (RT) followed by up to 15 min at 37°C, 5% CO2, 
until cells were visibly detaching. Cells were resuspended in CM recovery medium, 
containing 5 µmol/L ROCKi. For replating, cells were centrifuged at 300 g for 5 min and 
resuspended in CM basal medium (A2.6) without ROCKi. Cells were then transferred onto 
coated plates (Matrigel 1:120 or Synthemax at 25 µg/ml). Medium was changed 24 h post 
plating. 
2.1.12 Derivation of stroma cells from embryonic stem cells 
Culture dishes were coated with laminin-521 (Biolamina) (A2.6) at least 24 h before 
plating. For that, the stock was diluted to 2.5 µg/ml with PBS (+ Ca2+/Mg2+). HES2 cells 
were plated at 1.3 x 104/cm2 suspended in E8 medium containing 5 µmol/L ROCKi on 
laminin coated T75 flasks. Medium was changed daily and after 4 d, cells were treated 
with freshly prepared MIM10B medium for 3 more days, followed by cardiac 
differentiation medium at d 7 and d 9 (all media in A2.6). On d 10 of culture, cells were 
subsequently replated onto laminin-coated cell culture flasks in stromal cell specification 
medium (StC-SM) (A2.6) at 1.25 x 104/cm2 and medium changed 24 h, 48 h and 96 h later. 
On day 15, cellular morphology was controlled for epithelial/epicardial cell shape and StC-
SM Medium changed. 2 d later, medium was changed to FGM3 medium and cells grown 
to 90% confluence followed by passaging/freezing. Ready stroma cells were provided by 
technical assistants. 
Mesoderm induction  
CHIR 1 µmol/L 
Activin A 9 ng/ml 
FGF-2 5 ng/ml 
BMP4 5 ng/ml 
Cardiac specification  
IWP4 5 µmol/L 
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2.2 Engineered heart muscle (EHM) 
2.2.1 Cell dissociation and casting 
EHM input fibroblast and CM populations were detached using enzymatic treatment. 
Fibroblasts were washed once with PBS and then incubated with TrypLE until cells 
detached from cell culture surfaces. Cells were resuspended in CM medium and counted 
(2.1.8, all media in detail in A2.6). CMs were washed twice with PBS, followed by 
incubation with Accutase cell dissociation solution (A2.6) for 10 min at RT and then 15 
min at 37 °C and 5% CO2. CMs were collected in CM basal medium containing 5 µmol/L 
ROCKi (A2.6) and then counted. Cells were mixed in a defined ratio (in total 1.275 x 106 
cells (CM:HFF 2:1), centrifuged at 300 x g and RT, and resuspended in serum-free 
maturation medium (SFMM) (Table 2-2 and A2.6) containing TGFβ at 1 ng/ml. During 
centrifugation, the collagen master mix was prepared on ice (Table 2-6). Resuspended cells 
were mixed with the master mix and casted into EHM molds. Fresh EHM were incubated 
for 1 h at 37 °C, 5% CO2 and thereafter SFMM containing TGFβ was added to the tissue 
molds. Medium was changed 24 h after casting and after 3 d EHM were transferred, using 
forceps, to auxotonic stretchers (A2.5) into a 24-well format containing SFMM (without 
TGFβ). 
Table 2-6 EHM hydrogel preparation 
For 4 EHM/450 µl tissue 
Master Mix (Collagen) Batch 1  
(6.49 mg/ml) 
Lot 17CSA03 
Batch 2 
(6.1 mg/ml) 
Lot 15CSA02 
 V (µl) V (µl) 
Collagen I (Collagen Solutions) 284 305 
2X RPMI 284 305 
0.1 mol/L NaOH 53 57 
Total 621 667 
Ready EHM hydrogel   
Master Mix collagen +  665 667 
Cells in SFMM (+ TGFβ) 1435 1433 
Total* 2100 2100 
Volume (V) used per EHM/tissue 450 450 
*Note that this recipe contains 300 µl additional hydrogel V to compensate for the loss 
during pipetting of viscous solutions. The cell input is thus 4 x 106 CMs and 2 x 106 HFFs 
for 4 standard EHMs. 
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2.2.2 EHM culture 
EHM were kept in culture for 4 weeks until isometric force measurement. During this 
time, pharmacological treatment took place. Spontaneous beating was assessed by 
counting beats in a 10 s timeframe on a 37 °C heating plate under a binocular. 10 s values 
were extrapolated. To avoid temperature dependent bias, EHMs were sampled at random 
on the plate. 
2.2.3 Generation of engineered connective tissues  
Engineered connective tissues (ECTs) were generated from HFFs and cultured as 
described for EHM previously, omitting the use of CMs. The total cell count thereby was 
4.25 x 105 /tissue. 
2.2.4 Collagen I hydrogels for rheology measurements 
For both shear plate rheology and destructive tensile stress measurements, cells were 
prepared as described for EHM generation. Tissues were generated from collagen, CMs 
(8.5 x 105 cells/tissue) and HFFs (4.25 x 105 /tissue). Hydrogels with both CMs and HFF 
(2:1) contained a total of 1.275 x 106 cells (CM: HFF 2:1), all in 450 µl total V/tissue. For 
gels without cells, only SFMM medium was used. 
We used two different batches of collagen I (Table 2-6) during this work, which differed in 
their consolidation properties both on an absolute scale, as well as on a temporal scale (for 
comparison, see supplementary results section in A1). 
Table 2-7 Experiments and corresponding collagen I batches 
Experiment Batch  Samples taken (time) 
Shear plate rheology, time sweep 1  - 
Shear plate rheology, time sweep 2 - 
Cell morphological analysis 2 Cell-independent phase at: 30 min 
Cell-dependent phase at: 90 min 
RNA sequencing 2 Cell-independent phase at: 30 min 
Cell-dependent phase at: 90 min 
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2.2.5 Replacement of B27 
Table 2-8 Minimal component supplementation 
Preparation of minimal supplementation component for EHM culture 
Supplementation was prepared as 25X stock. For that, human serum albumin (HSA, 200 
g/ml; Baxalta) was diluted to a final concentration of 125 mg/ml or 50mg/ml for treatments. 
In the case of supplementation based on recombinant HAS (rHSA), rHSA (Sigma) was 
first dissolved in 0.9% NaCl solution. Other reagents were prepared as stock solutions 
according to (Table 2-8) and added to a final concentration of 25X or directly weighted in 
as powder and supplemented. The reagents were left over night at 4 °C to dissolve and 
were then mixed well and sterile filtered, followed by aliquoting and freezing at -20°C. 
Reagents were partially chosen based on the protocols published by the HANNA lab 
(adapted further from (Gafni et al., 2013), Weizmann Institute of Science), which can be 
accessed at https://hannalabweb.weizmann.ac.il/. 
Reagent Manufacturer Cat/PZN Stock in 
0.9% 
NaCl 
solution 
Final 
concentration 
in 25X CMR 
Final 
concentration 
in medium 
Human serum 
albumin (HSA) 
Baxalta (200g/l) 11128714 - 50/125 mg/ml 2/5 mg/ml 
Human 
recombinant 
albumin (rHSA) 
Sigma A9731-
10G 
- 12.5/50/125 
mg/ml 
0.5 /2 /5 mg/ml 
Holo- transferrin 
(Tra) 
Sigma T0665-
100MG 
5 mg/ml  250 µg/ml 10 µg/ml 
Sodium selenite 
(SodSel) 
Sigma S9133-
1MG 
1 mg/ml 0.8 µg/ml 0.032 µg/ml 
T3 Sigma T6397-
100MG 
2 mg/ml 0.1 µg/ml 0.004 µg/ml 
Liothyronin, 
Thyrotardin (T3) 
Sanofi 50885.00.0
0 
- 0.1 µg/ml 0.004 µg/ml 
Ethanolamine 
(Etha) 
Sigma E9508-
100ML 
- 0.05 µg/ml 0.002 µl/ml or 2 
µg/ml 
L-Carnitine (L-
Car) 
Sigma C0283-1G - 100 µg /ml 4 µg/ml 
Dexamethasone 
(Dexa) 
Fortecortin 
(Merck) 
81961  4 mg/ml 330 ng/ml 16 ng/ml 
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2.2.6 EHM dissociation 
In order to dissociate EHM (and ECT), EHM were incubated in a 48-well format with 300 
µl collagenase solution for up to 2 h at 37°C (airbath). The supernatant was subsequently 
collected in a 1.5 ml tube. EHM were washed once with 300 µl PBS containing 5% FBS, 
which was also collected into the tube on ice. Then, EHM were incubated up to 45 min 
with Accutase cell dissociation solution (A2.6). EHM were triturated and cells transferred 
into the tube. Wells were washed with PBS containing 5% FBS. The wash solution was 
also collected. The collected cell suspension was finally centrifuged at 4°C and 300 g for 5 
min and resuspended into 950 µl PBS containing 5% FBS (resulting in a total V of 1 ml). 
50 µl were used for cell counting using a CASY cell counter (Roche). The remaining cell 
suspension was centrifuged once more and resuspended either in ice cold 70% ethanol 
(EtOH) or 4% formaldehyde (FA)/PBS (Roti Histofix) for fixation. 
2.2.7 Irradiation of EHM 
EHM at culture day 3 were irradiated with 30 Gy (γ-irradiation, STS Biobeam 8000, 
Germany) in 50 ml sterile polypropylene tubes with SFMM. 
2.3 Genetic modification of cells 
2.3.1 Transfection of TSA cells 
TSA cells were subcultured when 90% confluent in a 1:4 ratio (see 2.1.9). 24 h after 
seeding, cells were transfected with Turbofect reagent (ThermoScientific) according to 
manufacturer´s protocol. Briefly, plasmid DNA (0.18 µg/cm2) was diluted in DMEM with 
P/S and Turbofect (0.35 µl/cm2) added (final V of suspension 7 µl/cm2). The solution was 
vortexed and centrifuged briefly and then incubated at RT for 30 min. Transfection mix 
was then added to cell culture medium. 6 h post transfection medium was changed for 
regular TSA medium (Table 2-2). Transduction was confirmed by fluorescence microscopy 
(GFP) 24-48 h after transfection. Selection based on antibiotic resistance (puromycin) was 
usually carried out 48 h post transfection. 
2.3.2 Production of Lentivirus 
TSA cells were transfected with target plasmids and plasmids encoding for lentiviral 
envelope and packaging proteins (psPAX2 and PMD.2 by Addgene, see A2.7) in TSA 
medium (A2.6). 6 h after transfection medium was replaced. After 48-72 h supernatants 
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containing lentiviral particles were collected, sterile filtered (0.2 µm) and applied directly 
at 1:1 to 1:4 V/V ratios for transduction of target cells together with polybrene 
(Hexadimethrine bromide, Sigma) solution at a final concentration of 8 µg/ml to enhance 
transduction. Transduced cells were selected in the presence of puromycin (0.6 µg/ml; 
Gibco) for at least 72 h. 
2.4 DNA manipulation 
2.4.1 Cloning of HAS2-Flag 
A lentiviral vector (Cumate-pLenti-Cloning-SV40-GFP; iCu2040584) encoding for the 
hyaluronan synthase 2 (HAS2) without a STOP codon (HAS2-noSTOP) was purchased 
(AbmGood). The HAS2-noSTOP sequence was PCR-amplified with primers containing 
specific restriction sites (NheI/BamHI) to facilitate cloning. PCR products were first 
size-verified by agarose gel electrophoresis and purified using the PCR cleanup kit by 
MachereyNagel according to manufacturer´s recommendations. Thereafter, products 
were controlled by Sanger sequencing (SeqLab, Göttingen; primers see A2.3). Target 
plasmids and inserts were both digested with NheI and BamHI (New England 
Biolabs). Restriction products were extracted after agarose electrophoresis and ligated 
over night at 4 °C (Table 2-11). Up to 5 µl of ligation reactions were used to transform 
50 µl of competent bacteria (TopTen). Clones were picked with a pipet tip and first 
duplicated onto a clonal plate followed by colony PCR. For that, the tip with bacteria 
were immersed in Thermus aquaticus (Taq) polymerase ready mix (NipponGenetics), 
containing appropriate primers for HAS2 (A2.3), and PCR was carried out according 
to Table 2-9. Clones that were positive for the target insert were amplified in 5 ml LB 
broth. 4 ml of LB were used for DNA extraction using the MiniPrep kit of Macherey 
Nagel. Correct insertion was verified by restriction digests and by Sanger sequencing 
(SeqLab, Göttingen). After verification, the remaining 1 ml LB was used to generate 
larger bacterial growth cultures and DNA was once more extracted using the Midiprep 
Kit (Macherey Nagel). Purified plasmids were used to transfect TSA cells together 
with pGIPZ-GFP to estimate transduction efficiency. Transgene expression was 
verified by western blot. For western blot, lysates of cells expressing the control 
protein IGFBP5-Flag was loaded to verify antibody specificity (A1). 
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2.4.2 PCR, restriction digest and ligation 
PCR was carried out using Thermus aquaticus (Taq) polymerase ready mix 
(NipponGenetics) (see Table 2-9). Optimal melting temperatures were adjusted according 
to the primer design or experimentally verified by gradient PCRs (52-64 °C). For colony 
PCR 66°C was used as melting temperature. PCR-products were Sanger sequenced 
(SeqLab, Göttingen) and analyzed using SerialCloner software (Open Source). 
Table 2-9 PCR 
PCR was started with an initial denaturation temperature of 95°C for 3 min followed by 
35 amplification cycles (denaturation at 95°C for 30 s, annealing at 52- 64°C depending on 
the primer pair, extending at 72°C for 1 min/kb) and finished with one round of final 
extension at 72°C (1 min/kb). 
Products and target plasmids were cut with restriction enzymes and dephosphorylated 
using alkaline phosphatase as described below (Table 2-10): 
Table 2-10 Restriction digest of plasmids and PCR products 
Reagent For 1X reaction (ul) 
2x FastGene mix 25 
Fwd primer 0.2 µmol/L 
Rev primer 0.2 µmol/L 
Template up to 250 ng 
H2O  Add to total V 
V total  50 
Reagent For 1X reaction (µl) 
Plasmid 
For 1X reaction (µl) 
Insert 
Restriction enzyme 1 1 1 
Restriction enzyme 2 1 1 
Alkaline phosphatase 1 - 
Fast digest buffer 2 1 
Plasmid DNA 1 µg - 
Insert DNA - 1 µg 
H2O 15 x V(plasmid) 7 x V (Insert) 
V total 20 10 
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Products were either purified directly (PCR cleanup, Macherey-Nagel) or via gel 
electrophoresis extraction (digested plasmids with inserts >100bp, gel extraction kit by 
Macherey-Nagel). Products were ligated as following: 
Table 2-11 Ligation scheme 
Incubation 4°C o.n. Products were then used for transformation of competent bacteria. 
2.4.3 Transformation and plating 
50 µl of competent Bacteria (TopTen, Thermo Fisher) per construct were thawed on ice 
and incubated with 10-50 ng plasmid DNA for 30 min. Cell suspensions were then heat 
shocked for 45 s at 42°C, cooled on ice for 2 min and then incubated with 450 µl Super 
Optimal broth with Catabolite repression (SOC) medium (Gibco) at 37°C shaking on a 
heatblock (Eppendorf). Cells were then plated on agar plates containing antibiotics 
(Ampicillin at 100 µg/ml or Kanamycin at 50 µg/ml). 
2.4.4 DNA preparation 
Bacteria were grown over night (o.n) at 37°C on agar plates. Colonies were picked and 
resuspended in 6 ml Lysogeny broth (LB) containing either Ampicillin (100 µg/ml) or 
Kanamycin (50 µg/ml). These cultures were grown o.n. at 37°C shaking at 300 rpm. 6 ml 
pre-cultures were either directly used for plasmid extraction using the Nucleospin mini 
Example: Plasmid 10 kb + insert 2 kb  
Required mass insert (g) =  
desired insert/vector molar ratio x mass of vector (g) x ratio of insert to vector lengths 
Ratio 1 to 3 1 to 5 1 to 7 1 to 10 
bp vector 10,000 10,000 10,000 10,000 
vector m (ng) 25 25 25 25 
vector c (ng/µl) 25 25 25 25 
vector V (µl) 1 1 1 1 
bp insert 2,000 2,000 2,000 2,000 
insert m (ng) 15 25 35 50 
insert c (ng/µl) 25 25 25 25 
insert V (µl) 0,6 1 1,4 2 
10x buffer (µl) 1 1 1 1 
T4 ligase (µl) 0.5 0.5 0.5 0.5 
H2O (µl) 6,9 6,5 6,1 5,5 
total V in µl 10 10 10 10 
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kit (Macherey-Nagel) or alternatively resuspended into a total V of 250 ml LB, incubated 
16 h at 37°C under constant shaking (300 rpm) and then used for larger yield plasmid 
preparation (Nucleospin Midi kit, Macherey-Nagel). Plasmids were eluted in provided 
elution buffer or water. 
2.4.4.1 Gel electrophoresis 
Agarose gels were prepared by dissolving agarose powder (Applichem) to 1% gels (1 g/ 100 
ml buffer), in Tris base with acetic acid and EDTA (TAE) buffer (A2.1). Per 100 ml of gel, 
8 µl of MidoriGreen (NipponGenetics) were added before the solution was poured into a 
gel casting system. 
2.5 Staining techniques 
2.5.1 Immunostaining (fluorescence) 
2.5.1.1 Monolayer 
Cells were fixed with 4% FA/ PBS (Roti Histofix) for 15 min RT and then washed with PBS 
(or stored at 4°C for several weeks in PBS) once before incubation with blocking buffer 
(A2.3). For intracellular antigens, permeabilization buffer (A2.1) was used, for 
extracellular proteins we used blocking buffer for surface proteins (A2.1) for 30 min at RT. 
Cells were then incubated o.n. with primary antibody (A2.3) in the appropriate blocking 
buffer at 4° C. The next day, cells were washed 3 times for 10 min, first with blocking 
buffer and then PBS, followed by incubation with secondary antibody (A2.3) and DNA 
staining reagent Hoechst 1:1,000 for 2 h at RT. After 3 more washes with PBS, cells were 
mounted using Fluoromount (SouthernBiotech). 
2.5.1.2 Tissue slices 
For EHM, that were embedded in Optimal Cutting Temperature (OCT) compound and 
had been sectioned, slides were thawed and air-dried for 30 min before applying a wax pen 
(liquid blocker super pap pen) to restrict the area of buffer on the objective plates. Slices 
were then treated and stained as described previously for monolayer cells. 
2.5.1.3 Whole mount 
Whole EHM were fixed in 4% FA/PBS overnight at 4°C and then washed/stored in PBS at 
4°C. Tissues were then incubated with 300 µl blocking buffer (A2.1) at RT for a minimum 
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of 8 h followed by incubation with the primary antibody (A2.3) at 4°C for 48 h. EHM were 
then washed 3 times for 2 h with PBS at RT, rocking and incubated with secondary 
antibodies (A2.3) and DNA stain Hoechst (Invitrogen) (A2.3) at 1:1000 for another 48 h at 
4°C. Finally, tissues were washed 3 times with PBS and mounted with Fluoromount 
(SouthernBiotech). Glass slides and coverslips were sealed after mounting with nail polish 
and stored at 4°C. 
2.5.2 Sirius red staining 
Tisses were fixed overnight with 4% FA and then underwent serial dehydration from PBS, 
H20, 70% EtOH, 80% EtOH, 96% EtOH (twice) to 100% EtOH (twice), 10 min each followed 
by toluol (Roth) twice for 15 min before embedding in paraffin (Roth). Tissues were 
sectioned (4 µm, Leica RM2255) and mounted on glass slides. 
For dewaxing, slides were left over night at 37 °C and then transferred into glass jars filled 
with graded EtOH concentrations (10 min of 100% EtOH twice, 96% EtOH twice, 80% 
EtOH, 70% EtOH, and then H2O). Thereafter, slides were submersed in Mayer's 
Hemalaun solution (AppliChem) for 5 min followed by washing under tap water for 10 min 
and then incubation with Picrosirius red solution (A2.1) for 1 h. Slides were washed twice 
with acetic acid (5% V/V glacial acetic acid in H2O) for 5 min, aqueous solution was 
removed thoroughly, and slides were then cleared in xylol (Roth) and mounted using Eukit 
(Roti Histokit II). 
2.5.3 Fluorescence and light microscopy 
Brightfield and fluorescence images were obtained with an Axiovert 200 equipped with an 
AxiCam MRc camera using Axiovision SE64 4.9.1 software (Zeiss). Confocal images were 
obtained on a Zeiss LSM710 using ZEN software (Zeiss). EHM images were taken with a 
Lumar binocular equipped with an AxiCam MRc camera using Axiovision SE64 4.9.1 
software (Zeiss). 
2.5.4 Flow cytometry 
2.5.4.1 Staining for fixed intracellular antigens 
Cells were pelleted at 300 x g for 5 min at 4°C. The supernatant was aspirated, the cells 
resuspended into blocking buffer (A2.1) and transferred into a round-bottom 96 well plate 
(Greiner). After 10 min incubation on ice, cells were centrifuged at 300 x g for 5 min at 4°C 
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and resuspended in 50 µl blocking buffer containing primary antibodies (A2.3). Cell 
suspensions were incubated 45 min on ice and then 150 µl of PBS were added, per well. 
Cells were then washed by centrifugation once more and resuspended in 50 µl blocking 
buffer containing secondary antibody and Hoechst 1:1,000 (Invitrogen; A2.3). After 30 min 
incubation on ice, 150 µl of PBS were added per well, cells were centrifuged, resuspended 
in blocking buffer and then spun down one more time before resuspension in 200 µl PBS. 
The suspensions were then transferred into flow cytometry tubes and samples were 
measured on a BD LSR II platform. Data was visualized using Flowing software 2.5.1 
(Perttu Terho, University of Turku, 2009). 
2.5.4.2 Flow cytometry of live CD90-FITC/GFP+/RFP+ cells 
For live staining, cells were resuspended in blocking buffer for surface antigens (A2.1), 
centrifuged once and then resuspended in blocking buffer with Sytox stain (Invitrogen, 
1:1,000; A2.3). Following incubation of 10 min at RT, cells were washed once with blocking 
buffer for surface antigens and finally, after centrifugation at 300 x g for 5 min, 
resuspended in PBS and measured directly. 
Gating strategy: Cell populations were first defined in Sideward Scatter (SSC) against 
Forward Scatter (FSC) view (Figure 2-1, A); live and dead cells were distinguished by the 
use of Sytox stain, which penetrates dead cells and causes a shift to the right in the 
Allophycocyanin (APC) channel (Alexa Fluor 633-conjugated) (Figure 2-1, B). The 
unshifted live cell population was then used to gate for positive and negative cells, by 
comparing unstained control cells and GFP+ or RFP+ test populations (as an example for 
GFP, Figure 2-1, C and D). 
 
Figure 2-1 Gating strategy for flow cytometry of live cells 
Example of gating for live FC of GFP analysis using appropriate controls with cells that do not express the 
construct. A SSC-A vs FSC-A gating to measure the full population of interest, followed by B gating for live 
cells using Sytox reagent (Thermo Scientific; dead cells are shifted to the right). Gating for GFP positive cells 
in C unlabeled control cells vs D GFP+ cells. 
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2.5.4.3 α-actinin 
Cells were stained for intracellular α-actinin (see protocol intracellular antigen staining 
for FC), using α-actinin antibody at 1:4,000 (Sigma, A2.3). 
Gating strategy: Cell populations were determined in SSC against FSC view. Then, 
individual cells were determined by analysis of DNA signal width (Pacific blue channel) 
vs SSC, followed by determination of specific α-actinin signal, using either Fluorescein 
isothiocyanate (FITC) (Alexa Fluor 488-conjugated secondary antibody) or APC channel 
(Alexa Fluor 633-conjugated secondary antibody) and an appropriate primary IgG control 
for every individual sample (A2.3). 
2.6 Photographs and videos 
Photographs and videos were taken with a digital camera (Sony, α X5000). 
2.7 Western blot 
2.7.1 Sample preparation, Bradford assay 
All steps were carried out on ice. Adherent cells were washed once with cold PBS. Cells 
were then incubated with ready protein lysis buffer (A2.1) (Bäuerle buffer with protease 
and phosphatase inhibitors, both Roche) and incubated for 5 min before collection of cell 
lysates using a cell scraper (200 µl/well of a 6-well plate). Lysates were collected into 1.5 
ml tubes and vortexed vigorously followed by incubation on ice for a minimum of 1 h. 
Lysates were then centrifuged for 30 min at 12,000 x g. The resulting supernatants were 
frozen and stored at -20°C. 
The concentration of protein in the lysates was determined using bovine serum albumin 
(BSA) assay. For that, BSA standards were prepared (0; 1; 2; 4; 8; 16 µg in 50 µl H2O). 
Standards and samples were diluted in 50 µl using H2O. Samples were distributed on a 
96-well plate (flat bottom, Greiner). 200 µl of 1X RotiQuant reagent (Thermo Scientific) 
were added per well and samples were incubated for 5 min at RT. Standards were 
prepared in duplicates, samples in triplicates. Absorbance at 595 nanometer (nm) was 
measured using the Flexstation® 3 Multi-mode microplate reader (Molecular Devices). 
Protein concentration was then determined using the standard curve generated from BSA 
(using R2 method in linear regression). 
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2.7.2 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
Gels for electrophoresis were prepared by mixing gel buffers, 10% Sodium dodecyl sulfate 
(SDS), polyacrylamide solution and water. To initiate polymerization, 10% Ammonium 
persulfate (APS) (Sigma) and Tetramethylethylenediamine (TEMED) (Roth) were added. 
The solutions were gently mixed and then poured into the Mini-PROTEAN® Tetra Cell 
(BioRad) hand-casting system. The concentration of polyacrylamide in protein gels was 
either 10% or 12% (Table 2-12). 
Table 2-12 SDS PAGE gels 
Equal amounts of protein (30-40 µg) were incubated with 6X Laemmli (A2.1) sample buffer 
for 5 min at 95°C, briefly centrifuged and followed by loading of the supernatant 
containing solubilized protein. As size standard, PAGE ruler prestained (Thermo 
Scientific) was used. Lysates were then separated by electrophoresis, 10 min at 80 V to 
cross the stacking gel followed by 1.5 h at 120 V through the separation gel, using the 
BioRad MiniProtean electrophoresis unit. 
2.7.3 Immunoblotting 
2.7.3.1 Transfer 
Polyvinylidene difluoride (PVDF) membranes (Protrean Bioscience) were prepared by 
activation in methanol, followed by a rinse in distilled H2O and transfer buffer (A2.1). 
Following gel electrophoresis, proteins were transferred via semi-dry blotting (transfer 
buffer containing 20% methanol (A2.1), using 120 mA for 1 h (6-20 V at the time, at 
Reagent (in ml) For 10% For 12% Stacking gel (4,4%) 
H2O 10.0 9.0 6.5 
40% Acrylamide 5.0 6.0 1 
Tris pH 8.8  5.0 5.0  
Tris pH 6.8   2.5 
10%SDS 0.2 0.2 0.1 
10%APS 0.2 0.2 0.1 
TEMED 0.008 0.008 0.01 
H2O 10.0 9.0 1 
    
V total 20 20 10 
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constant mA setting). Following transfer, membranes were briefly rinsed in H2O and then 
incubated while shaking with Ponceau solution (A2.1) for 2- 3 min. After rinsing with 
water, membranes were imaged using the ChemiDoc MP (BioRad) and the manufacturer´s 
software. Subsequently, membranes were incubated for 45 min in 5% milk/Tris buffered 
saline-Tween20 (TBST) (A2.1) to block unspecific binding of antibodies. 
2.7.3.2 Immunodetection 
Membranes were incubated with primary antibody (A2.3) o.n. at 4°C. The next day, 
membranes were washed 3 times for 10 min with TBST, following incubation with 
secondary antibody (A2.3) for 45 min at RT. After 3 more washes with TBST, each 10 min, 
binding of secondary horseradish peroxidase-conjugated antibodies was visualized by 
incubation with substrate solution (Supersignal West Femto/Thermo Scientific) in a 
ChemiDoc MP (BioRad). Obtained images were analyzed using ImageLab software 
(BioRad). Membranes were kept at -20°C. 
2.8 Hyaluronan enzyme-linked immunosorbent assay 
For HA determination, cells were washed twice with PBS before being incubated for 48 h 
with fresh growth medium. Then supernatant was collected, and HA content measured 
using the Hyaluronan Quantikine ELISA Kit (R&D systems), according to manufacturer´s 
protocols and by using the provided HA standard solutions. Firstly, standard HA solutions 
were prepared (20 ng/ml; 10 ng/ml; 5 ng/ml; 2.5 ng/ml; 1.25 ng/ml; 0.625 ng/ml), dissolved 
in Calibrator Diluent RD5-18 (R&D systems), which was also used directly as 0 ng/ml 
control. Standards were prepared in duplicates, samples in triplicates. Samples were 
diluted 1:100 from cell culture supernatants and 1:1,000 from EHM cultures. 50 µl of 
Assay Diluent RD1-14 (R&D systems) were loaded per well of a 96-well flat bottom ELISA 
plate from the manufacturer. Then, 50 µl of sample solution or prepared standards were 
added per well, gently mixed and incubated for 2 h at RT on an orbital shaker with gentle 
rocking. Thereafter, the well content was aspirated, and wells were washed altogether 5 
times with 100 µl of provided washing buffer (R&D systems). 100 µl of HA conjugate (R&D 
systems) were then added per well and incubated for another 2 h at RT while gently 
shaking, followed by 5 more washes. Subsequently, empty wells were incubated for 30 min 
with 100 µl substrate solution (R&D systems) and finally the reaction was terminated with 
100 µl stop solution (R&D systems) per well. The optical density was assessed by 
measuring the absorbance at 405 nanometer (nm) using the Flexstation® 3 Multi-mode 
microplate reader (Molecular Devices). Absorbance reads at 540 nm were subtracted from 
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reads at 405 nm to correct for optical imperfections on the plate, as recommended by the 
manufacturer. To normalize secretion to cell counts, cells were detached and counted after 
the supernatant was collected (from 6-well, in triplicates). Standard curves (four 
parameters logistic (4-PL) curve-fit) were generated using GraphPad Prism 7 software and 
concentration of samples determined. 
2.9 Gene expression analysis 
2.9.1 RNA preparation 
2.9.1.1 Cells 
RNA of cells and tissues was collected using Trizol reagent (Invitrogen) according to 
manufacturer´s protocol (see Trizol method). For 2D cell cultures, cells were either directly 
scraped from the cell culture plate with Trizol reagent or alternatively; centrifuged down 
at 300 x g, for 5 min at RT. Pellets were then snap frozen and resuspended in Trizol. 
2.9.1.2 EHM 
For EHM, tissues were snap frozen and then immersed in 1 ml Trizol (Invitrogen) with a 
steel marble for lysing using the Tissue Lyser (3 consecutive runs with 20 Hz for 3 min; 
Qiagen). After EHM had dissolved, the mix was centrifuged for 10 min at 5,000 x g to 
remove remaining fragments and fat. The supernatant was then used for RNA extraction 
with Trizol. 
2.9.1.3 Early phase consolidation collagen I gels 
To identify underlying cellular processes that play a role in the earliest consolidation 
stages of EHM, we generated hydrogels with CM, HFF and both cell types together (EHM) 
under identical conditions as previously used in shear plate rheology (23°C) and extracted 
RNA by the TRIZOL method. RNA was analyzed by next-generation sequencing (see 
2.9.2). 
2.9.1.4 Trizol method 
In short, cells or tissue lysates immersed in Trizol reagent were homogenized by vortexing. 
Per 1 ml Trizol reagent, 200 µl of Chloroform were added (AppliChem). Tubes were closed 
tightly and turned upside down 5 times followed by 5 min incubation at RT. Samples were 
then centrifuged at 10,000-12,000 g for 15 min. The aqueous phase, containing RNA, was 
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transferred to fresh tubes, followed by the addition of 500 µl isopropanol (Roth) to 
precipitate RNA. Tubes were vortexed, left at RT for 10 min and subsequently centrifuged 
for 10 more min at 12,000 x g. Supernatants were discarded and 1 ml of 70% EtOH/Diethyl 
pyrocarbonate (DEPC) H2O was added to wash RNA pellets. After gentle tipping of the 
tube to lift off and wash the RNA pellet, samples were centrifuged once more for 5 min at 
12,000 x g and supernatant removed. Pellets were left to dry for 5- 10 min, until remnant 
liquid had evaporated, and RNA was resuspended in DEPC H2O. RNA concentration and 
quality were assessed using the Nanodrop, ND-1000. 
2.9.2 RNA sequencing 
RNA for sequencing was prepared by the Trizol method (see 2.9.1) and analyzed by the 
Transcriptome and Genome Analysis Laboratory (TAL, Göttingen). Bioinformatics 
analysis were carried out by Dr. Sebastian Zeidler (Institute of Bioinformatics, Göttingen) 
and Lavanya M. Iyer (Institute of Pharmacology and Toxicology, University Medical 
Center, Göttingen). 
2.9.2.1 Cardiomyocyte and human foreskin fibroblast comparison 
Data was generated and analyzed as previously described in (Tiburcy et al., 2017). In 
short, RNA integrity and quality were controlled (Agilent Bioanalyzer 2100). Libraries 
were prepared (TruSeq Stranded Total RNA Sample Prep Kit, Illumina) and sequencing 
was carried out on an Illumina HighSeq-2000 platform (SR 50 bp; >25 Mio reads /sample). 
The resulting data was processed and transformed followed by mapping to the human 
genome. To determine CM- and fibroblast-specific genes, three types of PSC-derived CMs 
and three types of primary fibroblasts (HFF, GFB1 and CFB1, see Table 2-1) were 
analyzed in triplicates (for details, see (Tiburcy et al., 2017)). 
For the comparison of input CM and fibroblasts in EHM, we used HES2-CM and HFF 
RPKM values, that had been prefiltered for CM and HFF specific gene expression (see also 
(Tiburcy et al., 2017)) and compared genes with highest RPKM values, respectively. 
2.9.2.2 Cardiac and human foreskin fibroblast comparison 
Data was generated and RPKM values were retrieved as described above. Only previously 
determined fibroblast-enriched genes were analyzed in this context between HFF and 
CFB1 cells. 
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2.9.2.3 Early phase consolidation of collagen I gels 
This protocol can also be found in (Schlick et al., 2018) in a shortened version. 
Generation of RNA-seq libraries was performed using a modified strand-specific, 
massively-parallel cDNA sequencing (RNA-Seq) protocol (Illumina: TruSeq Stranded 
Total RNA (Cat. No. RS-122-2301)). The protocol was optimized to maintain the rRNA 
content in the data set under 5%. (RiboMinus™ technology) The remaining whole-
transcriptome RiboMinus™ RNA is suitable for direct sequencing. The ligation step was 
optimized to increase ligation efficiency (>94%), and PCR protocols were adjusted for an 
optimal final library product. The quality and RNA integrity were analyzed with the 
Fragment Analyzer from Advanced Analytical by (standard sensitivity RNA Analysis Kit 
(DNF-471)). All samples selected for sequencing exhibited an RNA integrity number over 
8. For accurate quantitation of cDNA libraries, a fluorometric based system, the 
quantiFluor™dsDNA System from Promega were used. The size of final cDNA libraries 
was determined by using the dsDNA 905 Reagent Kit (Fragment Analyzer from Advanced 
Bioanalytical) exhibiting a sizing of 300 bp in average. Libraries were pooled and 
sequenced on an Illumina HiSeq 4000 (Illumina) generating 50 bp single-end reads (30-40 
x 106 reads/sample). 
Raw read and quality check: 
Sequence images were transformed with Illumina software BaseCaller to BCL files, which 
was demultiplexed to fastq files with bcl2fastq v2.17.1.14. Quality was assessed with 
FastQC version 0.11.5 (Andrews, 2014). 
Mapping and normalization: 
Sequence reads were mapped to the human genome reference library (UCSC version hg19 
using Bowtie 2.0 (Langmead and Salzberg, 2012). Then the number of mapped reads was 
counted for every identified gene and DESeq2 utilized to assess differential gene 
expression (Anders and Huber, 2010). 
Gene ontology analysis: 
DAVID (Huang et al., 2009a, 2009b) was used for Gene ontology (GO) analyses and 
VennDiagrams were created with the online tool BioVenn (Hulsen et al., 2008). 
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2.9.3 Quantitative real time PCR 
2.9.3.1 DNAseI treatment 
RNA was thawed on ice and 1 µg of RNA was used per reaction for subsequent DNAse I 
(Thermo Scientific) digest and reverse transcription (RT) (RT kit, Promega), as described 
below: 
Table 2-13 DNAse I protocol 
Reagent Per 1X reaction (in µl) 
1 µg RNA X 
10x DNase buffer 1  
DNaseI 0.2  
H2O  Add up to total Vol 
Vol total 10  
Protocol steps  
1. 20 min 37°C 
2. Per sample, add 1 µl of 40 mmol/L EDTA  
3. 10 min at 75°C 
2.9.3.2 Reverse transcription 
Table 2-14 RT-PCR 
 Reagent Reagent for 1X reaction 
(in µl) 
Master mix 1 dT20 Primer (500 µg/µl)* 1  
 dNTPs (10 mmol/L)* 1  
 H2O 2.5 
 V total 4.5 
Master mix 2 M-MLV 5X Reaction Buffer* 4  
 MLV RT (200 U/µl)* 0.5  
 V total 4.5 
Master Mix 3  
(without reverse 
transcriptase) 
M-MLV 5X Reaction Buffer* 4  
 H2O 0.5  
 V total 4,5 
   
qRT-PCR reaction DNAseI treated RNA 11 
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 Reagent Reagent for 1X reaction 
(in µl) 
 Master Mix 1 4.5 
 MasterMix2 (or 3 for –RT control) 4.5 
 V total 20 
*Primer, dNTPs, enzymes and reaction buffer are contained in the M-MLV reagent kit. 
 
RNA and master mix 1 were mixed before and incubated for 5 min at 65°C. Then master 
mix 2 (or 3) were added and samples were incubated for 50 min at 42°C followed by 15 
min at 70°C. Resulting complementary DNA (cDNA) was diluted 1:5 (100 µl) and 
subsequently used for quantitative real time PCR (qRT-PCR). cDNA was stored at -20°C. 
2.9.3.3 Quantitative real time PCR and analysis  
Quantitative real time (qRT-) PCR and subsequent data analysis was carried out by Petra 
Rompel (HAS2 overexpression, 3.2.1). 
2.10 Isometric force measurements 
EHM isometric force measurements had been previously described (Zimmermann 2000). 
EHMs were cultured for 4 weeks. EHM were kept at 37°C on a heating plate, 
photographed and recorded using video capturing. Spontaneous beating frequency was 
determined by analyzing beats within a 10 s time window (values were then extrapolated 
for beats/min). 
Then tissues were transferred into isolated organ baths (Föhr Medical Instruments) 
(A2.5). EHM were immersed in Tyrode´s buffer (A2.1), containing 2 mmol/L [Ca2+] while 
perfused with carbogen (95% O2, 5% CO2), kept at a constant temperature of 37°C. EHM 
were prestretched carefully to an average value of 0.1 millinewton (mN) resting tension 
and left to equilibrate for up to 20 min. Spontaneous beating in this phase was 
documented. EHM were then electrically stimulated at 1.5-2 Hz (200 mA, 5 ms pulse). 
Subsequently, EHM were stretched (125 µm steps) until maximal force of contraction was 
achieved according to the Frank-Starling mechanism. 
Next, EHM contractile forces in response to increasing [Ca2+] were measured under 
constant stimulation at 1.5-2 Hz (0.2-4 mmol/L [Ca2+]). After reaching maximal forces at 
4 mmol/L [Ca2+], the half maximal effective (EC50) calcium concentration was calculated 
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and Tyrode´s buffer was adjusted to individual EC50 [Ca2+] values for each EHM. The 
force-frequency response was tested at increasing frequencies (from 1, 2 and 3 Hz for 4 
min each). After evaluation of the fore-frequency response, adrenergic responses were 
assessed by adding 1 µmol/L isoproterenol (at 1.5- 2 Hz), followed by 10 µmol/L carbachol 
(A2.1). Contractile forces (Force of contraction (FOC) = Fmax – Fmin) were recorded using 
BMON software and subsequently analyzed using AMON software (G. Jaeckel, Hanau). 
EC50s [Ca2+] were calculated by non-linear regression using GraphPad software. 
Time to 90% contraction and time to 50% relaxation were measured on 3 consecutive single 
contractions (stimulated with 1.5-2 Hz at 4 mmol/l [Ca2+]) and averaged. 
2.10.1 Data analysis 
Data was extracted to Excel (MicrosoftOffice) from Amon software as Fmin, Fmax and 
force of contraction (FOC) = Fmax – Fmin. Beating frequency was determined by 
analyzing beats in 4 s within a 1 min time window (averaging 3 measurements). EC50s 
[Ca2+] were calculated using GraphPad Prism 7 software. 
2.10.2 Cross sectional area (CSA) 
EHM cross sectional area (CSA) was determined by measuring arm width and thickness, 
using photos from the contraction setup. Photos were scaled using the 1 mm electrode in 
the pictures. CSA was determined by calculation of the arm width and arm thickness as 
half axes of an ellipse. Image J (Open Source) was used to determine numerical 
measurements. 
2.10.3 Tissue compaction 
2.10.3.1 Analysis of tissue compaction at 1 h after casting (DCM study) 
Compaction of 1 h old EHM gels was assessed by determining the gap between the 
polydimethylsiloxane (PDMS) tissue mold (A2.5) and the contracted gel. For this, images 
were taken using a digital camera and a ruler. Images were scaled from measuring the 
ruler with ImageJ 1.8.0 (NIH) and gaps determined accordingly. 
2.10.3.2 Analysis of consolidation at 24 h and 72 h 
For the analysis of compaction at 24 h and 72 h we determined the % of area that was free 
of collagen I hydrogels after 24 h and 72 h in circular 10 mm PDMS molds for EHM casting. 
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For that molds with gels were imaged with a Lumar binocular and a digital camera. 
Images were scaled with ImageJ software by measuring the mold diameter. Compaction 
was calculated by determining the % of area not occupied anymore by the gel after 24 h 
and 72 h. For that we determined the area free of gel divided by the whole mold area (66 
mm2; taking into account the area of the inner PDMS pole). 
2.11 Rheology 
2.11.1 Shear plate rheology 
EHM hydrogels were prepared according to 2.2 and Table 2-6, containing either no cells, 
only HFFs, only CMs or both cell types. 140 µl of the suspension was then transferred onto 
a chromium plate and sheered using constant strain and frequency (1%, 1Hz) under a 
CP25-2 conical plate (cone and plate geometry with an angle of 2° and a gap height of 103 
µm) in a bulk rheometer (MCR-501, Anton Paar, Austria). Here, strain is applied by 
shearing the hydrogel between two oscillating plates and the dynamic modulus is 
measured, which is a combined measurement of tensile storage (stiffness) and loss 
modulus of the tested gel. The loss modulus describes energy dissipated as heat, while in 
this setting, the storage modulus serves as an actual direct readout of gel stiffness and is 
thus of predominant interest. 
During measurements temperature was kept at a constant 23°C and humidified 
atmosphere to avoid evaporative loss. Time sweep measurements were recorded (every 30 
s). For analysis of stiffening behavior, slopes of the change in elastic storage modulus were 
analyzed and compared. 
2.11.2 Destructive tensile stress measurements  
EHM arm size was documented by light microscopy using a Lumar binocular (Zeiss), then 
EHM were fixed by two hooks in an organ bath containing PBS (no Ca/Mg) at 35°C (it was 
not possible to keep 37°C constant temperature in this setup). EHMs were prestretched to 
slack length. At this stage the motor transducer setup was zeroed and subsequently 
constant strain was applied at a speed of 0.025 mm/s until EHMs ruptured. Hooks were 
designed in-house by Dr. Tim Meyer (Figure 2-2). Data was recorded with TRIOS software. 
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Figure 2-2 Destructive tensile stress measurement 
A Setup of EHM immersed in PBS for measurement. B Hook design and measurements (provided by Dr. Tim 
Meyer). C Axial stress is applied to EHM tissues at constant strain rate of 0.025 mm/s. D Resulting stress vs 
strain curves in destructive tensile stress measurements (Hartmann, 2016). 
2.12 Statistical analysis 
Data are presented as mean±SEM. Statistical analysis was performed using GraphPad 
Prism 7 (GraphPad Software Inc., San Diego). 
Results 
48 
3 Results 
3.1 Fibroblasts are essential for EHM formation 
3.1.1 EHM is a highly defined system of cardiomyocytes and fibroblasts 
To investigate the fibroblast-CM crosstalk, EHM were generated from homogenous CM 
populations containing >90% α-actinin+ cells (95±2%; n=3) and human foreskin fibroblast 
(HFF) populations containing >90% CD90+ cells (94±5%; n=3). We used HFFs here as a 
prototypic fibroblast type (Figure 3-1). 
 
Figure 3-1 EHM generation from defined cell populations. 
A Schematic of EHM content: Highly purified PSC-derived CMs and fibroblasts (Fibs) are mixed in a ratio of 
2:1 in a collagen I hydrogel that develops over a time of 4 weeks into functional EHM. B Representative 
examples for flow cytometry (FC) analysis of CM and fibroblast (Fib) populations (here: HFF cells) with a 
typical purity of CM being >90% actinin+ and >CD90+ (Thy1) respectively. Data from (Schlick et al., 2018). 
We analyzed RNA expression patterns of input CMs and HFFs, demonstrating distinctive 
cellular expression patterns, specific for both cell types (data published in (Tiburcy et al., 
2017). The most predominantly expressed transcripts in CMs were found to encode for 
components of the sarcomere, such as cardiac troponin T (TNNT2), both troponin I 1 and 
3 (TNNI1 and 3), many members of the myosin family (myosin light chain-MYL and 
myosin heavy chain – MYH), and sarcomeric α-actinin (Figure 3-2 A). Variants and 
mutations in these proteins have been associated with familial forms of DCMs (Cho et al., 
2016). In line with the dependence of CM contractility on the calcium (Ca2+) handling 
machinery, we also found high expression level of ryanodine receptor 2 (RYR2), a calcium-
activated calcium release channel that plays a major role in the contractile cycle. A 
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dysfunction of this channel leads to detrimental pathologies of the heart (Jóna and Nánási, 
2006). 
The transcripts we found most abundantly expressed in fibroblasts were, as anticipated, 
associated with ECM generation and homeostasis (Figure 3-2 B). Here, we identified 
thrombospondin 1 (TSP1) mRNA as the highest expressed transcript in fibroblasts, which 
is important component of the ECM and involved in matrix remodeling, also after 
myocardial infarction (Frangogiannis, 2005). Other ECM components of interest were 
CD44, a structural protein that mediates HA binding, but also controls its degradation 
through hyaluronidases 1 and 2 (HYAL1 and 2) (Harada and Takahashi, 2007) and 
regulators of the ECM, such as MMP-2 and neprilysin (MME). 
 
Figure 3-2 Expression profile of EHM input cell populations 
Selected, highly expressed, cell-specific enriched transcripts in A CMs (derived from HES2) and B human 
foreskin fibroblasts (HFFs), used as prototypic fibroblast source for EHM. *p<0.05 by student´s unpaired two-
tailed t-test. Values of RNA sequencing (RNAseq) data in RPKM (reads per kilobase of transcript per million 
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mapped reads). n=4/group and gene. Parts of these data were published in (Tiburcy et al., 2017). Figure 
adapted from (Schlick et al., 2018). 
By combining highly purified and well characterized populations of CMs and fibroblasts 
in EHM, a robust 2-cell type model of the developing myocardium was generated in which 
crosstalk of CMs and fibroblasts can be investigated under controlled in vitro conditions. 
3.1.2 Fibroblasts determine EHM functionality 
To assess the effect of fibroblasts on the formation of the EHM syncytium, we measured 
the force of contraction in EHM formulations comprising only CMs or mixtures of CMs 
and fibroblasts as reported previously (Tiburcy et al., 2017); (Figure 3-3). CMs in collagen 
I hydrogels showed spontaneous beating but failed to develop a functional syncytium 
capable of developing considerable forces (FOC at 4 mmol/L [Ca2+] in mN: 0.15±0.05 in CM 
only EHM vs 1.2±0.15 in CM+ HFF EHM; n=4/group). These findings confirm the 
important role of fibroblasts in heart muscle assembly. 
 
Figure 3-3 Fibroblasts are crucial for the functional development of EHM 
Isometric force measurement of 4-week-old EHM. Force of contraction (FOC) in EHM constructed from CM or 
CM+ HFF (2:1) in collagen type I (n=4/group). FOC was measured as a function of extracellular calcium (0.2-
4 mmol/L). *p<0.05 by 2-way ANOVA with Sidak´s multiple comparisons post-hoc test. Data from (Schlick et 
al., 2018). 
The spatial- and temporal assembly of CMs in EHM was further analyzed by 
immunostaining. From day 1 until 4 weeks of EHM culture, in the presence of 
fibroblasts, sarcomeric proteins such as α-actinin increased in abundance and CMs 
underwent spatial organization into an anisotropic, aligned syncytium (Figure 
3-4). This is in line with increasing force production between 2 and 4 weeks 
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(Tiburcy et al., 2017). Taken together with the crucial role of cardiac fibroblasts in 
early cardiac development and the proper spatial compaction of the developing 
myocardium (Camelliti et al., 2005; Takahashi et al., 2014), we aimed to further 
dissect the fibroblast derived-cues that govern muscle formation in EHM. 
  
Figure 3-4 Muscle formation process in EHM 
Sarcomere development during EHM maturation at indicated time points. Immunostaining for α-actinin 
(green) and f-actin (red), nuclei (blue). Scale bar: 50 µm. Data from (Schlick et al., 2018). 
3.1.3 Biophysical cues for fibroblast-mediated muscle formation 
To investigate the role of fibroblast-mediated collagen I handling during the assembly of 
CMs into higher order contractile units within the developing EHM, we first explored the 
compaction behavior of collagen I hydrogels at early days of EHM development 1 and 3 
(Figure 3-5). Indeed, in line with the described capability of fibroblasts to compact gels of 
collagen I in vitro (Bell et al., 1979; Chapuis and Agache, 1992), we found that the presence 
of fibroblasts was clearly responsible for the consolidation of compact tissues compared to 
collagen I hydrogels with and without CMs. At 24 h compaction was mostly completed (in 
% at 24 h: Collagen I 1.5±0.9; Collagen I + CM 28.1±2.9; collagen I + HFF 61.6±2.9; collagen 
I + CM + HFF 70.1±0.9; at 72 h: Collagen I 5.4±1; Collagen I + CM 25.9±1.8; collagen I + 
HFF 78.5±2.1; collagen I + CM + HFF 70.3±3.1; n=4/4/4/4) (Figure 3-5 B). Of note, in the 
CM only group, the level of compaction was clearly higher than in collagen I only, which 
is likely the result of a small fraction of remnant stroma cells from the differentiation 
process. Interestingly, we also observed a continuous increase in tissue compaction in the 
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HFF only group indicating that there may also be “inhibitory” cross-talk between CM and 
fibroblasts in EHM (HFF+ CM group) (Figure 3-5 B). 
 
Figure 3-5 Fibroblasts drive tissue consolidation 
A Representative images of hydrogels with collagen I on day 3. Diameter of casting molds: 10 mm. B 
Consolidation of tissues in PDMS molds 24 h and 72 h after casting. *p<0.05 by 2-way ANOVA with Sidak´s 
post hoc test for multiple comparisons. n=4/group at 24 h and n=9/5/8/5 at 72 h, 2 independent experiments. 
Data from (Schlick et al., 2018). 
To further quantify fibroblast-mediated EHM compaction in more detail, we chose to 
utilized shear plate rheology under physiological conditions (1 Hz and 1% strain). For 
viscoelastic gels, the elastic modulus (a combination of storage and loss modulus) describes 
the deformation response of a material when it is under stress (Figure 3-6). After an initial 
lag-phase in which the hydrogels settled in the instrument, collagen I hydrogels 
underwent a gelation step in the first 30 min, which was independent of the presence of 
cells (Figure 3-6 B). This occurs when a solution of collagen I, which solubilized in a highly 
acidic solution at a pH of 2, undergoes polymerization by neutralization of the pH. After 
gelation, only hydrogels with cells further stiffened (Figure 3-6 B). We quantified this cell-
mediated process by comparing the change in tensile storage modulus (“stiffening rate”) 
in this phase (Figure 3-6 C). The stiffening rates of hydrogels with HFF or CMs and HFFs 
were significantly higher than of collagen I or collagen I with CMs (Slopes of storage 
moduli in Pa/min: Collagen I 0.04±0.03; Collagen I+ CMs 0.03±0.02; Collagen I + HFFs 
0.53±0.07; Collagen I + CMs + HFFs 0.29±0.03; n≥ 3/group). Interestingly, hydrogels with 
only CMs behaved like collagen gels, while gels containing fibroblasts clearly consolidated 
most effectively. In the presence of both fibroblasts and CMs the consolidation was 
intermediate, indicating that the presence of CMs dampened fibroblast-mediated gel 
compaction. 
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Figure 3-6 Early consolidation phase characterization of collagen I hydrogels 
A Schematic overview of experimental set-up using the Anton Paar rheometer for shear plate rheology with a 
CP25.2. shear plate at 1% strain and 1 Hz (at 23°C). B Storage (Elastic) and Loss (viscous) moduli of collagen 
I hydrogels either without cells, with CM alone (CM), fibroblasts alone (HFF) and EHM (HFF+ CM) over time. 
fibroblasts were subjected to shear plate rheology and storage and loss modulus were recorded. C Storage 
modulus slopes at 40-60 min in collagen I hydrogels without cells, with CM alone (CM), fibroblasts alone (HFF) 
and EHM (HFF+CM). n=3/collagen and CM groups, n=4 for HFF and HFF + CM groups; *p<0.05 by 1-way 
ANOVA followed by Tukey´s multiple comparisons post hoc test. Data from (Schlick et al., 2018). 
3.1.3.1 Transcriptome signatures in EHM 
To unravel the impact of tissue compaction on cell phenotypes, we studied the differential 
transcriptome during the cell-independent gelation (up until 30 min after casting) and 
cell-dependent collagen compaction (30-90 min after casting) phases (Figure 3-7 A). As 
anticipated CM, HFF and CM+HFF (early EHM culture) sample transcriptomes were 
clearly distinguishable (Figure 3-7 B), as 91% of variance could be attributed to cell 
composition of hydrogels (PC1). Cocultures of CM:HFFs in EHM occupied a distinct cluster 
(PC2, 7% of variance), compared to CM and HFF only groups. This segregation indicated 
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transcriptome dynamics that can be specifically attributed to the coculture of the two cell 
types in EHM (CM:HFF 2:1). Generally, the changes in transcriptomes within the groups 
were small, which was expected due to the short timeframe between the two measurement 
points. 
  
Figure 3-7 Distinct transcriptomes in EHM models 
A Experimental design. Collagen I hydrogels with CMs, HFFs (Fibs) and both CMs and HFFs (2:1, EHM) were 
generated and RNA samples collected in the gelation process (cell-independent polymerization, 30 min after 
casting) and during collagen compaction, the cell-dependent phase (90 min after casting). B Principal 
component analysis (PCA) of the indicated sample groups: tissue comprised of CMs, HFFs or both (CM+HFF 
at a 2:1 ratio). n=3 samples/group. Data from (Schlick et al., 2018). 
3.1.3.2 EHM consolidation transcriptomes resembles cardiac compaction and 
wound healing 
The comparison of differentially expressed genes during the cell-independent and 
dependent phases (Figure 3-7 A) demonstrated that the HFF only group was 
transcriptionally more responsive (DEG: 727) compared to the CM and early EHM groups 
(DEGs: 106 and 107, respectively) (Figure 3-8). 
The DEG overlap was larger between the EHM and HFF groups (434) than the EHM and 
CM groups (48 genes; Figure 3-8). The CM and HFF groups shared only 13 commonly 
regulated DEGs, which may be due to the fibroblast-like component in the CM group (on 
average 96% α-actinin+ CM preparation, n=3 batches). 202 genes were regulated in all 
three groups (CM, HFF and CM + HFF), indicating similarities in tissue compaction 
associated transcriptome regulation (termed here “General tissue formation processes”). 
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Using gene ontology (GO) analyses we scrutinized the cell type-dependent processes 
(Figure 3-8). Among the general tissue formation processes (Figure 3-8 B), we found 
responses to BMP signaling, (cardiac) epithelial to mesenchymal transition (EMT) and 
endocardial cushion formation, together with biosynthetic processes of EHM 
polysaccharides and the regulation of wound healing. In the fibroblast (HFF) group 
transcriptional changes involved processes such as ECM organization and general heart 
development (Figure 3-8 A). Of note, both TGFβ and PDGFβ signaling could be specifically 
identified. TGFβ signaling is stimulated in EHM in the presence of exogenous TGFβ1 
supplemented with the culture medium to enhance EHM compaction (Tiburcy et al., 2017). 
In the CM group (Figure 3-8 C), GO term analyses suggest cellular and in particular 
endoplasmic-reticulum (ER) stress in response to the 3D environment. With only four 
unique GOs in EHM (not shown) and the large overlap of DEG in EHM and fibroblast 
samples it appears that the fibroblast fraction is highly responsive to the changes in tissue 
compaction. Of note, we identified many regulatory RNAs of the micro and noncoding 
family in the DEGs of the EHM (CM:HFF 2:1) group (45 up- and 405 downregulated genes, 
including 210 micro/long non-coding RNAs). 
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Figure 3-8 Regulated biological processes during fibroblast-mediated collagen I 
compaction 
Venn diagram of genes that are differentially regulated (DEGs) as a result of fibroblast-specific collagen I 
compaction. Selected gene ontology (GO) terms of regulated genes that are A fibroblast-specific (EHM and 
HFF only group), B regulated in all groups or C CM-specific. Data from (Schlick et al., 2018). 
Among the DEGs regulated in all groups, we found regulators of early cardiac 
morphogenesis and endocardial cushion/cardiac jelly formation (HAS1, HAS2, BMP2 and 
TGFβ (Figure 3-9 A). During cardiac development, cardiac compaction and jelly formation 
are guided by the developing fibroblast(-like cell) population (Ieda et al., 2009; Takahashi 
et al., 2014) and crucially dependent upon HA synthesis by the HASs, particularly HAS2 
(Camenisch et al., 2000, 2001; Meran et al., 2011; Missinato et al., 2015; Porsch et al., 
2013), which is regulated via BMP2 signaling (Ma, 2005). Furthermore, PDGFβ can 
stimulate HA production also by CMs (Hellman et al., 2010) and the PDGF receptors are 
crucial for EMT during cardiac early development (Smith et al., 2011). In the fibroblast-
specific group (Figure 3-9 B), we identified genes of ECM turnover and anchorage (ELN 
(elastin), DSP, and JUP) and the master transcriptional regulator SOX9 that is involved 
in heart development and associated with a majority of fibrotic processes (collagen I 
deposition) in the heart (Hanley et al., 2008; Lacraz et al., 2017). 
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Figure 3-9 Selected genes regulated during the cell-dependent phase  
Trajectory of transcriptional alterations during the cell-independent collagen I gelation and cell-dependent 
collagen I compaction phases of early tissue development. A DEG present in all groups. B Selected DEG from 
the fibroblasts containing groups (HFF, EHM (CM:HFF 2:1). Ordinates indicate relative RPKM values. Data 
from (Schlick et al., 2018). 
3.1.3.3 Fibroblasts remodel the ECM and determine EHM viscoelasticity 
Next, we analyzed the morphology of tissues with CM, HFFs or both cell types (EHM) 
after 4 weeks (Figure 3-10 A and B). In line with our results at 1 and 3 days, we found 
that only collagen I gels with HFFs had formed compacted tissues as measured by the 
thickness of arms (in mm: Collagen I 5.1±0.27; Collagen I + CM 4.8±0.24; Collagen I + 
HFF 1.1±0.06; Collagen I + CM + HFF 1.3±0.03; n=12/9/10/12; Figure 3-10 B). 
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We further evaluated the viscoelastic properties of tissues with CM, HFFs or both cell 
types (EHM; Figure 3-10 C) by destructive tensile stress measurements. The linear phase 
of the generated strain vs stress curve was used to calculate the Young´s modulus. Tissues 
with HFF were significantly stiffer than either collagen I hydrogels or collagen I hydrogels 
populated with CMs only. There was no difference in stiffness between either collagen I 
with and without CMs; HFF populated as well as HFFs and CMs (EHM) populated 
collagen hydrogels were clearly stiffer (Young´s modulus in kPa: Collagen I 0.07±0.06; 
Collagen I + CM 0.02±0.01; Collagen I + HFF 2.2±0.37; Collagen I + CM + HFF 0.89±0.13; 
n=6/5/9/11; Figure 3-10 C). 
 
Figure 3-10 Fibroblasts are major determinants of EHM viscoelasticity 
A Images of constructed cell-free or cell containing tissues at 4 weeks (scale bar: 1 mm; applies to all panels). 
B Tissue arm thickness used to calculate the Young´s modulus of collagen I (Col I) without cells, with CMs, 
with HFFs or with both CMs and HFFs after 4 weeks (n=12/9/10/12). C EHMs were prestretched and tension 
applied at 0.025 mm/s (n=6/5/9/11). *p<0.05 by 1-way ANOVA followed by Tukey´s multiple comparisons post 
hoc test. Data from (Schlick et al., 2018). 
In order to evaluate the structure of ECM, we compared Sirius red staining of 4-week-old 
hydrogels (Figure 3-11), which clearly indicated that collagen I used as EHM input 
material had been remodeled extensively and replaced during the 4 weeks of culture when 
fibroblasts were present (compare collagen I hydrogel loose lattice with highly compacted 
ECM of collagen I containing HFFs and both HFFs and CMs). This small level of 
compaction observed in CM only gels can likely be attributed to the presence of 
contaminant stroma cells found in HES2- derived CM preparations. 
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Figure 3-11 Collagen remodeling in 4-week-old collagen I hydrogels 
Collagen I hydrogels with and without cells were generated and cultivated for 4 weeks and then stained with 
Sirius red. A Collagen I without cells. B CMs in collagen I. C HFF in collagen I. D EHM (CM:HFF 2:1). Scale 
bar 100 to 400 µm (in magnified view). Data from (Schlick et al., 2018). 
Collectively, these data demonstrate the crucial role of HFFs during the early phase of 
EHM compaction and long-term tissue development where they control tissue 
viscoelasticity and ECM integrity. 
3.1.4 Fibroblasts from different origin support EHM formation  
Since most of the experiments so far were performed with HFF as prototype for fibroblasts, 
we asked whether our observations were universal across all fibroblasts cell types or HFF-
specific mechanisms. Firstly, we chose to compare HFFs with endogenous cardiac 
fibroblasts (CFBs) derived from the ventricle of healthy patients (organ donors, Lonza) 
and we hypothesized that these cells may be more likely to reconstitute an organotypic 
EHM for in vitro modeling of native myocardium. Additionally, we chose fibroblasts 
derived from the gingiva of patients (GFBs). These cells can be obtained to generate 
patient-specific EHMs for in vitro use and potentially for clinical applications (Figure 3-12 
A), see also section 3.3.1 for in depth analysis. 
We generated EHM from HFFs, CFBs (3 different patients, CFB1-3) and GFBs (4 patients, 
GFB1-4). All fibroblasts tested were able to support the formation of functional syncytia 
with some evidence of differences to the functional outcome (Figure 3-12 B): EHMs 
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generated from HFFs performed significantly better than either GFBs and CFB EHMs, 
while there was no difference in EHMs containing GFBs and CFBs (FOC at 4 mmol/L 
[Ca2+]: HFF 1.01±0.06; GFB 0.67±0.04; CFB 0.61±0.04; n=58/31/59; Figure 3-12 B). The 
analysis of CSA revealed that EHM with CFBs were thicker compared to EHM containing 
HFFs and GFBs (CSA in mm2: HFF 0.7±0.03; GFB 0.7±0.04; CFB 1.2±0.07; n=46/20/39; 
Figure 3-12 C). 
  
Figure 3-12 Fibroblast origin affects EHM function and appearance 
A Origin of primary fibroblasts used in this study and their potential application. Patient-specific gingiva 
fibroblasts could be obtained from biopsies. Ventricular cardiac fibroblasts (CFBs) (Lonza) from healthy 
patients can be used for organotypic modeling. HFF provide a large, homogenous cell population which is ideal 
for method development and screening purposes. B EHM were generated from fibroblasts of different origin 
and compared after 4 weeks of culture. Pooled data from EHM with HFF, CFB, or GFB. FOC at increasing 
extracellular calcium (0.2-4 mmol/L) was compared. *p<0.05 by 2-way ANOVA and Tukey´s multiple 
comparisons post hoc test (n=58/31/59). C CSA in EHM with HFF, CFB, or GFB. *p<0.05 by 1-way ANOVA 
followed by Tukey´s multiple comparisons post hoc test (n=46/20/39). 
To assess the variability between fibroblasts from the same source, we compared EHM 
constructed with CFB from 3 different individuals. CFB1 performed consistently poorer 
than all other groups (FOC at 4 mmol/L [Ca2+] in mN: HFF 1.0±0.07; CFB1 0.43±0.05; 
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CFB2 0.78±0.08; CFB3 0.59±0.08; n=45/24/15/8; Figure 3-13 A). Morphologically, all CFB 
EHMs were significantly enlarged in CSA compared to HFF controls (CSA in mm2: HFF 
0.7±0.03; CFB1 1.4±0.1; CFB2 1.1±0.1; CFB3 1.1±0.1; n=42/20/10/9), without obvious 
difference between individual CFB EHMs, indicating small patient-specific, but larger cell 
source-specific variances in EHM phenotype (Figure 3-13 B; compare also Figure 3-29 for 
EHM with GFB from 4 different individuals). 
 
Figure 3-13 Low patient-dependent variability of EHM function and morphology 
A Isometric force analysis of EHM containing fibroblasts from different sources (HFF, CFB from 3 different 
individuals) after 4 weeks of culture; n=45/24/15/8 (HFF/CFB1-3). FOC at increasing extracellular calcium 
(0.2-4 mmol/L) was compared. *p<0.05 by 2-way ANOVA with Tukey multiple comparison post hoc test. B 
CSA in EHM with HFF and CFB from 3 different individuals n=42/20/10/9 (HFF/CFB1-3). *p<0.05 by 1-way 
ANOVA followed by Tukey´s multiple comparisons post hoc test. 
3.1.4.1 EHM of cardiac fibroblasts from one patient represent a pathological 
phenotype 
In subsequent experiments, we analyzed CFB1 EHMs in more detail, as they likely 
represented a pathological phenotype. We evaluated the EC50 for [Ca2+] of tissues which 
was increased in CFB1 EHMs, indicating lower calcium sensitivity (in mmol/L: HFF 
0.5±0.03; CFB1 0.6±0.04; n=19/11) (Figure 3-14 A). All EHMs responded to a similar extent 
to adrenergic stimulation with the receptor agonist isoproterenol (1µmol/L) (at EC50 and 
1.5 Hz, FOC increase in %: HFF 94±18; CFB1 85±15; n=20/12) (Figure 3-14 B). 
Subsequently, we enzymatically digested EHMs. When evaluating the resulting cellular 
content of HFF vs CFB1s we observed that, while the CM content was unchanged between 
groups (α-actinin+ cells) (Myocyte count x 105: HFF 2.1±0.52; CFB1 2.4±0.24; n=6/group) 
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CFB1 EHMs yielded higher non-myocyte cell counts (non-myocyte count x 105: HFF 
6.4±0.4; CFB1 8.3±1.4, n=6/group) (Figure 3-14 C), concurrent with the significant 
increase in CSA (Figure 3-13 B). Finally, the analysis of EHM responses to strain revealed 
no significant differences between groups (Figure 3-14 D), indicating no major difference 
in matrix stiffness. 
 
Figure 3-14 Cardiac fibroblast EHM are distinct in cellular composition 
4-week-old HFF EHM vs CFB1 (n=20/12). A EC50 for [Ca2+] and B % increase in FOC at EC50 to 1 µmol/L 
isoproterenol. 3 independent experiments. A and B *p<0.05 by unpaired t-test. n=19/11 C Cellular content of 
EHMs. n=6/6 in 2 independent experiments. D Stress (Force per CSA of tissue) vs strain response in different 
tissues. n=12/8. 2 independent experiments. 
Further analysis of cryosections revealed clear differences in α-actinin abundance and 
spatial organization (Figure 3-15) between the groups, which was concurrent with the 
developed forces of these EHMs (Figure 3-13 A). Wheat germ agglutinin (WGA) staining 
of sialic acid and N-acetyl glucosamine indicated a more diffuse ECM network in CFB1 
tissue when compared to HFF controls (Figure 3-15). 
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Figure 3-15 Cardiomyocyte alignment and sarcomeric abundance in EHM of 
fibroblasts from different origin 
Representative cryosections of HFF vs CFB1 EHM. Immunostaining for α-actinin (red), wheat germ agglutinin 
(WGA) (red) and nuclei (blue). Scale bar 100 µm and 50 µm in magnified view. Scales apply for all images. 
3.1.4.2 Cardiac fibroblasts transcriptome reveals cardiac origin and 
myofibroblast characteristics 
We analyzed CFB1-specific gene expression and found that transcription factors GATA4 
and TCF21 were highly expressed in CFB1 cells compared to HFF (RPKM in CFB1 vs 
HFF GATA4 10±0.3 vs 0.01±0.01; TCF21 7.7±0.1 vs 0.3±0.01; n=3): GATA4 is of high 
importance in mammalian embryonic heart development and TCF21 is known as a marker 
of cardiac fibroblasts. Thereby the expression of both markers in CFB1 compared to HFF 
confirmed the cardiac origin of these cells. Furthermore, CFB1 expressed higher levels of 
periostin and CTGF when compared to HFF (RPKM in CFB1 vs HFF: POSTN 1376±53 vs 
3±0.2 and CTGF 868±1 vs 141±4; n=3/group) (Figure 3-16 B), indicating a myofibroblast 
phenotype of CFB1 cells. In contrast, THY1 was highly expressed in HFFs vs CFB1 
(RPKM in CFB1 vs HFF: 72±9 vs 3±0.3; n=3/group), which was in line with subsequent 
live FC analysis of CD90 (THY1) expression (n=1/group) (Figure 3-16 C and D). 
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Figure 3-16 CFB1-specific genes reflect cardiac origin and a myofibroblast phenotype 
Selected, highly expressed, CFB1-specific genes that represent A cardiac transcription factors and B ECM 
genes. C THY1 expression in HFF vs CFB1 cells. *p<0.05 by unpaired t-test comparing HFF vs CFB1. 
n=3/group. These data were published in (Tiburcy et al., 2017). D Live FC analysis of CD90+ cell populations 
in HFF and CFB1 cultures. n=1/group. 
In conclusion, we could demonstrate that all fibroblasts were able to constitute functional 
EHM, however the cues provided by HFF appeared more optimal as to functional and 
structural outcome as compared to GFBs and CFBs (Figure 3-12). 
In-depth analysis of EHM morphology and functionality indicated that CFB1 EHM could 
represent a pathological phenotype (Figure 3-13 and Figure 3-14). In agreement with the 
functional data we obtained previously, we confirmed the cardiac origin of CFB1 cells on 
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transcriptome level and found that CFB1 cells represent a myofibroblast phenotype. 
Collectively, these findings all indicated that in CFB1 EHM, fibroblast-specific signaling 
mechanisms to guide proper alignment and development of CMs was impaired. We thus 
investigated this phenotype further. 
3.2 Fibroblast-cardiomyocyte crosstalk in EHM 
3.2.1 Excessive deposition of hyaluronan leads to EHM dysfunction 
The analysis of morphology, histology, and contractile function of CFB1 EHM indicated 
that these fibroblasts were suboptimal to support EHM formation and maturation 
compared to HFF (Figure 3-13 A). The apparent “swelling“ of ECM in CFB1 EHM, as 
evidenced by a larger CSA (Figure 3-13 B), led us to hypothesize that excessive H2O may 
have been retained in the ECM, interfering with EHM development and contractile 
function. Analysis of ECM distribution by WGA staining (Figure 3-15) suggested an 
involvement of hyaluronic acid (HA) (Figure 3-17). This large molecular mass 
glycosaminoglycan is attached exclusively via non-covalent interactions with other 
proteins of the ECM (Rienks et al., 2014), sequesters water and thereby confers structure 
and stability to tissues. 
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Figure 3-17 The role of hyaluronan and its chemical structure 
A Schematic overview of HA in ECM (Rienks et al., 2014). B The chemical structure of HA allows for the large 
H2O-binding capacity of HA polymers. HA is constituted of repeating disaccharide molecules of D-glucuronic 
acid and D-N-acetylglucosamine, bound via alternating β-1,4 and β-1,3 glycosidic bonds (graphic taken from 
(Rienks et al., 2014)). HA is synthesized by hyaluronan synthases (HAS) 1-3. Hyaluronidase enzymes degrade 
HA by cutting the enzymatic bond. High and low molecular weight (HMW and LMW) HA play distinctive 
biological roles. C Representative images of HFF EHM vs CFB1 EHM. 
Excessive HA deposition is found in fibrosis and associated with contractile 
pathophysiologies of the heart (Chowdhury et al., 2013, 2017; Hellström, 2007; 
Waldenström et al., 1991). Thus, based on our earlier findings that the HA biosynthesis 
system is regulated during early consolidation of tissues, we hypothesized that HA is a 
key mediator of EHM development and hence function. 
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The HA content of the ECM is determined by HA synthesis and degradation. HA is 
synthesized by the HASs. We thus first investigated the abundance of transcripts encoding 
for HAS enzymes in the different fibroblasts (Figure 3-18 B). HAS1-3 have distinct 
spatiotemporal expression patterns during development (Tien and Spicer, 2005) and 
HAS2, the predominant synthase in human, plays an important role in the heart. Its 
knockout results in failure of cardiac cushion formation (Camenisch et al., 2001). Indeed, 
while there was no difference in HAS1 expression (in RPKM: HFF 0.02±0.14; CFB1 
0.02±0.14; CMs 0.12±0.04; n=3/group), HAS2 transcript abundance was markedly higher 
in CFB1 cells and CFB1 also expressed significantly more HAS3 than other cell types 
(HAS2 in RPKM: HFF 5.3±2.4; CFB1 27.8±0.3; CM 3.9±1; and HAS3 in RPKM: HFF 
0.3±0.08; CFB1 10.1±0.2; CM 0.4±0.1; n=3/group). 
While HA is synthesized by the HAS enzymes, homeostasis is achieved via its controlled 
degradation by hyaluronidases (HYALs). For instance, a lack of HYAL2 leads to congenital 
heart defects and heart failure (Chowdhury et al., 2017). We could not detect any 
differences in transcript abundance in the two investigated fibroblast entities (Figure 3-18 
C) (HYAL1 in RPKM in: HFF 0.6±0.2; CFB1 0.3±0.1; CM 4.2±1.6; HYAL2 in RPKM in: 
HFF 10.0±0.3; CFB1 11.2±0.2; CM 6±0.9; HYAL3 in RPKM: HFF 2±0.01; CFB1 2.5±0.4; 
CM 1.4±0.02 and HYAL4 in RPKM all fibroblasts 0; CM 0.1±0.02; n=3/group). Of note, 
HYAL expression was generally lower in CMs compared to fibroblasts. 
Furthermore, ECM components that bind HA were evaluated (Figure 3-18 D): Versican 
(VCAN) transcript abundance was significantly higher in CFB1 compared to HFF (VCAN 
in RPKM in: HFF 2.4±0.07; CFB1 355±1; CM 92±10; n=3/group). VCAN and HA 
functionally cooperate in the ECM. In VCAN-/- mice, HA can be detected but is highly 
disorganized which results in septal and cushion defects resembling the HAS2-/- 
phenotype. (Hatano et al., 2012). In contrast, aggrecan RPKM values were lower than 1 
in all cell types and thereby excluded from analysis, indicating that aggrecan expression 
in 2D cells is generally very low. 
The presence of HA-mediated motility receptor (HMMR) is crucial for HA-mediated EMT 
in development (Missinato et al., 2015). We found HMMR transcript significantly 
upregulated in CFB1 cells (HMMR in RPKM in: HFF 37±13; CFB1 178±5; CM 11±3; 
n=3/group). In contrast, the HA receptor CD44 which is also required for HA degradation 
by HYAL1 and HYAL2 (Harada and Takahashi, 2007), was downregulated in CFB1 cells 
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(CD44 in RPKM: HFF 454±110; CFB1 97±3; CM 1.4±0.1; n=3/group) (Figure 3-18 D). Of 
note, CD44 levels were significantly lower in CMs compared to both fibroblast species. 
 
Figure 3-18 Expression of genes involved in hyaluronan metabolism in HFF and CFB1  
A Hyaluronan (HA) in the heart. Selected phenotypes of knockout mice for hyaluronan synthase 2 (HAS2; HA 
biosynthesis), versican (VCAN; HA binding in ECM) and hyaluronidase 2 (HYAL2; HA degradation) 
emphasize the importance of a controlled HA content in the myocardial ECM for proper myocardial 
development and homeostasis (References, see main text). Gene expression in HFF, CFB1 and HES2-derived 
CMs B of HAS enzymes. C Transcript abundance for the HA degrading enzymes HYAL 1-4. D Expression of 
HA-binding components of the ECM: VCAN and aggrecan (ACAN) are proteoglycans whereas CD44 and HA-
mediated motility receptor (HMMR) are hyaladherins. *p<0.05 by 2-way ANOVA with Dunnett’s multiple 
comparisons post hoc test vs HFF control). n=3/group. 
From these findings, we hypothesized that an increased expression of HAS enzymes (in 
particular of HAS2) combined with lower expression of CD44 and thus low HYAL activity 
may result in excessive HA deposition in the ECM of CFB1 EHM. This could be responsible 
for the pathological phenotype we observed in CFB1 EHMs. 
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We validated HAS2 expression with qRT-PCR (Figure 3-19), which indicated higher HAS2 
expression in CFB1 vs HFF cells (mRNA levels compared to S18 control mRNA: HFF vs 
CFB1: 0.4±0.3 vs 5.0±1.2; n=3/group). However, the difference was not significant. 
  
Figure 3-19 Validation of RNAseq data for HAS2 with qRT-PCR 
Expression of HAS2 mRNA normalized to ribosomal S18 mRNA in HFF and CFB1 cells grown in 2D. 
n=3/group. Statistical analysis using unpaired t-test with Welch correction between HFF and CFB1. RT 
reaction and qRT-PCR carried out by Petra Rompel, lab of Prof. Jens Fischer, Department of Pharmacology, 
Düsseldorf. 
To test if the HA content affects EHM function, we aimed to restore the optimal HA 
content in CFB1 EHM by treatment with increasing concentrations of hyaluronidase 
(HYAL). Interestingly, HYAL treatment boosted CFB1 EHM function in a concentration 
dependent manner (Figure 3-20 B). At higher HYAL concentrations, a detrimental effect 
on functionality was observed (relative increase compared to CFB1 control at 4 mmol/L 
[Ca2+]: Control: 0.96±0.2; 0.015 U/ml 0.9±0.3; 0.15 U/ml 1.8±0.2; 1.5 U/ml 3.4±0.7; 15 U/ml 
1.1; 150 U/ml 0.4; n=11/3/4/4/1/1) (Figure 3-20 B). HYAL treatment also reduced CSA to 
levels comparable to HFF EHMs (CSA in mm2: Control: 2±0.1; 0.015U/ml: 1.1±0.1; 0.15 
U/ml: 0.8±0.1; 1.5 U/ml: 0.8±0.1; 15U/ml 1; 150 U/ml 0.6; n=12/3/4/3/1/1) (Figure 3-20 C). 
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Figure 3-20 CFB1 EHM function can be enhanced by hyaluronidase (HYAL) treatment 
A FOC of control and CFB1 EHM treated with 1.5 U/ml HYAL for 4 weeks, n=4/3 (Control/treated). B FOC 
normalized to average of respective control CFB EHM. n= 11/3/4/4/1/1. *p<0.05 by 1-way ANOVA followed by 
Dunnett´s multiple comparisons post hoc test comparing treated EHM to untreated controls. C CSA of HFF 
vs CFB1 EHM. n=12/3/4/3/1/1. *p<0.05 by 1-way ANOVA followed by Dunnett´s multiple comparisons post hoc 
test comparing treated EHM to untreated controls. B-C, data of 2 independent experiments. 
Immunostaining of CFB1 EHMs treated with HYAL revealed that sarcomeric 
organization and CM alignment were improved compared to controls (Figure 3-21), which 
is in line with the observed enhancement in contractile performance in these tissues 
(Figure 3-20). Our findings indicate that excessive HA in CFB1 EHM contributes to the 
observed phenotype. 
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Figure 3-21 Hyaluronidase treatment improves CM morphology and alignment 
Cross sections of A untreated CFB1 EHM and B HYAL (0.15 U/ml) treated CFB1 EHMs stained for sarcomeric 
actinin (red) and with Hoechst (blue nuclei). Scale bars: 500 µm and 100 µm in magnified views. 
Of note, when comparing HFF, GFB1 and CFB1 EHM cellular content (Figure 3-14), we 
observed that the non-myocyte content in CFB1 EHMs seemed increased when compared 
to HFF EHMs. We thus further hypothesized, that, proliferative behavior may somehow 
contribute to the phenotype development. 
To test this, we irradiated CFB1 EHM with 30 Gy at day 3 and measured FOC and CSA 
after 4 weeks (Figure 3-22 A). Interestingly, irradiation improved the contractile function 
of CFB1 EHM (FOC at 4 mmol/L [Ca2+] in mN: Control: 0.07±0.02 vs irradiated 0.2±0.04). 
As expected, irradiation reduced cell numbers in treated EHMs, although this effect was 
not significant (Figure 3-22 C), concurrent with a reduction in CSA (CSA in mm2: Control 
2.2±0.3 vs Irradiated 1.2±0.1; n = 4/group) (Figure 3-22 B and D). 
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Figure 3-22 The HA phenotype can be modulated by anti-proliferative treatment 
A CFB EHM were irradiated with 30 Gy on day 3 of culture before transfer to stretchers. Forces of contraction 
were assessed after 4 weeks of culture. *p<0.05 by 2-way ANOVA followed by Sidak´s multiple comparisons 
post hoc test. n=4/4 B EHM morphology at 4 weeks. C Cell count after enzymatic digestion of EHM (n=3 for 
controls, n=2 for irradiated group). D CSA analysis of CFB EHM without and with irradiation. n=4/4. *p<0.05 
by unpaired t-test. 
Taken together, both HYAL treatment and irradiation to abolish proliferative capacity in 
CFB1 EHM improved CFB1 EHM function, suggesting that HA content in CFB1 EHM 
and proliferation of non-myocytes in these tissues are collectively involved in the 
development of the observed pathophysiological phenotype (contractile failure and EHM 
swelling). 
In order to validate our findings and gain insight into the underlying mechanisms, we 
generated HFFs overexpressing HAS2 by transduction with a lentiviral overexpression 
construct (kindly provided by the lab of Prof. Jens Fischer in Düsseldorf) (Figure 3-23). 
We generated virus particles by transfection of TSA cells with packaging plasmids and our 
plasmid of interest with the HAS2 insert (and without as control). Virus production was 
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confirmed using LentiGo sticks from Takara. After selection, we validated that HAS2 
expression was increased in cells with the HAS2-constructs compared to control constructs 
with cells from the second transduced colony (HAS2-2) expressing the highest levels of 
HAS2 (mRNA HAS2/S18 ribosomal mRNA expression: Control 1 0.9±0.2; Control 2 
1.1±0.07; HAS2-1 389±39; HAS2-2 830±51; n=3/group) (Figure 3-23 B). Concurrent with 
these findings, the secretion of HA was highest in HAS2-2 cells > HAS2-1 > control 1 +2 
(HA secretion in ng/105 cells in 48 h: Control 1 116±19; control 2 142±13; HAS2-1 327±38; 
Has2-2 447±48; n=3/group) (Figure 3-23 C). 
 
Figure 3-23 Generation of stable HAS2-overexpressing fibroblasts 
A Construct and transduction protocol. TSA cells were transfected with target plasmid containing HAS2 (or 
no ORF for controls) and 2 lentiviral packaging plasmids. Virus was then used to generate HFF with a stable 
overexpression of HAS2 B Validation of HAS2 overexpression by qRT-PCR. n=3/group. *p<0.05 by 1-way 
ANOVA with Dunnetts´s multiple comparisons post hoc test of treatments vs control 1 and control 2, *p<0.05). 
C HA secretion quantified by ELISA. n=3/group. *p<0.05 by 1-way ANOVA with Dunnetts´s multiple 
comparisons post hoc test of overexpression and HYAL treatments vs control 1 and 2, *p<0.05). qRT-PCR was 
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carried out in cooperation with Prof. Jens Fischer (Department of Pharmacology, Duesseldorf) and carried out 
by Petra Rompel. 
After confirming the overexpression of HAS2 in 2D, we generated EHM from these cells 
and assessed HA secretion and functionality, as well as morphology, after 4 weeks of 
culture (Figure 3-24). EHM with HAS2-1 HFFs secreted around three times as much HA 
in 48 h as control EHMs (HA secretion in ng/EHM in 48 h: Control 1 456±44; control 2 
482±54; HAS2-1 1442±18; n=3/group). However, when assessing forces, HAS2-
overexpressing EHM did not perform differently from respective controls (Figure 3-24 B). 
HAS2 overexpressing EHM treated with 1.5 U/ml HYAL developed even lower FOC than 
control groups (FOC in mN at 4 mmol/L: Control 1 0.9±0.17; control 2 1.0±0.1; HAS2-1 
0.89±0.2; HAS2-1 + HYAL 0.6±0.1, n=4/4/3/3), although this was not significant. 
Morphologically, no difference between groups in CSA and total cell output following 
enzymatic digestion could be detected (CSA in mm2: Control 1 1.2±0.16; control 2 1.5±0.15; 
HAS2-1 1.2±0.14; HAS2-1 + HYAL 1.1±0.07; n=4/4/3/3) (Cell output x 105: Control 1 
6.7±1.1; control 2 10±0.5; HAS2-1 6.5±2.1; HAS2-1 + HYAL 8.6±2.2; n=4/4/3/3) (Figure 
3-24 C, D and E). 
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Figure 3-24 Analysis of EHM from HAS2-overexpressing fibroblasts 
EHM was generated from cells overexpressing HAS2 and controls A ELISA of 48 h supernatants of EHM. 
*p<0.05 by 1-way ANOVA with Tukey´s multiple comparisons post hoc test. n=3/group. B Forces of 4-week-
old EHM. C Representative images of control vector 1 and HAS2 overexpressing HFF EHMs. D CSA of 4-week 
old EHM E Cell counts after enzymatic digestion, from 4-week-old EHM after contraction analysis n=4/4/3/3 
(Control1/control 2/HAS2-1/HAS2-1 + 1.5 U/ml HYAL). 
Contrary to our hypothesis, we did not observe a pathological phenotype (reduced FOC 
and swelling as in CFB1 EHM) upon application of HAS2-overexpressing HFFs (Figure 
3-24 B and D), suggesting fundamental differences in the HFF and CFB1 entities. 
3.2.2 Dilated cardiomyopathy fibroblasts in EHM 
IPS-derived CMs have been utilized to recapitulate DCM, HCM and long QT syndrome 
phenotypes in vitro (Karakikes et al., 2015; Sun et al., 2012). Collectively, however, these 
models have so far neglected the role of other cell types and the surrounding 3D 
environment in cardiac pathologies (Bang et al., 2014; Cartledge et al., 2015; Gaudesius, 
2003; Ieda et al., 2009). As the role of cardiac fibroblasts both in development and 
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pathology of the myocardium is becoming increasingly appreciated, better models that 
take cellular crosstalk into account need to be established. EHM of IPS- derived CMs has 
recently been used to model DCM with an underlying mutation in RBM20 protein 
(Streckfuss-Bömeke et al., 2017). However, also the predominant focus of this work was 
on the DCM-affected CMs which were cocultured with non-organotypic HFFs. 
We thus sought to generate a comprehensive DCM-disease model that also involved 
fibroblasts of affected individuals (Figure 3-25 A). Compared to EHM generated from the 
CMs of the healthy donor (CTR EHM and DCM CFB EHM), tissues containing DCM-
affected CMs (DCM CM EHM and DCM EHM) did not produce any measurable forces (we 
define FOC< 0.03 mN as background in isometric force measurements) (Figure 3-25 B). 
Interestingly, there was also a significant decrease in contractile performance when 
disease-affected cardiac fibroblasts were used (FOC in mN at 4 mmol/L [Ca2+]: CTR 
0.9±0.1; DCM CFB 0.3±0.06; DCM CM and DCM <0.1; n=3/3/3/4) (Figure 3-25 B). These 
data suggest that apart from the obvious dysfunction of disease-affected CMs, CFBs also 
clearly contribute to the contractile pathophysiology of DCM. 
 
Figure 3-25 Modeling of DCM in EHM: Elucidating fibroblast- and CM-specific effects 
A Experimental outline for the modeling of DCM in EHM. Both IPS-derived CMs and CFBs from a DCM-
affected individual (red) were obtained and cocultured in EHM with IPS-derived CM of a healthy donor (nude) 
and CFBs from a healthy individual* (CFB3 obtained from Lonza) (dark nude). B FOC of 4-week-old EHMs. 
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*p<0.05 by 2-way ANOVA with Tukey´s multiple comparisons post hoc test. n=3/3/4/4 (CTR; DCM CFB; DCM 
CM; DCM). 
We previously demonstrated the crucial role of fibroblasts in early tissue consolidation, 
compaction during maturation and the resulting viscoelasticity in 4-week-old EHM. We 
thus further scrutinized these fibroblast-specific characteristics in our DCM model. We 
found significant differences in early tissue consolidation between the groups: EHM 
containing DCM-affected CFBs condensed significantly stronger than those with CFBs of 
the healthy proband (Gap from mold in mm: CTR 0.4±0.07; DCM CFB 1.0±0.01; DCM CM 
0.4±0.03; DCM 1.1±0.05; n=3/3/3/4) (Figure 3-26 A). After 4 weeks, EHM containing DCM-
affected CFBs had completely bent the silicone poles they resided on suggesting a 
myofibroblastic phenotype (Figure 3-26 B). In DCM CM EHM, we observed a partial 
condensation (Pole distance in mm: CTR 2.4±0.06; DCM CFB 0±0; DCM CM 0.6±0.1; DCM 
0±0; n=3/3/3/4). We further evaluated the viscoelasticity of 4-week-old EHMs and found 
that all EHMs containing DCM-affected cells were significantly stiffer than CTR EHMs 
(Figure 3-26 D). Between these three groups, however, we could not observe significant 
differences (slope of the stress vs strain curve: CTR 0.002±0.0005; DCM CFB 0.008±0.002; 
DCM CM 0.008±0.0001; DCM 0.009±0.001; n=3/3/3/4) (Figure 3-26 C). Collectively, these 
data suggest a pro-fibrotic profile of DCM-affected CFBs. Interestingly, in combination 
with CMs of our DCM patient also CFBs from a healthy donor seem to develop a similar 
phenotype (see DCM CM EHM in Figure 3-26 B), which may result from DCM-affected 
remnant stroma cells of impure CM preparations (Figure 3-27). 
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Figure 3-26 Modeling DCM in EHM: Fibroblast-specific characteristics of EHM 
A Degree of consolidation of EHMs one hour after casting measured by the gap between mold and consolidated 
hydrogel in mm. *p<0.05 by 1-way ANOVA with Tukey´s multiple comparisons post hoc test. n=3/3/4/4. B In 
4-week-old EHM we measured the distance of flexible PDMS poles, EHM tissues resided on. *p<0.05 by 1-way 
ANOVA with Tukey´s multiple comparisons post hoc test. n=3/3/4/4. C Stress vs strain in EHM. *p<0.05 by 1-
way ANOVA and Tukey´s multiple comparisons test of slopes. n=3/3/4/3 for (CTR/DCM CFB/DCM CM/DCM). 
All slopes of tested groups were significant vs the CTR group but not among each other. 
Based on these findings, we further investigated the non-myocyte population of EHMs. 
For that we analyzed the expression of the myofibroblast marker α-SMA. We detected α-
SMA+ cells in all EHMs, yet tissues generated with the CMs of the healthy donor contained 
significantly less SMA+ cells when compared to EHM of DCM-affected CMs (α-SMA in % 
of viable output cells: CTR 49±3; DCM CFB 50±2; DCM CM 72±1; DCM 78±4; n=3/3/3/4) 
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(Figure 3-27 A). Of note, the addition of DCM-affected CFB did not affect SMA+ 
populations when compared to CTR EHM. 
Flow cytometry analyses revealed that concurrent with functional performance, EHM 
generated from DCM-affected CFBs and CMs contained significantly lower numbers of α-
actinin+ cells (CMs) than control EHM (α-actinin in % of viable output cells: CTR 23±2 
DCM CFB 14±1 DCM CM 8±0.6 DCM 2±0.3; n=3/3/3/4). Of note,, cellular input populations 
of DCM-affected CMs used to generate these tissues were already lower in α-actinin 
content at casting (original input for CTR CMs vs DCM CMs 85 vs 69% α actinin+) (Figure 
3-27 B). Interestingly, the presence of healthy CFBs in DCM CM EHMs seems to have a 
beneficial effect on CM retention when compared to DCM EHMs. Collectively, FC and cell 
content analysis revealed that also the total amount of α-SMA+ cells found in DCM EHM 
was significantly increased compared to CTR EHMs (α-SMA + non-myocytes in x 105: CTR 
1.8±0.2 DCM CFB 1.8±0.4 DCM CM 2.9±0.9 DCM 4.9±1; n=3/3/3/4) (Figure 3-27 C). 
 
Figure 3-27 Modeling DCM in EHM: Cellular content of EHM 
A Proportion of actinin+ cells after enzymatic digestion of EHMs and FACS analysis. In the small inset, the 
purity of input CM populations is depicted. B % of SMA+ cells in digested EHM. C Total cellular content with 
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actinin+ CMs and actinin- non-myocytes that were either α-SMA+ or α-SMA- in viable cells from digested EHM 
after FACS. A-C, *p<0.05 by 1-way ANOVA with Tukey´s multiple comparisons post hoc test. n=3/3/3/4 
(CTR/DCM CFB/DCM CM/DCM). 
In conclusion, these findings emphasize that the DCM phenotype in EHM is a result of 
both CM dysfunction and the presence of DCM-affected CFBs. Our results suggest, that 
both DCM-affected CFBs and DCM-stroma cells harbor myofibroblast characteristics that 
interfere with proper EHM functional development. 
3.3 Towards fully defined EHM for pharmacological testing and clinical 
application – focus on fibroblasts 
With the emphasis on fibroblasts, several aspects have to be considered for better control 
of EHM application in in vitro platforms and as potential HF therapeutic: 
First, suitable sources of fibroblasts need to be accurately defined for the following: 1) 
patient-specific disease modeling and in vitro screening, 2) safe and feasible application of 
EHM in vivo as therapeutic. Second, a complete understanding of culture medium, 
supplements and their biological action is essential for the large-scale production and 
subsequent application of EHM in the clinics. 
3.3.1 Non-myocytes pose a bottleneck for cardiac tissue engineering 
application in the clinics 
3.3.1.1 A patient-specific fibroblast source for functional EHM 
In the context of disease-modeling and in vitro investigation of EHM, patient-specific and 
easily obtainable yet well characterized fibroblasts are of great importance. We first 
investigated the potential to derive sufficient amounts of fibroblasts from gingiva of 
patients. Outgrowth cultures were easily obtained within 1-2 weeks post explantation 
from gingival biopsies (average time until first fibroblast culture outgrowth was 
observable was 13±1 days; n=6) (Figure 3-28 D). Cultures could be passaged at least 5 
times and at 90% confluence yielded 30.000±1.600 cells/cm2 (n=4) (Figure 3-28 E). 
Depending on tissue sizes and quality, at P1 we generally were able to obtain at least two 
T25 flasks/patient, that could then be passaged further at ratios of up to 1:5. It has been 
hypothesized that for cardiac repair 1 billion cells would be necessary to sufficiently 
regenerate a dysfunctional MI scar (Gepstein, 2002). We observed that EHM patches can 
be generated from cell preparations containing only 10% fibroblasts, thus 100 x 106 
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fibroblasts would be required to generate such a large tissue graft (approximate to 12X 
T175). Accordingly, this would require 5 passages. 
 
Figure 3-28 Generation of primary fibroblasts from human gingiva 
A Schematic of cell harvest procedure. B Cellular outgrowth from attached gingiva tissue after several days 
in culture on Synthemax II surface (Corning). Scale bars: 500 µm in B and 100 µm in C. D Outgrowth time 
(n=6 independent patients) and E potential yield/cm2 (4 patients) at 90% confluency in culture dishes. 
For proof of principle, we generated EHM composed of CM and GFB from 4 subjects 
(GFB1-4). We found that EHM containing GFB1-4 developed significant lower forces than 
HFF EHMs in line with our observations with CFBs. There were no significant differences 
as to maximal contractile performance between EHM with GFB1-4 (FOC at 4 mmol/L 
[Ca2+] in mN: HFF 1.1±0.1; GFB1 0.71±0.1; GFB2 0.52±0.1 GFB3 0.55±0.1; GFB4 0.7±0.1; 
n=22/12/4/4/4) (Figure 3-29 A). These findings were in line with morphological analyses: 
GFB EHMs were similar to each other and control HFF (CSA in mm2: HFF 0.6±0.04; 
GFB1 0.7±0.06; GFB2 0.6±0.06; GFB3 0.7±0.1; GFB4 0.8±0.08; n=11/8/4/4/4) (Figure 3-29 
B). 
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Figure 3-29 Patient-specific variances in EHM from gingiva fibroblasts 
A FOC of 4-week old EHM from different GFB patients 1-4 compared to HFF controls (n =22/12/4/4/4 for 
HFF/GFB1-4). *p<0.05 by 1-way ANOVA with Tukey´s multiple comparisons post hoc test. B CSA of EHMs. 
(n = 11/8/4/4/4 for HFF/GFB1-4. 
Collectively, these findings suggest, that patient-specific fibroblasts can be easily 
generated and used for individualized EHM studies in vitro and potentially even for in 
vivo application. We observed minimal variances in resulting EHMs between patients, 
indicating that our system is robust. However, the use of patient-specific cells requires 
intensive quality control and is time and cost-intensive. 
3.3.1.2 PSC-derived non-myocytes offer new potential for EHM generation in 
clinical context 
The need of primary fibroblasts for tissue engineering may now be circumvented as 
significant progress has been made in the development of protocols to derive epicardium 
and cardiac fibroblast-like cells from PSCs (Bao et al., 2017; Iyer et al., 2015; Tan et al., 
2016; Witty et al., 2014). These cells were characterized by the expression of markers such 
as DDR2, periostin and PDGFRα (Iyer et al., 2015) (compare to Figure 3-16 of CFB1 
specific transcription we identified in RNAseq). 
For this study, RFP+ HES2 cells were differentiated (see 2.1.12, cells were provided readily 
differentiated) into fibroblasts to produce non-myocyte populations that could be utilized 
in EHM. We found, that HES2 RFP+-derived cardiac fibroblast-like cells (PSC-CFBs) were 
able to support EHM formation to a similar degree as neonatal HFFs (FOC at 4 mmol/L 
[Ca2+] in mN: HFF controls 0.84±0.1; PSC-CFBs 0.72±0.2; n=7/6) (Figure 3-30 A). They 
demonstrated a slightly decreased [Ca2+] sensitivity (EC50 [Ca2+] in mmol/L: HFF 0.4±0.02 
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vs PSC-CFBs 0.5±0.01; n=7/6), while adrenergic responsiveness was comparable to HFF 
controls (Figure 3-30 B) (% increase FOC at EC50: HFF 64±3 vs PSC-CFBs 67±6; n=7/6) 
(Figure 3-30 C). Furthermore, we found that CSA in PSC-CFB EHMs was significantly 
increased (in mm2: 1.6±0.15 vs 0.8±0.07 in HFF EHM; n=7/6) (Figure 3-30 D) concurrent 
with a higher cellular content that we measured after enzymatic digestion (viable cell 
counts x 105: 8.5±1.1 vs 5.5±0.7 in HFF EHM; n=5/6) (Figure 3-30 F). 
 
Figure 3-30 EHM can be generated from PSC-derived cardiac fibroblast-like cells 
A EHM were generated from HFF and HES2 RFP+-derived cardiac fibroblast like cells (PSC-CFBs) using the 
standard protocol. After 4 weeks FOC was assessed. B EC50 of [Ca2+] for HFF vs PSC-CFBs. (n=7/6). C 
Response to 1 µmol/L isoproterenol at EC50 and 1.5 Hz stimulation. D CSA of HFF and PSC-CFB EHM. 
(n=7/6). E Representative images of the two EHM groups. F Cellular content of EHM. For B, D, and F 
statistical analysis using unpaired t-test, two-tailed, *p<0.05 n=6/HFF and 5/PSC-CFB group. 
In summary, we show that EHMs can be robustly generated from PSC-CFBs. In light of 
developing new in vitro models and their potential clinical application, these cells need 
further characterization. In EHM of HFFs, we found that fibroblasts do generally not 
proliferate (Tiburcy et al., 2017). The increased cell content of PSC-CFB EHMs thus 
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suggests that some proliferation may have taken place, which could pose a safety issue for 
transplanted EHMs (see next section). 
3.3.1.3 Anti-proliferative treatment does not impair EHM function 
To ensure safety of clinical applications of the EHM, potential cellular overgrowth through 
remnant PSCs (formation of potential teratoma and other cancer) and infections must be 
well controlled. One such option is the irradiation of a tissue. Thus, we next investigated 
whether irradiation would adversely affect EHM functionality. We found that EHM 
treated at day 3 with 30 Gy were similar in function to untreated controls (FOC at 4 
mmol/L [Ca2+] in mN: Control 0.83±0.2; Irradiated 0.9±0.1; n=3/10) (Figure 3-31 A). 
Irradiated EHMs were slightly decreased in CSA, possibly due to reduced levels of 
proliferation (CSA in mm2: Control 0.7±0.1; Irradiated 0.4±0.03; n=4/10) (Figure 3-31 B). 
This difference was significant when comparing irradiated and control EHM. In line with 
arrested proliferation, we were unable to detect any Ki67+ cell population in irradiated 
EHM (Ki67+ cells in %: Control 4±0.9; Irradiated 0±0; n=4/10) (Figure 3-31 D). Concurrent 
with these findings, non-myocyte content in both treated groups was significantly reduced 
compared to untreated controls (Non-myocytes x 105: Control 4.3±0.6; Irradiated 1.2±0.2; 
CMs x 105: Control 1.3±0.1; Irradiated 0.9±0.2; n=4/10) (Figure 3-31 C). Taken together, 
our irradiation strategy would ensure high in vitro reproducibility of PSC-CFB EHMs and 
provide for a safe method for clinical applications of the EHM. 
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Figure 3-31 EHM function and content upon anti-proliferative treatment 
A HFF EHM were irradiated on day 3 with 30 Gy and subsequently cultured for 4 more weeks before functional 
assessment, compared to control HFF EHM. n=3/10 (Control vs irradiated). B CSA in tissues. *p<0.05 by 
Welch´s test comparing control vs treated EHMs. n=3/10 (Control vs irradiated). C Cellular content of EHMs. 
*p<0.05 by unpaired t- test. n=4/10 (Control vs irradiated). D Proliferation in EHM assessed by Ki67+ FACS. 
n=4/10 (Control vs irradiated). *p<0.05 by Mann-Whitney test. 
3.3.2 EHM can be generated under chemically defined conditions 
Next, to better understand cell-cell specific processes in EHM, we aimed at further 
defining our experimental model. While we were able to demonstrate that fibroblasts alone 
in ECT (Figure 1-7) and EHM can be robustly generated under serum-free conditions 
(Tiburcy et al., 2017), a further definition of the culture medium components would be 
required to ensure reproducibility. One such component of high complexity is B27. We 
thus aimed at defining the minimal requirements of B27 for EHM reconstitution. 
First, we compared B27 control to EHM supplemented serum albumin (recombinant 
(rHSA) or purified serum albumin (HSA)), as bovine serum albumin is the major 
component of B27. Indeed, we found that albumin alone could support EHM development 
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and function in a concentration dependent manner with optimal support at 5 mg/ml and 
HAS being superior to rHSA (fold of control FOC at 4 mmol/L [Ca2+]: Control B27 1±0.09; 
no supplement 0.5±0.06; rHSA 0.5 mg/ml 0.5±0.07; rHSA 2.5 mg/ml 0.8±0; rHSA 5 mg/ml 
0.9±0.07; HSA 2 mg/ml 0.7±0.08; HSA 5 mg/ml 1.5±0.02; n=20/4/8/4/4/4) (Figure 3-32 A). 
The use of albumin derived from serum, however, is suboptimal for highly standardized 
applications. 
We thus combined rHSA next with triiodothyronine (T3), transferrin (Tra) and sodium 
selenite (SoSel), L-carnitine (L-Car) and ethanolamine (Etha) or dexamethasone (Dexa). 
Many of these factors were tested before with data on their supportive function in EHM 
(Naito et al., 2006) and fibroblast culture as well as stem cell-differentiation Although 
none of the tested factors significantly enhanced EHM force production (Figure 3-32 B), 
they also did not reduce EHM function compared to respective controls. At this point we 
did not investigate further, more subtle differences (for instance calcium handling) in 
EHM and focused on their most prominent and integrative function, i.e., force of 
contraction developed under optimally preloaded isometric conditions. 
 
Figure 3-32 Essential components of EHM culture 
Comparison of FOC at 4 mmol/L [Ca2+] in 4-week-old EHM. A Data from EHM exposed to no supplement (no 
B27) and either recombinant (rHSA) or serum-derived human albumin (HSA) compared to control conditions 
defined in Tiburcy et al. 2017 (including B27); n=20/4/8/4/4/4. B Screening of additional factors included in 
B27 for EHM development supporting effects: Transferrin (Tra), sodium selenite (SodSel), L-Carnitine (L-
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Car), ethanolamine (Etha), dexamethasone (Dexa). Data is displayed as fold difference in FOC from control 
EHM constructed according to the defined serum-free protocol reported by our group previously (Tiburcy et 
al. 2017), without B27 but with 5 mg/ml rHSA. The solid and dotted lines display the control mean±SEM. 
*p<0.05 by 1-way ANOVA with Tukey’s multiple comparisons post hoc test. 
From the earlier findings of Parikh et al., we investigated the combined addition of rHSA, 
T3 and Dexa, hypothesizing that these two ingredients could potentially support both CM 
development or even maturation and fibroblast maintenance in our system. 
Indeed, rHSA in combination with both T3 and Dexa enhanced EHM function significantly 
(FOC at 4 mmol/L [Ca2+] in mN: Control B27 0.25±0.04; rHSA 0.26±0.02; rHSA + T3 
0.2±0.03; rHSA + T3 + Dexa 0.39±0.08; n=4/4/4/4) (Figure 3-33 A). Supplementation of 
EHM culture with rHSA and additional factors reduced spontaneous beating frequency, 
which was significant when combining T3 and Dexa, compared to both B27 and rHSA 
controls (in beats/min: B27 69±8; rHSA 56±3; RHSA + T3 51±2; rHSA + T3 + Dexa 35±5; 
n=4/group) (Figure 3-33 B). In tissues supplemented with rHSA, rHSA with T3 and in 
combination with Dexa, we also found that during isometric force measurements, the time 
until 90% contraction was reduced (time of contraction at 4 mmol/L [Ca2+] and 1.5 Hz 
stimulation in ms: B27 172±4; rHSA 180±2; rHSA + T3 166±1; rHSA + T3 + dexa 153±4; 
n=4/group) (Figure 3-33 C). The trend in time until 50% relaxation of individual peaks was 
opposed (time until relaxation at 4 mmol/L [Ca2+] and 1.5 Hz in ms: B27 100±2; rHSA 
104±4; rHSA + T3 112±3; rHSa + T3 + Dexa 119±4; n=4/group) (Figure 3-33 D). In 
summary, these findings indicate vast changes in the calcium handling machinery of EHM 
supplemented with rHSA, T3 and Dexa. 
Analysis of cellular composition revealed that rHSA +T3 and Dexa EHM contained less 
CMs but increased numbers of fibroblasts - this difference was significant when compared 
to B27 controls (RFP+ CM x 105: B27 2.7±0.5; rHSA 1.8±0.1; rHSA + T3 2.1±0.3; rHSA + 
T3 + Dexa 1±0.1; and GFP+ HFF x 105: B27 1.4±0.07; rHSA 1.9±0.2; rHSA + T3 2.2±0.4; 
rHSA + T3 + Dexa 2.8±0.1; n=3/4/4/4) (Figure 3-33 E). 
Collectively, we could define minimal EHM supplementation that can sustain full EHM 
development and functionality. Indeed, even the use of albumin was sufficient to allow the 
generation of functional tissues. 
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Figure 3-33 Minimal supplementation of EHM with albumin, T3 and dexamethasone 
A FOC at 0.2-4 mmol/L [Ca2+] in 4-week-old EHM supplemented with either B27 or rHSA in combination with 
Triiodothyronine (T3) and Dexamethasone (Dexa). *p<0.05 by 2-way ANOVA with Tukey’s multiple 
comparisons post hoc test to compare defined supplement groups with B27 control. B Spontaneous beating 
frequency of EHM. n=4/group. C Contraction time at 4 mmol/L [Ca2+] of EHMs and D Relaxation time at 4 
mmol/L [Ca2+]. For B-D: *p<0.05 by 1-way ANOVA with Tukey’s multiple comparisons post hoc test. E Cellular 
content of EHM (RFP+ CMs and GFP+ HFFs). Difference in CM and HFF content: *p<0.05 by 1-way ANOVA 
with multiple comparisons post hoc test. n=3/4/4/4 (B27/rHSA/rHSA + T3/ rHSA+ T3 + Dexa). 
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In conclusion, while the defined and controlled derivation of primary fibroblasts is 
challenging, PSC-derived non-myocytes are now available for the use in EHM. Potential 
risks posed by remnant mesodermal progenitor or pluripotent stem cells in EHM can be 
diminished by radiation treatment without functional loss. These findings, taken together 
with the option of minimal and chemically defined supplementation, are very promising 
for the improvement of EHM as a defined in vitro model of fibroblast-CM crosstalk within 
the myocardium and its future application in the clinics. 
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4 Discussion 
The role of cardiac fibroblasts in development and disease has become increasingly 
appreciated. Through the intrinsic complexity of the myocardium, however, the study of 
fibroblast-CM crosstalk has been hampered by the availability of suitable in vitro model 
systems. 
In this work, we hypothesized that fibroblasts, by controlling the extracellular 
environment, are key for heart muscle assembly and homeostasis. 
By utilizing the EHM model, which enables the reduction of the complex myocardium to 
a controlled 2-cell type system, we could specifically address 3 major questions and 
observed the following: 
1. The role of fibroblasts for EHM development:  
• Fibroblast, but not cardiomyocytes compact the collagen I hydrogel environment 
during EHM formation. 
• Collagen I compaction leads to an activation of fibroblasts with subsequent ECM 
synthesis and assembly 
• The cardioinstructive cues necessary for EHM formation are to a certain degree 
universal to fibroblasts of different origin 
2. Fibroblast-specific signaling to support healthy and diseased myocardium: 
• A tightly controlled HA content is crucial for proper EHM development and 
function 
• Fibroblast from DCM patients contribute to contractile failure of EHM 
3. Optimization of EHM culture  
• PSC-derived fibroblast-like cells support EHM formation similarly as primary 
fibroblasts  
• rHSA, T3, and Dexa were identified as cardiomyogenesis-supporting factors in 
EHM 
4.1 The role of fibroblasts in EHM development 
The developing epicardium provides the necessary cues for cardiac compaction and guides 
the assembly of CMs into higher order contractile units (Takahashi et al., 2014). Cardiac 
fibroblasts were shown to first arise during cardiac compaction and their presence is a 
perquisite for hyperplastic growth of CMs during this phase (Ieda et al., 2009). The 
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endogenous role of fibroblasts is recapitulated in the generation of cardiac tissue 
constructs, where they are necessary to compact matrix and drive CM development 
(Kensah et al., 2013; Liau et al., 2011; Naito et al., 2006; Sur, 2016; Tiburcy et al., 2017; 
Wang et al., 2016; Zhang et al., 2017). Indeed, in the absence of suitable fibroblasts or 
comparable yet undefined stroma cell populations, engineered myocardial tissue does not 
consolidate and fails to form functional syncytia comprised of electromechanically 
integrated CMs. These findings could be confirmed in the present study, which 
demonstrated that that fibroblasts are essential for the early EHM compaction process. 
During development, epicardium-derived cardiac fibroblasts interact with CMs via 
paracrine modulators (Bang et al., 2014; Cartledge et al., 2015). The ablation of paracrine 
signaling from the epicardium leads to a failure of the compaction process (Bax et al., 2010; 
Gittenberger-de Groot et al., 2012; Li et al., 2011). However, our lab has previously 
demonstrated, that paracrine signaling alone was insufficient for CMs in collagen I 
hydrogel supplemented with other matrix components such as Matrigel to drive 
compaction of tissue and form functional syncytia (Sur, 2016). Instead, these findings 
suggest the need for structural or biomechanical cues provided by the surrounding ECM 
during development. We thus investigated how fibroblasts affected the ECM of EHMs. 
Comparing 4-week old tissues without cells, with only CMs, HFFs or both cell types 
(EHM), we could appreciate the ECM consolidation process was highly dependent on the 
presence of fibroblasts. In earlier studies of rat engineered heart tissues, upregulation of 
collagen I and III transcripts, evidence of collagen I synthesis by electron microscopy, and 
the detection of increased levels of transcripts from MMPs 2 and 14 during development 
supported that extensive ECM modulation had taken place in vitro. Furthermore, already 
at culture day 12, CMs in this model were aligned in an anisotropic manner and tissues 
demonstrated phenotypic properties of native neonatal myocardium (Tiburcy et al., 2011). 
Thus, fibroblast-mediated ECM compaction in EHM likely coincides with functional 
development of CMs. 
In addition, viscoelastic properties of the three-dimensional ECM environment in EHM is 
a key determinant for spatiotemporal maturation of CMs, a finding supported also in 2D 
and 3D models of CM maturation (in 2D: (Boothe et al., 2016; Engler et al., 2008; Ribeiro 
et al., 2015); in 3D (Lee et al., 2017). We evaluated the viscoelastic properties of EHM after 
4-weeks of culture. Fibroblast only tissues showed the most profound stiffening as 
compared to cell-free, CM-containing, and EHM (CM+HFF) hydrogels. These findings 
were concurrent with the profound ECM structural changes that tissue constructs had 
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undergone, as evidenced by Sirius red staining. Notably, with a Young’s modulus of 1-3 
kPa, EHM are still rather soft compared to the endogenous myocardium, which ranges 
from 10 kPa in embryonic to 40 kPa in postnatal hearts (Jacot et al., 2010). This 
discrepancy has also been observed in other microtissues of collagen with cardiac 
fibroblasts (van Spreeuwel et al., 2017) and may for instance be explained by a different 
collagen I/III ratio of in vitro tissue constructs compared to endogenous myocardium and 
also the type of measuring method and mathematical model used. 
Collectively our findings emphasize the fibroblast´s impact on integrity and viscoelasticity 
of the ECM. The maturation and mechanical development of cocultured CMs in EHM is 
driven and accompanied by the dynamical changes the ECM undergoes over time. For 
future studies, tuning of the EHM stiffness should be evaluated as a potential measure to 
further mature CMs. Application of external mechanical stress through dynamic 
stretching has already been extensively used to optimize the stress-strain behavior and 
thus functionality of EHM (Liaw and Zimmermann, 2016; Tiburcy et al., 2017). 
4.1.1 Fibroblasts, but not cardiomyocytes, compact the collagen I hydrogel 
environment during EHM formation  
From our findings of 4-week-old tissues we next sought to better understand the 
compaction of early developing EHM. In our previous work, we observed that proper 
collagen I compaction, which occurs within a timescale of hours post-casting (Tiburcy et 
al., 2014), was necessary to obtain functional EHM (Tiburcy et al., 2017). From our data, 
we could identify 3 distinct phases of collagen I hydrogel stiffening. First, collagen I 
hydrogels would settle in the instrument (lag), followed by a pH-dependent gelation step, 
independent of cellular content and finally a plateau, when the pH dependent reaction 
slowed (Figure 4-1)(Schlick et al., 2018). These observations were in line with the well-
described properties of pH-dependent polymerization of collagen type I hydrogels: As a 
result of changes from acidic to physiological conditions, dimer and trimer collagen 
molecules are nucleated (lag phase), followed by a linear growth during which 
fibrillogenesis takes place that eventually reaches a plateau (equilibrium of fibrillogenesis 
and fibril breakdown) (Djabourov et al., 1993). In the presence of fibroblasts, collagen I 
compaction did not reach equilibrium and stiffening was further enhanced. 
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Figure 4-1 Temporal phases of collagen I polymerization 
The polymerization of collagen I hydrogels with and without cells (here HFFs) in shear plate rheology can be 
divided into three stages. First the gel settles in the instrument (lag), then pH-dependent polymerization takes 
place (cell-independent), followed by a cell-dependent polymerization in the presence of fibroblasts. Figure 
modified from (Schlick et al., 2018). 
The cell-driven collagen gel contraction is thought to be mediated by three consecutive 
processes that compact the collagen fibers and expel water: First, cell traction forces: 
Fibroblasts attach to the ECM and compact collagen fibrils into thicker fibers through 
tension mediated from the integrin-containing adhesion complexes. Secondly, within 
fibroblasts, active cell contraction involving myosin motors and the actin cytoskeleton 
transmit tension onto the surrounding gel. Finally, on a time-scale of hours, cell elongation 
and spreading of fibroblasts that attached to collagen I pulls fibers along the cells, 
effectively ridding the gel further of water (Dallon and Ehrlich, 2008). 
The initial collagen I-fibroblast interaction is predominantly mediated by the integrins 
which can be found in focal adhesions. A major role in gel contraction is attributed to α2β1-
integrin, which is upregulated when fibroblast are exposed to a 3D collagen I environment 
(Jokinen et al., 2004; Klein et al., 1991; Schiro et al., 1991), and to a lesser degree α1β1 
(Carver et al., 1995; Jokinen et al., 2004; Zhang, 2006), α10β1 (Tulla et al., 2001; Varas et 
al., 2007) and α11β1-integrins (Varas et al., 2007). In line with the findings of others 
(Carver et al., 1995; Kondo et al., 2004), our lab has previously demonstrated that the 
integrin subunits α1, α2 and β1 were predominantly expressed on fibroblasts and their 
blockage impaired the consolidation of both mouse and human EHM (Sur, 2016). Of note, 
we also observed a dosage-dependent effect on collagen I stiffness as doubling the input 
HFF cell number resulted in a markedly increased slope of storage modulus/time (n=1, see 
A1). In the work of Streeuwel and colleagues, increasing fibroblasts density in 
microtissues accelerated the early compaction process, but did not affect final elasticity of 
the tissues. Together with our findings, this suggests, that during initial gel contraction, 
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the extent to which a gel is compacted is dependent upon the number of cells that can bind 
collectively to the matrix via direct receptor-ECM interactions and contract the tissues 
through cytoskeletal rearrangements (van Spreeuwel et al., 2017). Thus, a higher number 
of cells will result in more effective gel contraction. 
Cardiac tissues have also been generated from fibrin/Matrigel gels (Mannhardt et al., 
2016; Schaaf et al., 2014). In fibrin-only gels, using an experimental setup very similar to 
ours, consolidation was shown to require cell-ECM binding and subsequent cytoskeletal 
dynamics, as it could be inhibited by treating fibroblasts with blebbistatin, demonstrating 
intracellular requirement for myosin II motor proteins and the actin cytoskeleton (Jansen 
et al., 2013). This second phase of cell-mediated gel contraction requires further 
investigation in our EHM model. 
In the work of others, it was observed that gel contraction resulting from morphological 
changes of embedded cells generally appears much later (Dallon and Ehrlich, 2008). For 
instance, fibroblasts in contracted collagen I gels extend dendritic like protrusions only 
after hours and days (Rhee, 2009; Rhee and Grinnell, 2007) and also Jansen and 
colleagues found in their work, that fibrin gel polymerization had completed after 1 h, but 
the cellular morphology of fibroblasts changed on a timescale of several hours (6 h) (Jansen 
et al., 2013). Thus, as anticipated, during early gel consolidation, we could not detect 
distinct morphological differences in HFF and CM cell populations (see A1). 
In EHM, consolidation was finished by 24 h. Indeed, it has previously been demonstrated 
that fibroblasts in collagen I gels immediately initiate gel compaction and that this process 
is mostly finished within the first 24 h (Yang et al., 2015; Zhang, 2006). Accordingly, the 
initial gel compaction we observe is a temporally very restricted process that involves cell-
hydrogel binding and cytoskeletal rearrangements on a short time-scale. The large 
morphological changes involving the elongation of CMs and upregulation and assembly of 
α-actinin into functional sarcomeres take place on a timescale of days to weeks although 
the earliest signs of sarcomeric formation can be observed already at day 1 and 3 of EHM 
culture. 
In summary, we could demonstrate, and for the first time quantify, fibroblast-dependent 
collagen compaction in EHM. Further maturation over several weeks of culture depends 
on fibroblast-mediated modeling of the ECM and de novo synthesis of ECM components 
resulting in changes in the viscoelasticity of developing tissues beginning at consolidation 
with 29 Pa (EHM at 60 min) to 0.9 kPa in 4-week-old EHM. These changes coincide with 
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CM elongation and spatial alignment that confer syncytium functionality. Interestingly, 
we found that fibroblast-mediated gel consolidation and subsequent stiffening over the 4-
week culture time of EHMs was attenuated by the presence of CMs. We hypothesize that 
this may result from the “softer” characteristic of cells compared to the stiffer matrix, or 
be the consequence of cellular crosstalk between CMs and fibroblasts, both which require 
further investigation. 
4.1.2 Collagen I compaction leads to an activation of fibroblasts with 
subsequent ECM synthesis and assembly 
To better understand the cell-specific processes in early consolidating tissues, we analyzed 
the transcriptome changes of collagen I hydrogels with HFF, CMs and both cell types 
between cell-independent and dependent phase (Figure 3-7/Figure 3-8/Figure 3-9). 
Interestingly, GO analyses suggested similar processes in EHM as observed in embryonic 
cardiac jelly formation and endocardial cushion development, which include HA synthesis 
(Camenisch et al., 2000, 2001). The EHM collagen matrix thus appears to mimic the 
environment of the early developing myocardium. In line with our hypothesis that 
fibroblast-mediated processes dominate tissue compaction, we found that fibroblasts 
responded strongest to the stiffening environment with enhanced transcription of ECM-
related genes and genes of general tissue formation processes. 
Among key factors in the fibroblast-specific group we identified SOX9, a master regulator 
of the fibrotic response in the heart (Lacraz et al., 2017) and TGFβ which controls ECM 
contraction and synthesis (Chen et al., 2005; Dobaczewski et al., 2011; Lijnen et al., 2003; 
Montesano and Orci, 1988). Other genes identified played a role in glycosaminoglycan 
biosynthesis and wound contractile processes (VCAN, PDGFβ and its receptor). Also, 
anchorage proteins (junction plakoglobin (JUP) and desmoplakin (DSP)) were specifically 
regulated in the fibroblast group. Collectively, all these factors clearly emphasize the 
fibroblast-specific function of ECM-binding and subsequent contraction during 
consolidation in EHM. Of note, BMP2 was also specifically regulated in the fibroblast-
group, a factor that is important for HA-mediated cardiac jelly formation and thus 
endocardial cushion development (Ma, 2005). This is also the case for VCAN, which 
cooperates with HA in cardiac development (Hatano et al., 2012) (see also 4.2.1 on the role 
of HA in endogenous myocardium and EHM). 
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GO terms unique to CMs (154 DEGs in the CM only and EHM group) were indicative for 
ER stress, which is in line with earlier findings of our group that demonstrated an increase 
in caspase activity and CM-specific apoptosis (and anoikis) during early formation of EHM 
(Tiburcy et al., 2011, 2017). Surprisingly, around half of the DEGs in EHM were comprised 
of micro- and long non-coding-RNA species(Schlick et al., 2018). RNAs of this family have 
been reported to be transported between cells by means of exosomes (Bang et al., 2014; 
Fatima et al., 2017; Hayashi and Hoffman, 2017). This axis of fibroblast-CM crosstalk will 
be the subject of further work in the EHM model. 
Collectively, these data illustrate how early EHM development recapitulates bona fide 
heart formation at the stages of cardiac jelly formation and compaction, involving HA 
biosynthetic processes in both cell types, while ECM assembly and contractile processes 
could be clearly attributed to the fibroblast fraction of tissues. The reshaping of the 
viscoelastic matrix activates predominantly the fibroblast fraction in EHM in a reciprocal 
manner and is itself controlled by the presence of CMs. 
4.1.3 All fibroblasts can provide cardioinstructive cues 
We observed cardioinstructive properties in all fibroblasts, irrespective of their origin, i.e., 
skin, gingiva or heart. These data are in agreement with observations of other groups that 
have utilized various sources fibroblasts to generate functional cardiac tissue constructs, 
for instance from whole heart preparations (Conradi et al., 2015; Jackman et al., 2018; 
Tiburcy et al., 2011; Zimmermann et al., 2002, 2006), or PSC-derived CM preparations 
from differentiations at various levels of purity (Lemoine et al., 2017; Mannhardt et al., 
2016; Naito et al., 2006). In this case, remnant mesodermal cells with fibroblast-like 
function have likely mediated tissue contraction and development. Finally, our finding 
that neonatal fibroblasts (HFF) supported the formation of functionally superior EHM 
compared to EHM containing fibroblasts from adults (GFB, CFB) is in line with the data 
of others (Liau et al., 2017). Here, cocultures with fetal rather than adult cardiac 
fibroblasts resulted in significantly higher expression of α-actinin and also connexin 43, 
concurrent with functional superiority, in cardiac tissue patches (Liau et al., 2017). It has 
also been observed that “younger” fibroblasts are more effective in contracting collagen I 
gels (Wilson et al., 2011), which may facilitate initial EHM development. Furthermore, it 
has been shown that fibroblasts of different origin differentially express MMPs (Lindner 
et al., 2012). Resulting variances in matrix-remodeling capabilities of different fibroblasts 
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may result in changes in EHM functionality since the presence of MMPs controls proper 
CM development in tissues (Nichol et al., 2008). 
4.2 Fibroblast-specific signaling to support healthy and diseased myocardium 
Utilizing EHM as in vitro model of fibroblast-specific signaling in the myocardium, we 
investigated the contribution of primary cardiac fibroblasts to pathological phenotypes. 
4.2.1 A tightly controlled hyaluronan content is crucial for EHM development 
and function 
The presence of HA is critical for cardiac cushion development (Camenisch et al., 2001; 
Ma, 2005; Shirai et al., 2009) and pericardial EMT (Shirai et al., 2009). In contrast, an 
excessive accumulation of HA results in severe cardiac pathologies with fibrosis, including 
hypertrophy and myofibril disarrangement in CMs (Chowdhury et al., 2013, 2017). The 
HA content of the ECM is tightly regulated during development, homeostasis and disease 
by the complex interplay between HA synthesis by HAS enzymes and degradation by 
HYALs. Our data of CFB1 EHMs suggest that the same accounts for EHM development. 
Analysis of the CFB (from patient 1) transcriptome revealed increased levels of HASs, 
while no difference in HYAL expression was detected compared to HFF cells. Taken 
together with low levels of CD44, which is necessary for HYAL-mediated degradation of 
HA (Harada and Takahashi, 2007), excessive HA deposition in CFB1 EHM was implied. 
Coincidentally a higher abundance of HA-binding proteoglycans such as VCAN could 
enhance binding and thus incorporation of HA in the ECM of CFB1 EHMs (Keller et al., 
2012). In line with our hypothesis, HYAL treatment of EHMs reduced CSA and 
concurrently boosted function in a dose-dependent manner. When treating EHM with 
higher concentrations of HYAL, function progressively deteriorated suggesting that there 
is also a minimal level of extracellular HA required during development. 
HA is crucially involved in all structural changes of the myocardium and found 
upregulated upon MI injury (Müller et al., 2014; Waldenström et al., 1991), where it plays 
an important role in myofibroblast regulation (Müller et al., 2014). Although analysis of 
CFB1-EHM viscoelastic properties did not indicate a fibrotic phenotype, RNAseq analysis 
revealed a higher expression of myofibroblast markers periostin (Snider et al., 2009) and 
CTGF (Leask et al., 2003; Lin et al., 2013). Of note, in periostin knock-out cells, HA 
secretion is reduced and it has been demonstrated that periostin-integrin interaction 
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controls HAS2 activity via PI3K signaling (Ghatak et al., 2014). These findings indicate a 
direct regulation between periostin and HA. Upon myofibroblast differentiation, more HA 
is detected in media of fibroblasts in vitro, which is not necessarily only associated with 
an increase in synthesis, rather a decrease in HA degradation (Jenkins et al., 2004). These 
findings would be in line with comparable HYAL levels but different levels of VCAN and 
CD44 in CFB1 and HFF control cells. 
While HFF cells are proliferative in 2D, they do not outgrow CMs in EHM (Tiburcy et al., 
2017; Zimmermann et al., 2006). Indeed this quiescent behavior of dermal fibroblasts in 
3D collagen matrices has been described and investigated and it could be demonstrated 
that cells in surroundings of physiological stiffness normally undergo a mitotic stop 
(Nishiyama et al., 1990). Although they were of comparable stiffness as HFF EHMs, CFB1 
EHM contained higher numbers of non-myocytes. Excessive cell numbers were shown to 
impair CM development as observed in other cardiac tissue models (van Spreeuwel et al., 
2017), which may also apply for EHM. There is a close connection between HA and non-
myocyte proliferation: HA is initially required for TGFβ-dependent myofibroblast 
transition and maintenance of the fibrotic phenotype (Webber et al., 2009a, 2009b) and 
HA stimulates TGFβ-dependent proliferative activity (Meran et al., 2011). Thus, 
myofibroblasts sustain their phenotype and proliferative capacity in an autocrine TGFβ- 
and HA-dependent feedback loop (Webber et al., 2009a). Intriguingly, in HYAL2-deficienct 
mice, HA accumulates which results in higher non-myocytes populations (Chowdhury et 
al., 2017). Reciprocally, inhibition of HAS2 also leads to a reduction of proliferation (Chao 
and Spicer, 2005). Notably, similarly to HYAL, anti-proliferative treatment in EHM did 
boost function and restored CSA to levels, comparable to HFF EHMs. However, at this 
point, we are unable to segregate whether proliferation was the consequence of high HA 
levels or whether proliferating non-myocytes resulted in the secretion of higher levels of 
HA within EHM. Both mechanisms may contribute to the CFB1 phenotype. 
To investigate our phenotype further, we first generated HAS2-Flag overexpressing 
constructs (A2.7), but failed to confirm the successful overexpression of HAS2-Flag (see 
A1). We then generated stable HAS2-overexpressing HFFs with a commercial vector and 
validated HAS2 overexpression on mRNA levels and resulting HA secretion. Interestingly, 
RNA transcript levels were greatly increased (600X in HAS2-overexpressing HFFs vs 
controls compared to only 6-8X in CFB1 cells vs HFFs). In contrast, HA secretion in 2D 
was only 3X higher in HAS2-overexpressing cells when compared to controls. These 
findings suggest that much higher levels of HAS2 mRNA do not necessarily lead to 
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comparable HA output, likely due to intrinsic regulation of HAS2 activity with endogenous 
antisense RNA HAS2-AS1 (Chao and Spicer, 2005) or HA degradation by HYALs. Next, 
we generated EHM from these cells: Although we confirmed increased HA secretion in 
HAS2-overexpressing EHMs, we could not recapitulate our previous phenotype suggesting 
the need to establish 1) whether a certain HA concentration range is supportive for EHM 
development and 2) whether the HFF-background may affect HA synthesis and retention 
in this model through other members of the HA system (for instance VCAN, CD44). 
4.2.2 Fibroblasts from DCM patients contribute to contractile failure EHM 
Initial studies of DCM disease modeling in EHM focused on defects in cardiomyocytes, 
such as observed in subjects with mutations in the RBM20 gene (Streckfuss-Bömeke et 
al., 2017). Whether DCM phenotypes could also be associated with a fibroblast dysfunction 
has not been studied, so far. To address this, we combined DCM-affected CFBs and CMs 
in our EHM model. Decreased contractile performance in EHM with DCM-fibroblasts was 
in agreement with an earlier hypothesis that heart failure can be a consequence of a 
fibroblastopathy (Tiburcy and Zimmermann, 2014). 
As a high prevalence of fibrosis is typically found in DCM pathologies (Ohtani et al., 1995; 
Unverferth et al., 1986), we investigated this matter in more detail: Within an hour after 
casting, the presence of DCM CFBs had resulted in significantly more consolidated gels. 
This indicated a contractile, potentially myofibroblast phenotype since myofibroblasts 
were shown to exert stronger contractile forces on gels than resident cardiac fibroblasts 
(Wrobel et al., 2002). And indeed, 4-week-old EHM of DCM CFBs had contracted so 
forcefully, that the PDMS poles they were placed on had been bent maximally. That was 
also the case for EHM with DCM CMs, suggesting that DCM remnant stroma cells 
retained similar, pathological characteristics. In agreement with these observations, 
analysis of viscoelasticity revealed that the presence of DCM-affected cells had resulted in 
higher tissue stiffness, indicating fibrotic ECM modulation. 
High levels of mechanical strain in cardiac fibroblasts were found to result in 
myofibroblast activation and subsequent ECM remodeling that progressively stiffens the 
ECM in a positive feedback loop (Baum and Duffy, 2011; Schroer and Merryman, 2015; 
Tomasek et al., 2002; Travers et al., 2016). Thus, in consolidating DCM-affected EHM a 
stiffer environment could further enhance fibrotic modulation of the ECM. Furthermore, 
in EHMs that progressively condensed the poles, cells were subjected to high mechanical 
load while tissue movement was restrained (static stretch). These processes could 
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adversely affect CM development, as optimal load and auxotonic (not static) stretching of 
EHMs are essential for CM development and thus optimal functionality in EHM (Abilez 
et al., 2018; Zimmermann, 2013; Zimmermann et al., 2006). 
Notably, in agreement with a myofibroblast phenotype, α-SMA content in 4-week-old 
EHMs of DCM CMs and EHM with both DCM CMs and DCM fibroblasts was increased, 
but not in EHMs of DCM fibroblasts. α-SMA content alone thus cannot fully explain the 
fibrotic behavior of DCM-affected CFBs. 
Further analysis of cellular content revealed: CM content of EHMs containing DCM-
affected CMs and CFBs was reduced, which was concurrent with a trend in functional 
deterioration. Impure DCM-CM preparations can partially explain this finding. However 
less CMs were recovered when either healthy or DCM-affected CMs were coculture with 
DCM-affected CFBs, demonstrating fibroblast-specific mechanisms that adversely 
affected CM retention. 
Of note, EHM of DCM-affected CMs did not develop measurable forces. These findings 
were anticipated as previous studies had demonstrated the contractile dysfunction of 
DCM-affected CMs in 2D (Sun et al., 2012) and EHM (Streckfuss-Bömeke et al., 2017). 
In summary, our data demonstrate the suitability and importance of physiological in vitro 
systems to study CM- and fibroblast-specific processes in the myocardium. By using EHM 
of both DCM-affected CMs and cardiac fibroblasts we were able to distinguish cell-specific 
contributions to the contractile and fibrotic pathophysiology of DCM and our findings 
further emphasized the underestimated role of cardiac fibroblasts in this context. 
4.3 Optimization of EHM culture  
To gain a comprehensive understanding of the role of nonmyocytes in cardiac tissue 
engineering and of endogenous cardiac fibroblasts in the myocardium, better in vitro 
systems are needed. Future applications of fibroblasts in EHM both in the context of in 
vitro screening and clinical application require: 1) the determination of suitable fibroblast 
sources, 2) safe application of the tissue constructs in preclinical models and 3) improved 
and chemically defined culture conditions for resulting EHMs. 
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4.3.1 PSC-derived fibroblast-like cells support EHM formation similarly as 
primary fibroblasts  
Although primary fibroblasts could clearly support EHM development and patient-specific 
variances were low, for robust in vitro disease models including large-scale screening 
applications and the potential use of EHM in vivo, larger amounts of well characterized 
non-myocytes are required. These needs can now be met by the directed differentiation of 
cardiac fibroblast(-like) cells (characterized by the expression of markers such as DDR2, 
PDGF receptor α, or periostin (Bao et al., 2017; Hewitt et al., 2011; Iyer et al., 2015, 2015; 
Witty et al., 2014)) from PSCs. 
EHM from PSC-derived cardiac fibroblast-like cells performed similarly to EHM 
containing HFF. Of note, morphological analysis and enzymatic digestion revealed a 
higher cellular content, suggesting that proliferation, potentially by remnant PSCs, had 
occurred. Uncontrolled growth of PSCs and teratoma formation have been observed both 
in other tissue engineering approaches and when using PSCs in vivo (Nelson et al., 2009; 
Nussbaum et al., 2007). In order to both abolish cellular proliferation and rid EHM of 
potential pathogens, we previously tested γ-ray irradiation of HFF EHM, which preserved 
function while completely abolishing Ki67 activity. We thus suggest this treatment also 
for PSC-CFB EHMs. 
In summary, this preliminary data indicates that PSC-derived cardiac fibroblast-like cells 
could serve as a reproducible and stable source of fibroblasts for EHM. Their large-scale 
production in combination with biological safety treatment could allow a future 
therapeutic application of EHM. 
4.3.2 Further definition of EHM culture supplements 
Our standard defined EHM culture conditions utilize B27 supplementation (Tiburcy et al. 
2017). To our surprise we observed that both recombinant and serum-derived albumin 
alone could replace B27 and support the development of functional EHM. However, two 
additional factors, T3 and dexamethasone, appeared to support maturation of the calcium 
handling machinery as evidenced by shortened contraction and prolonged relaxation time. 
The general observation that albumin, T3 and corticoids enhance maturation is in line 
with previous reports (Naito et al., 2006; Parikh et al., 2017; Yang et al., 2014). We 
furthermore found that the addition of Dexa specifically supported fibroblasts in EHM, 
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which is in agreement with the use of Dexa in defined growth media for fibroblast 
maintenance (Bettger et al., 1981; Phillips and Cristofalo, 1980; van der Valk et al., 2010). 
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5 Conclusion and outlook 
By utilizing EHM, a model system resembling structural, molecular, and functional 
properties of postnatal myocardium (Tiburcy et al. 2017), we demonstrated the crucial role 
of fibroblasts in early EHM formation and subsequent maturation of functional cardiac 
tissue constructs. Fibroblasts controlled the compaction of the collagen type I hydrogel 
environment, the main EHM ECM component, and appeared to be activated by ECM 
stiffening to provide cardioinstructive cues. Fibroblasts of different origin supported 
cardiomyogenesis in EHM suggesting a common cardioinstructive function. As a potential 
specific cardioinstructive fibroblast-derived ECM factor HA was identified. The 
requirement for a tight regulation of its ECM content was demonstrated as an important 
parameter for optimal EHM function. Furthermore, we showed that EHM can serve as a 
powerful tool to study the pathophysiological role of fibroblast-CM crosstalk with evidence 
for a specific role of fibroblasts in DCM associated contractile dysfunction. Finally, with 
the definition of a protocol for scalable derivation of fibroblasts from iPSC and rHSA, T3, 
and Dexa as important culture medium supplements we further optimized the EHM 
technology for applications in disease modelling, drug development, and potentially also 
for heart repair. 
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Appendix 
A1. Supplementary results 
 
Figure A 1 Cell morphology during early EHM early consolidation 
To investigate if changes in stiffness are correlated with changes in cell morphology, we generated hydrogels 
with GFP+-HFFs and RFP+-CMs. This allowed us to clearly distinguish fibroblasts and CM populations based 
on their endogenous fluorescence signal. A Purity of GFP+-HFF (GFP fluorescence) and B RFP+-CM (RFP-
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fluorescence) populations used for tissue generation/hydrogel cultures was tested by flow cytometry 
(representative flow cytometry plots are depicted). C Whole mount histology of collagen I hydrogels containing 
either RFP+-CMs, GFP+-HFFs, or mixtures of both at a 2:1 ratio either 30 or 90 minutes post reconstitution, 
which represent phases of cell-independent and cell-dependent hydrogel condensation; green: endogenous 
GFP, red: immunofluorescence staining for α-sarcomeric actinin, magenta: f-actin (phalloidin-labelling); note 
that the RFP, but not the GFP signal is lost during 4% FA treatment; scale bars: 100 µm. 
 
Figure A 2 Fibroblast dosage affects stiffening of collagen I gel 
Time sweep of polymerizing collagen I gel (storage modulus) with standard concentration of HFF and doubled 
HFF content (2X HFF), compared to collagen I hydrogel without cells. n=3/3/1 (Collagen I/+HFF/+2X HFF). 
 
Figure A 3 Comparison of different collagen I batches 
A Time sweep of polymerizing collagen I gels (storage modulus) without cells (batch 1 and 2). n=4/3 (Batch 
1/2). B Slopes of storage moduli in cell-dependent polymerization phase. Batch 1 n=3/4/3/4; Batch 2 n=3/3/4/3; 
(Collagen/+HFF/+CM/+HFF+CM). Parts of data from (Schlick et al., 2018). 
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Figure A 4 HAS2-Flag expression in TSA cells 
Protein abundance in TSA cells 72 h after transfection with HAS2-flag sequence encoding plasmids. A Ponceau 
stain indicates equal loading without evidence for a particularly enhanced protein band. B Western blot of 
several constructs with control Flag-expressing proteins. In cells transfected with HAS2-Flag containing 
constructs no flag expression could be detected (red boxes), suggesting instability or lack of expression of the 
HAS2-flag protein. This was observed despite confirmation of a correctly cloned HAS2-Flag sequence by 
Sanger sequencing. 
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A2. Supplementary material 
A2.1. Chemicals and buffers for molecular techniques 
Chemicals 
Table A 1 List of chemicals 
Chemical Manufacturer Catalogue number 
1,4 Dithiotreitol (DTT) Roth 6908.2 
2-[4-(2-hydroxyethyl)-1- piperazinyl]-
ethanesulfonic acid (HEPES)  
Roth 3908.3 
Acetic acid Roth  T179.2 
Ammoniumpersulfate (APS) Roth 9592.3 
Ampicilin sodium salt Sigma A9518 
Bovine Serum Albumin Sigma A3311 
Bromphenol blue Sigma Aldrich B0126 
Calcium chloride dihydrate (CaCl2 X 2H2O) Carl Roth GmbH & Co. KG 52391 
Carbachol (Carbamoyl choline chloride) Sigma C4382 
Complete Mini Protease Inhibitor EDTA free Roche 11836170001 
Deoxycholic acid AppliChem A2835.0025 
Diethyl pyrocarbonate (DEPC) Sigma 159220 
Dimethyl sulfoxide (DMSO) AppliChem / Sigma A3672,0100 / D2650 
EGTA Sigma E3889 
Ethanol Roth 0911.6 
Ethanol molecular grade Roth P076.1 
Ethylenediaminetetraacetic acid (EDTA) Roth 8040.1 
Eukit (Roti-Histokit II) Roth T160 
Glacial acetic acid Roth 3738 
Glucose Carl Roth GmbH & Co. KG X997.2 
Glycerol Roth 3783.2 
Glycine Roth 3908.2 
Hydrochloric acid (HCl) 25%  Roth 4625.2 
Isoproterenol (Isoprenaline hydrochloride) Sigma I5627 
Kanamycin/Streptomycin Sigma K4000 
L-Ascorbic acid (for Tyrode) Roth 3525.1 
L-ascorbic acid 2 phosphate sesquimagnesium 
(L-AAP) 
Sigma A8960 
Lysogeny broth (LB) powder Sigma L3022 
Mayer´s haemalaun solution AppliChem T865 
Methanol Roth 4627.5 
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Chemical Manufacturer Catalogue number 
Milk powder Roth T145.4 
Phosphatase inhibitor, PhosSTOP Roche 000000004906845001  
Picrosirius red- Direct Red 80 Sigma 365548 or 43665 
Polybrene  Sigma 107689-10G 
Ponceau S Carl Roth GmbH & Co. KG 5938.1 
Potassium chloride (KCl) Roth P017.2 
Potassium hydrogenphosphate monobasic 
(KH2PO4) 
Roth T875.1 
Rotiphorese gel 30/ 
30% Acrylamide-solution 
Roth 3029.1 
Rotiphorese gel 40% Acrylamide-solution Roth 7748 
Saturated aqueous solution of picric acid (1.3% 
in water) 
Sigma P6744-1GA 
Sodium (di-) hydrogenphosphate dihydrate 
(Na2HPO4 X 2H2O)  
Carl Roth GmbH & Co. KG 4984.1 
Sodium Chloride (NaCl) Roth 6771.1 
Sodium Deoxycholate  AppliChem 30970 
Sodium dodecyl sulfate (SDS) Roth  2326.2 
Sodium hydroxide solution (NaOH) Carl Roth GmbH & Co. KG 0993.1 
Sodium lactate Sigma 71723 
Tetramethylethylenediamine (TEMED) Roth 2367.3 
Toluol Roth 7591 
Trasylol  Bayer 34579.01.00 
Triton X100 AppliChem A4975 
Trizma base (Tris-HCl) Roth  4855.2 
Tween 20 AppliChem  A49740100 
Xylol Roth 3791 
β-Mercaptoethanol Sigma 31350-010 
Buffers 
Table A 2 Buffers and solutions 
Buffer Composition/ Recipe Protocol  
6X Laemmli buffer 
 
0.35 mol/L Tris pH 6.8 
30% Glycerol (w/v) 
10% SDS (w/v) 
9.3% Dithiotreitol (DTT) (w/v) 
0.02% Bromphenol blue (w/v) 
WesternBlot, SDS-PAGE sample 
loading buffer 
Acetic acid solution 5% 
(v/v) 
5% glacial acetic acid in 1l H2O Sirius red staining 
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Buffer Composition/ Recipe Protocol  
Bäuerle buffer 4.77 g/l HEPES 
20.45 g/l NaCl 
200 g/l glycerol 
0.2 g/l MgCl2 
0.186 g/l EDTA 
0.038 g/l EGTA 
10 g/l NP-40 
Protein extraction for 
WesternBlot 
Blocking buffer, 
permeabilizing 
500 ml PBS  
25 ml FBS 
5 g Bovine Serum Albumin (BSA)  
2.5 ml Triton X-100  
FC; IF  
Blocking buffer, surface 
proteins 
PBS  
5-10%FBS 
FC; IF 
Blocking solution/ 
Antibody solution 
Milk powder 5%(w/v) in TBST Western Blot 
Carbachol stock 10 
mmol/L 
10 mmol/L in 300 µmol/L L-AAP Isometric force measurement 
DEPC H2O 1 ml DEPC in 1 l H2O, leave o.n. at RT, 
then autoclave 
RNA extraction 
Isoproterenol stock 1 
mmol/L 
1 mmol/L in 300 µmol/L L-AAP Isometric force measurement 
Phosphate buffered 
saline (PBS) 
24 mmol/L NaCl 
0.27 mmol/L KCl 
0.81 mmol/L Na2HPO4 X 2 H2O 
0.15 mmol/L KH2PO4  
pH 7.4 
IF, washing cells for protein and 
RNA preparations. 
For cell culture use, see Gibco 
PBS 
Picrosisurs red in 
Saturated aqueous 
solution of picric acid  
1 g/l in H2O Sirius red staining 
Ponceau S solution 0.1% Ponceau S (w/v); 0.5% acetic acid 
(v/v) 
Western Blot 
Protein preparation 
buffer ready 
Bäuerle buffer 750 µl + CI 150 µl and PI 
100 µl 
Protein extraction for Western 
Blot 
Ready phosphatase 
inhibitor solution (PI) 
Tablet dissolved in 1 ml H2O Protein extraction for Western 
Blot 
Ready protease 
inhibitor solution (CI) 
Tablet dissolved in 1.5 ml H2O Protein extraction for Western 
Blot 
Running-Buffer for 
SDS-PAGE 
0.1% SDS  
25 mmol/L Tris (30.3 g/l) 
192 mmol/L Glycine (144 g/l) 
Western Blot 
Separating gel buffer 1.5 M Tris-HCl pH 8.8 (181.7 g/l) Western Blot 
Stacking gel buffer 0.5 M Tris-HCl, pH 6.8 (60.56 g/l) Western Blot 
TAE (50X) 242.2 g/l TrisBase 
18.6 g/l EDTA 
57.1 ml/l glacial acetic acid 
Agarose gel-electrophoresis 
TBS-Tween (TBST) 0.05 % Tween in TBS Western Blot 
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Buffer Composition/ Recipe Protocol  
Transfer buffer  
20% methanol 
25 mmol/L Tris 
192 mmol/L Glycin 
20% Methanol 
Western Blot 
Tris buffered saline 
(TBS) 
100 mmol/L Tris 
150 mmol/L NaCl  
pH 7.5 
Western Blot 
Buffers for isometric force measurement 
Table A 3  Buffers for isometric force measurement 
Buffer Composition/ Recipe 
CaCl2 stock (2.25 mol/l) 165.57 g CaCl2 x 2H2O (MW = 147.02) 500 ml H2O 
MgCl2 stock (1.05 mol/l) 106.83 g MgCl2 x6H2O (MW = 203.01) 500 ml H2O 
Tyrode Solution I 175 g NaCl 
10 g KCl 
2.22 ml CaCl2 stock 
25 ml MgCl2 stock 
In 1 l H2O 
Tyrode Solution II 50 g NaHCO3 in 1l 
Tyrode Solution III 5.8 g NaH2PO4 in 1l 
Tyrode´s buffer 
complete 
For 1 l 
1 g glucose (cell culture grade) 
100 mg L-ascorbic acid (Roth) 
40 ml Tyrode solution I 
38 ml Tyrode solution II 
10 ml Tyrode solution III 
A2.2. Labware, consumables and kits 
Labware 
Table A 4 Labwear 
Labwear Manufacturer 
12-well plates Greiner, Sarstedt, Thermo Scientific 
6-well plates Greiner, Sarstedt, Thermo Scientific 
6-well cell culture plates Greiner, Sarstedt, Thermo Scientific 
96-well plates, round bottom, straight bottom Greiner, Sarstedt, Thermo Scientific 
Duran glass petri dishes (60x20 mm) Duran 
Canules B.Braun 
Cell culture dish (6, 10 cm) Greiner, Sarstedt, Thermo Scientific 
Cell culture flasks (T25,75,175) Greiner, Sarstedt, Thermo Scientific 
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Other consumables 
Table A 5 Other consumables 
Consumable Manufacturer Catalogue number Corresponding 
protocol 
BAM HI New England Biolabs R0136S Cloning of HAS2-Flag 
DNA ladder 1 kb 
ruler 
Thermo Scientific SM0321 Agarose gel 
electrophoresis 
DNA ladder 100 bp 
plus 
Thermo Scientific SM0321 Agarose gel 
electrophoresis 
DNAseI Thermo Scientific 18047019 cDNA synthesis 
Immobilon Western 
Chemiluminescent 
HRP Substrate 
Merck Millipore WBKLS0500 Western Blot 
LentiGo stick Takara Clontech 631243 Virus production and 
transduction of cells 
MidoriGreen Nippon Genetics MG04 Agarose gel 
electrophoresis 
NHE I New England Biolabs R0131S Cloning of HAS2-Flag 
Nitrocellulose 
Membrane 
Protran Bioscience 10 401396 Western Blot 
PAGE ruler 
prestained, 
(10 to 170kDa) 
Thermo Scientific 26617 Western Blot 
Reverse 
transcriptase 
Promega M3681 cDNA synthesis 
Rotiquant Thermo Scientific K015 Bradford assay 
Silicone Elastomer 
Kit 
Dow Corning Sylgard®185 Generation of EHM mold 
Supersignal West 
Femto 
Pierce Thermo Scientific 34095 Western Blot 
Tag polymerase 
2X mix 
Nippon Genetics LS27 Colony PCR, cloning of 
HAS2-Flag 
Cell scraper (16 mm) Sarstedt 
Cryotubes 1.8 ml Nunc, Greiner  
Filter tips (0.5-10 µl, 2-200 µl, 1000 µl) Labsolute 
MrFrosty® Freezing container Thermo Scientific 
Pipet tips (0.5-10 µl, 2-200 µl, 1000 µl) Greiner 
Pipets, serological (5 ml, 10 ml, 25 ml) Sarstedt 
Reaction tubes (1.5 ml, 2 ml) Eppendorf 
Reaction tubes (15 ml, 50 ml) Greiner 
Sterile filter 0,2 and 0,45 µm Sartorius 
Syringe 1,2,5,10,20 and 50 ml Henke-Sass, Wolf,Braun 
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Consumable Manufacturer Catalogue number Corresponding 
protocol 
Trypan blue stain 
0.4% 
Thermo Scientific T10282 Cell counting, live/dead 
exclusion 
Whatman Blotting 
Paper 
Whatman 10 426 669 Western Blot 
Kits 
Table A 6 Kits 
Kit name Manufacturer Catalogue 
number 
Corresponding 
protocol 
cDNA Synthese: QuantiTect 
Reverse Trabscription Kit 
Qiagen 205313 cDNA (Petra Rompel) 
Gel extraction and PCR clean 
up 
Macherey Nagel 740986.20 Cloning of HAS2-flag 
Hyaluronan Quantikine 
ELISA kit  
R&D Systems DHYAL0 ELISA 
Plasmid isolation (Mini, Midi) 
Nucelospin kits 
Macherey Nagel AX20 and AX100 
740499.250 
Cloning of HAS2-flag 
Platinum SYBR Green qPCR 
SuperMix-UDG 
Invitrogen 11733-046 qRT-PCR (Petra 
Rompel) 
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A2.3. Antibodies  
Table A 7 Primary and secondary antibodies 
Target 
Protein 
Antibody 
specification/Cat 
Source Manufacturer Dilution  Dilution 
in WB 
Primary Antibodies  
α-
sarcomeric 
Actinin 
A7811 Mouse Sigma 1:1000 IF, 
1:100 whole 
mount 1:4000 
FC 
 
α-Tubulin T6199/T8203 Mouse Sigma  1:3.000 
BUV395 
Mouse anti 
Human 
CD90 
5E10/563804 Mouse BD 5 µl/test  
FLAG M2, 
monoclonal/F1804/F3
165 
Mouse Sigma  1:200 
IgG Isotype 
control 
SAB3701169 Rabbit Sigma 1:2000  
IgG1 MAB002 Mouse R&D Systems 1:100  
Ki67 SP6/16667 
 
Rabbit Abcam 1:100 in FC  
Other primary binding reagents 
Wheat 
Germ 
Agglutinin 
– 488 
labeled 
tagged 
W11261 - Invitrogen   
Secondary Antibodies 
anti-Mouse-
Alexa 488 
A11001 Goat Invitrogen/Life 
Technologies 
1:1000 IF/FC  
anti-Mouse-
Alexa 546 
A11003 Goat Invitrogen/Life 
Technologies 
1:1000 IF/ FC  
anti-Mouse-
Alexa 633 
A21050 Goat Invitrogen/Life 
Technologies 
1:1000 IF/ FC  
anti-
Rabbit-
Alexa 488 
A11008 Goat Invitrogen/Life 
Technologies 
1:1000 IF/ FC  
anti-
Rabbit-
Alexa 546 
A11010 Goat Invitrogen/Life 
Technologies 
1:1000 IF/ FC  
anti-
Rabbit-
Alexa 633 
A-21071 Goat Invitrogen/Life 
Technologies 
1:1000 IF/ FC  
HRP 
conjugated 
Mouse IgG 
P0260 Goat Dako  1:10.000 
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Target 
Protein 
Antibody 
specification/Cat 
Source Manufacturer Dilution  Dilution 
in WB 
HRP 
conjugated 
Rabbit IgG 
P0448 Goat Dako  1:5.000 
Other staining reagents 
Hoechst H3570/33342  Invitrogen/BD 1:1000 IF/ FC  
Phalloidin 
488 
A22284  Invitrogen 1:100 IF  
Phalloidin 
546 
A22283  Invitrogen 1:100 IF  
Phalloidin 
633 
A22284  Invitrogen 1:100 IF  
Sytox Red 
Dead Cell 
Stain 633 
S34859  Invitrogen 
/Molecular Probes 
1:1000 FC  
IF (Immune fluorescence), FC (Flow cytometry) 
A2.4. Plasmids, primers, competent bacteria 
Table A 8 Plasmids for the production of lentivirus in TSA cells 
Plasmid Description of vector Manufacturer/Source 
Cumate-pLenti-
Blank-SV40-GFP 
Cumate repressible vector 
without insert 
AbmGood ICu008 
GIPZ Lentiviral vector Open Biosystems 
HAS2 Lentiviral 
Vector (Cumate) 
Cumate 
pLenti-Cloning-SV40-GFP), see 
appendix 
AbmGood iCu2040584 
pCDNA3  pCDNA3  Invitrogen  
pCDNA3 HAS2 flag pCDNA3 containing HAS2-Flag 
CDS 
Cloned by S. Schlick (see A2.4) 
pGIPZ modified-
HAS2 flag 
pGIPZ containing HAS-flag 
CDS 
Cloned by S. Schlick (see A2.4) 
pMD2.G Vector encoding lentivirus 
envelope proteins  
Addgene 12259, source Didié Trono lab 
pReceiver-Lv205 Lentiviral plasmid (control) 
EX-NEG-Lv205 
GeneCopeia, gift of the Department of 
Pharmacology (Fischer lab), Düsseldorf 
Petra Rompel 
pReceiver-Lv205 
with HAS2 insert 
Lentiviral plasmid with HAS2 
insert for constitutive 
overexpression 
EX-U0330-Lv205 
GeneCopeia, gift of the Department of 
Pharmacology (Fischer lab), Düsseldorf 
Petra Rompel  
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Bacteria, competent 
Table A 9  Competent bacteria 
Bacteria Manufacturer/source Genotype 
TOP10 Produced inhouse F– mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 araD139 Δ(ara leu) 7697 galU galK rpsL 
(StrR) endA1 nupG 
Primer 
Primers were designed using standard settings of PrimerBLAST. Primers for cloning were 
generated using SerialCloner software (adaptor function). All primers listed were 
targeting human genes. 
Table A 10  Primers 
Target gene Fwd/Rev Sequence (5’→3’) 
18S Fwd GCAATTATTCCCCATGAACG 
18S Rev GGCCTCACTAAACCATCCAA 
HAS2 Fwd GTGGATTATGTACAGGTTTGTGA 
HAS2 Rev TCCAACCATGGGATCTTCTT 
HAS2 (cloning-Flag tag) Fwd tacaagctagctggcATGCATTGTGA 
HAS2 (cloning-Flag tag) Rev caaagtggatccTACATCAAGCACC 
HAS2 (sequencing) Fwd TCGCAACACGTAACGCAAT 
HAS2 (sequencing) Rev ACTTCTCTTTTTCCACCCCATTT 
A2.5. Technical devices, machines and software 
Technical devices 
Table A 11  Technical devices 
Device Manufacturer 
Agarose gel casting system and electrophoresis unit Generic 
Axiovert 40CFL microscope with HBO100 lamp and 
Axiocam ICm 1 
Zeiss 
Biovortexer MHX (E) Xenox 
CASY Model TT Roche 
Centrifuge 5417C Eppendorf 
Centrifuge 5417R Eppendorf 
Centrifuge 5810R Eppendorf 
Centrifuge Megafuge 1.0R Thermo Scientific  
Centrifuge MIKRO 22R Hettich GmbH & Co. KG  
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Device Manufacturer 
Freezer (-20°C) Liebherr 
Freezer -152 Heraeus, Thermo Scientific 
Freezer Hera freeze (-80°C) Heraeus, Thermo Scientific 
Fridge Liebherr 
Heating block Eppendorf 
Incubator for cell culture, Hera Cell 150 Heraeus, Thermo Scientific  
Isometric force measurement apparatus Föhr Medical Instruments (FMI) 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific 
Magnet stirrer MR3001 Heidolph Instruments GmbH & Co.KG  
Mini-PROTEAN® Tetra Cell (electrophoresis unit) and 
hand casting system 
BioRad 
NanoDrop® ND-100 spectrophotometer Peqlab 
Neubauer counting chamber, improved Brand GmbH & Co. KG 
P25T Powerpack Biometra 
Personal computers Dell, HP Compaq 6715b 
pH meter  Sartorius 
Pipets (0,1-2.5μL; 2-20μL; 20-200μL; 100-1000μL) 
Eppendorf Research Series 2100 
Eppendorf/Sartorius/Gilson/Peqlab 
Power supply unit Powerpack P25T Biometra 
Precision balance Sartorius 
Refrigerator (4°C) Liebherr 
Rheometer RSA-G2 
(destructive tensile stress measurement) 
TA Instruments 
Rheometer AntonPaar MCR-501 
(shear plate)) 
AntonPaar 
Rotator PROMAX 2020 Heidolph Instruments GmbH & Co.KG 
Shaking device “Rocky“ Schütt Labortechnik 
StepOnePlus Real Time PCR Applied Biosystems (qRT-PCR in Düsseldorf) 
Thermomixer comfort  Eppendorf 
Custom made tissue culture molds 
PDMS was prepared according to the manufacturer´s protocol. In short, polymerization 
reagent and silicone were mixed in a 1:10 (5 ml and 45 ml) ratio. The solution was inverted 
till it was homogenous, centrifuged briefly to remove bubbles and then loaded either by 
pouring or with a cannula into stretcher molds. The solution was allowed to settle for 
several hours at RT (o.n.) and then baked in the drying cabinet at 60°C until it was 
polymerized and solidified properly (non-stick test). Negative molds were provided by the 
workshop (UMG, and custom-made). 
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Figure A 5  EHM PDMS molds and auxotonic stretchers 
A Standard EHM mold, V per tissue 450 µl. Central hollow poles can be removed for EHM to be transferred 
onto stretchers. B Auxotonic PDMS stretcher, both images taken from (Tiburcy et al., 2014). C Positioning of 
EHM onto auxotonic stretchers (carried out manually). 
Contraction setup 
 
Figure A 6 Organ bath apparatus for isometric force measurements 
The isolated organ bath apparatus was designed and constructed by FMI. It consists of 16 individual organ 
baths with a 20 ml buffer reservoir. The hollow glass mantle is warmed by a steady flow of prewarmed 37°C 
warm water containing anti-microbial supplements. EHM can be stimulated electrically. Forces are measured 
via force transducers. The force of contraction (FOC) is calculated by Forcemax – Forcemin exerted by the EHM. 
For isometric force measurements, EHMs were immersed in Tyrode´s solution containing a basal 
concentration of 0.2-4 mmol/L [Ca2+] during measurements. 
A B C
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Software 
Table A 12 Software 
Software Manufacturer Purpose 
Adobe Photoshop CS Adobe Image processing 
AxioVision 4.8 Zeiss Imaging 
FACS DIVA BD Flow cytometry 
Flowings University of Turku Flow cytometry analysis 
Gimp Open source/freeware Image processing 
GraphPad Prism 7 GraphPad Software Inc., 
San Diego 
Data analysis, generation of figures 
ImageJX2 Open source/freeware Image processing 
Linux Ubuntu Canonical Operating system 
Microsoft Office (PowerPoint, Excel, 
Word) 2010 and 2013 
Microsoft Data management, generation of 
documents and presentations 
Microsoft Windows 7, 8, and 10 Microsoft Operating system 
ND-1000 v3.7.0 Peqlab Nanodrop 
Rheometer AntoonPaar Rheoplus AntonPaar Rheology 
SerialCloner Open source Cloning 
TRIOS TA Instruments Rheology, tensile stress 
Zotero Open source/freeware Citations, bibliography 
A2.6. Primary cells, cell lines and cell culture 
Basic cell culture ingredients 
Table A 13 Reagents for cell culture 
Base media/Chemicals/growth 
factors/inhibitors 
Cat Manufacturer 
100X penicillin/streptomycin (10.000 
U/ml) 
15140 Life technologies/Gibco 
100X penicillin/streptomycin, -20°C  15140 Life technologies/Gibco 
100X sodium pyruvate (NaP) (100 
mmol/L) 
11360 Life technologies/Gibco 
10X PBS 70011044 Life technologies/Gibco 
10X RPMI powder 52800-035 Life technologies/Gibco 
Accutase Solution  SCR005, Milipore 
Acid-soluble Collagen  01APA006 Collagen Solutions 
Activin A 338-AC R&D systems 
B27- insulin supplement A1895601 Life technologies/Gibco 
B27 supplement 17504-044 Life technologies/Gibco 
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BD Matrigel Basement Membrane Matrix 
Growth Factor Reduced  
354230 BD 
FGF (for stem cell differentiation) 130-093-841 Stemgent 
CHIR 04-0004 Stemgent 
Collagenase from Clostridium 
histolyticum Type I 
C0130 Sigma 
DMEM for TSA cells 42430-082 Life technologies/Gibco 
DNaseI 260913 Calbiochem 
DNaseI 3750 Calbiochem 
Dulbecco’s Modified Eagle Medium 
(DMEM) (Glutamax) 
61965-059 Life technologies/Gibco 
EDTA 0.5 mmol/L, 2 mmol/L In-house  
Fibroblast Basal Medium (FBM) CC-3131 Lonza 
Fetal bovine serum (FBS) 11573397 Life technologies/Gibco 
FGF (for EHM culture) AF-100-18B Peprotech 
FGM-3 SingleQuots CC-4525 Lonza 
Fungizone/Amphotericin B 11510496 Life technologies/Gibco 
IGF AF-100-11 Peprotech 
IMDM (Glutamax) 21980-065 Life technologies/Gibco 
IWP4 04-0036 Stemgent 
Knockout DMEM 10829-018 Life technologies/Gibco 
Knockout serum replacement (KOSR) 10828-028 Life technologies/Gibco 
Laminin-521 (100 µg/ml)  LN521-03 Biolamina 
L-ascorbic acid 2 phosphate 
sesquimagnesium salt hydrate (L-AAP) 
A8960 Sigma 
L-Glutamine, 100X (200 mmol/L) 35050061 Life technologies/Gibco 
Matrigel Basement Membrane Matrix 
Growth Factor Reduced 
354230 BD 
Non-essential amino acids (NEAA) 100X 
(10 mmol/L) 
11140050 Life technologies/Gibco 
PBS (+CaCl2/+MgCl2) 14040-091 Life technologies/Gibco 
PBS without CaCl2/MgCl2 14190144 Life technologies/Gibco 
Polybrene  107689 Sigma 
Polybrene - Hexadimethrine bromide H9268 Sigma 
Puromycin A1113803 Life technologies/Gibco 
Retinoic acid  R2625 Sigma 
Rock inhibitor Y27632 (ROCKi) 04-0012-10 Stemolecule 
RPMI 1640 (Glutamax) 61870-044 Life technologies/Gibco 
RPMI 1640 without glucose, without 
HEPES  
11879020 Life technologies/Gibco 
StemPro® Accutase® Cell Dissociation 
Reagent 
A11105-01 Life technologies/Gibco  
Synthemax II CLS3535 Corning via Sigma 
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Cell culture media and working solutions 
TeSR™-E8™ Kit 05940 Stem Cell Technologies 
TGFβ1 AF-100-21C Peprotech 
TrypLE 12604 Life technologies/Gibco 
Trypsin 2.5%, 15090-046 Life technologies/Gibco 
VEGF165 AF-100-20 Peprotech 
Versene  15040-033 Life technologies/Gibco 
Solution/buffer Recipe/Instructions Protocol 
10X RPMI RPMI powder dissolved in H20  
10.4g in 10ml 
Generation of EHM 
2X RPMI 2 ml 10X RPMI, 7 ml H20, 200 µl of 
100X P/S solution and 800 µl B27 
minus insulin 
Generation of EHM 
Accutase cell dissociation 
solution  
Accutase solutionAccutase Solution  
0.025% Trypsin  
20 μg/ml DNaseI 
Subculture of CMs 
Collagenase solution 2 g/l PBS (+ Ca2+ and Mg2+) with 20% 
FBS 
EHM dissociation  
DNaseI 1 mg/ml in H2O Cell and EHM dissociation 
DNaseI stock solution 
 
100 µg/ml in H2O CM dissociation 
EDTA 0.5 mmol/L  Add 1 ml of the 0.5 mol/L EDTA 
stock solution (pH 8.0) into 1 l PBS 
with 0.9 g NaC 
HES dissociation 
EDTA 0.5 mol/L stock 18.6 g/L EDTA in H2O  
FGF-2 stock 10 µg/ml in PBS containing 0.1% 
rHSA 
Generation of EHM, EHM culture 
IGF-1 stock 100 µg/ml in PBS containing 0.1% 
rHSA 
Generation of EHM, EHM culture 
IWP4 stock solution 5 mmol/L IWP4 in DMSO  Cardiac specification 
L-AAP stock at 300 
mmol/L  
L-AAP dissolved in H2O Standard cell culture  
Laminin coating solution Dilution of stock (100 µg/ml) to 2.5 
µg/ml in PBS (+ Ca2+ and Mg2+) 
Stromal cell differentiation 
Matrigel coating solution 1 ml Matrigel thawed on ice, diluted 
1:120 in PBS (Gibco) 
CM differentiation and replating 
Polybrene stock 8 mg/ml in H2O Transduction of cells 
Retinoic acid solution For 100 mmol/L: 50 mg in 1.67ml 
DMSO  
For 1 mmol/L stock dilute 1:100 in 
100% EtOH  
Stromal cell differentiation 
Rock Inhibitor 
(Stemolecule Y27632) 
Stock solution 
10 mmol/L in DMSO Dissociation and subculture of PSC 
cells and CMs 
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All cell culture media and supplements from powder or unsterile solutions were sterile 
filtered through 0.2 µm filters (Sartorius). All growth factor stocks and enzyme solutions 
were kept at -20°C for storage. Coating solutions for cell culture dishes were kept at 4°C 
once prepared. 
Table A 14 Cell culture media and supplements 
Synthemax II coating 
solution 
Dilute stock 1:40 in H20 (25 µg/ml) Derivation of primary cells 
Synthemax II stock 10 ml H20 in 1 vial (1 mg/ml) Derivation of primary cells 
TGFβ1 stock 5 µg/ml in PBS containing 0.1% 
rHSA 
Generation of EHM, EHM culture 
VEGF165 stock 5 µg/ml in PBS containing 0.1% 
rHSA 
Generation of EHM, EHM culture 
Medium/Buffer Recipe Protocol 
Cardiac fibroblast culture 
medium (FGM3 Medium) 
FBM medium containing all 
supplements (FGM3 bullet kit) 
Culture of cardiac fibroblasts 
Cardiac specification 
medium 
CM basal medium  
5 µmol/l IWP4  
Cardiac specification 
CM basal medium RPMI 1640 with Glutamax 
100 U/ml / 100 µg/ml P/S 
1 mmol/l of sodium pyruvate  
2% B27 supplement  
200 µmol/L L-AAP 
CM maintenance and 
differentiation, stromal cell 
differentiation 
HES2 medium Kockout DMEM  
20% Knock-out serum replacement 
(KOSR) 
10 ng/ml FGF-2 
Culture of HES2 cells 
HFF/GFB culture medium DMEM Glutamax  
15% FBS 
100 U/ml P/S 
HFF and GFB culture 
Lactate selection medium RPMI without Glucose  
100 U/ml / 100 µg/ml P/S 
2.2 mmol/L Na lactate 
0.1 mmol/L 2-mercaptoethanol  
CM differentiation, metabolic 
selection after cardiac specification 
Mesodermal induction 
medium (MIM10-B) 
CM basal medium 
1 µmol/L CHIR  
10 ng/ml BMP4  
9 ng/ml Activin A  
5 ng/ml FGF-2 
Stromal cell differentiation  
Serum free maturation 
medium (EHM Medium) 
IMDM Glutamax 
100 U/ml / 100 µg/ml P/S 
0.1 mmol/L NEAA 
300 µmol/L L-AAP 
4% B27 minus insulin 
EHM generation, EHM long-term 
culture 
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All cell culture media were kept at 4°C. Media that did not contain FBS were prepared 
fresh every time for use. Media with FBS were kept up to 2 weeks. 
5 ng/ml VEGF165 
10 ng/ml FGF-2 
100 ng/ml IGF-1 
5 ng/ml TGFβ1 (days 1-3) 
Stromal cell specification 
medium (StC-SM; prepare 
fresh) 
 
CM basal medium 
50 ng/ml BMP4  
4 µmol/L retinoic acid  
1 µmol/L CHIR  
Stromal cell differentiation  
TSA culture medium DMEM (for TSA)  
10% FBS  
100 U/ml / 100 µg/ml P/S  
2 mmol/L L-Glutamine 
TSA culture 
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A2.7. Vector maps 
Standard and commercial vectors 
 
Figure A 7 Maps of commercial vectors 
A Lentiviral envelope plasmid pMD2.G vector by Addgene (Lab of Didié Trono). B Lentiviral packaging 
plasmid psPAX2 vector by Addgene (Lab of Didié Trono). C Cumate-p-Lenti_Blank-SV40-GFP from AbmGood 
used for generation of GFP+ HFF cells. D GeneCopeia pReceiver-Lv205 vector with/without HAS2 insert used 
for the generation of HAS2-overexpressing HFF. 
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Vectors containing HAS2-Flag 
 
Figure A 8 Vectors generated for HAS2-Flag overexpression 
A pGIPZ-based vector and B pcDNA3.1 based vector with HAS2-Flag CDS. 
